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ABSTRACT 
Depression is a common comorbidity in rheumatoid arthritis (RA), yet it may not 
be adequately recognized during routine clinical care.  RA symptoms may confer a risk 
for depression, and vice versa; depression may affect RA disease activity and response to 
treatment.  The study aims were to compare patient- and physician-reported depression 
measures, evaluate the temporal bi-directional association between RA disease activity 
and depressive symptomology, and assess depression as a moderator of RA treatment.  
Patients were identified using a national RA registry sample (Consortium of 
Rheumatology Researchers of North America; CORRONA).  Depression prevalence and 
incidence rates were estimated, and concordance and disagreement using measures 
reported separately by patients and physicians, as well as baseline cross-sectional 
associations between RA disease and a history of depression.  A survival analysis was 
conducted to temporally predict the incident onset of self-reported depressive symptoms 
using the different metrics of RA disease activity.  Also, mixed effects models were used 
to assess prospective changes in RA disease activity by prevalent and incident depressive 
symptom status.  Lastly, logistic regression models compared the likelihood of clinical 
response to RA treatment during follow-up in those with and without depression when 
starting biologic disease modifying anti-rheumatic drug (DMARD) therapy.   
Patient-reported depression rates were much higher and significantly different 
from physician based comorbidity estimates.  Patient and physician RA disease activity 
measures were associated with an increased risk for depression onset, but not laboratory-
reported serum biomarkers.  Similarly, depression was temporally associated with 
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significantly slower rates of decline regarding every patient-reported disease activity 
measure, some physician-reported metrics, but not acute phase reactants.  Moreover, 
there was a significantly lower probability of achieving clinical remission among those 
with depression on a biologic DMARD after 6 months and an analogous effect at 12-
months that was slightly lower in magnitude, which did not reach statistical significance.   
Rheumatologists under-reported the occurrence of prevalent and incident 
depressive symptoms, and thus are likely unaware of its presence in their RA patients.  
Further, the results suggest the bi-directional effects between these conditions are related 
to the cognitive and behavioral aspects of depression and their interactions with disease 
activity, rather than shared immunological mechanisms in the context of cell-mediated 
immunity.  When also considering the impact on clinical response to biologic DMARDS, 
the findings collectively imply that rheumatologists must address any challenges due to 
depression to provide the best care to their patients. 
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PREFACE 
  
This dissertation was written as a compilation of four manuscripts (Chapters 2-5) 
derived from three research aims, of which, the second was divided into two separate 
research studies, and all have been, or will be, submitted for peer-review and publication. 
 
Part of this thesis work has be accepted for publication and is currently in press: 
Rathbun AM, Harrold LR, Reed GW. A Description of Patient and 
Rheumatologist Reported Depression in an American Rheumatoid Arthritis 
Registry Population.  Clin Exp Rheumatol (In Press). 
 
Furthermore, publications related to this dissertation but not presented in this thesis 
include the following: 
Rathbun AM, Reed GW, Harrold LR.  The temporal relationship between 
depression and rheumatoid arthritis disease activity, treatment persistence and 
response: a systematic review. Rheumatology (Oxford) December 2012. 
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CHAPTER I: 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
1.1 Rheumatoid Arthritis and Depression 
Rheumatoid arthritis (RA) is a chronic debilitating disease that affects 
approximately 1.29 million adults in the United States [1].  RA causes joint swelling and 
joint deformities and requires chronic medical care that has been estimated to cost as 
much as $26,697 per patient per year [2].  Psychiatric comorbidity, particularly 
depression, is a significant problem in this population and is two to three times more 
common among RA patients when compared to the general population, and this increased 
risk is independent of sociodemographic determinants [3-5].  The ramifications of 
depression in RA patients are numerous and far reaching, and the effect of this condition 
on quality of life and indirect societal costs is immense.  Depression exacerbates the 
unfavorable health outcomes of RA and is associated with higher mortality, an increased 
risk for myocardial infarction (MI), greater work disability, and elevated healthcare 
expenditures [6, 7, 7-9].     
 The impact of depression is further compounded because depression is not 
adequately recognized in RA patients and up to 50% of all people do not receive the 
appropriate treatment for it [10-13].  When occurring in the context of chronic physical 
illness, depression may lead to poorer outcomes when compared to the occurrence of 
either condition alone, and evidence suggests medical management frequently becomes 
difficult [14, 15].  The causal pathways between RA disease activity and depression may 
be bi-directional, where the joint symptoms of RA increase patients’ for risk for 
depression, and conversely, that depression influences changes in RA disease activity 
[10, 11, 16].  RA and depression could be fundamentally related via biological, 
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psychological, or behavioral mechanisms, or by some combination thereof [16-24].  
However, the relationship between RA disease activity and depression is still unclear, and 
few longitudinal studies have examined the temporal associations between these two 
conditions. 
  
1.2 Estimates and Effects of Depression in Rheumatoid Arthritis 
The prevalence of RA among United States (US) adults 18 or older is 
approximately 0.6%, and depression is a frequent problem experienced by RA patients, 
with data suggesting the cumulative risk for depression reported over nine years to be 
38.3% (95% CI 36.6-40.1%) [1, 25].  Meta-analysis evidence of studies using diagnostic 
criteria to assess major depressive disorder (MDD) in RA patients has estimated the 
prevalence to be 16.8% (10%-23%), as compared to 6.8% in the general population [26, 
27].  Moreover, depression is under-recognized in routine rheumatology practice by 
treating physicians [10, 12].  Yet notably, National Institute for Health and Care 
Excellence (NICE) guidelines recommend that physicians be aware of depression among 
patients with chronic physical disease [28].  The co-occurrence of depression may 
influence disease activity, treatment persistence, and outcomes from therapy, and thus 
rheumatologists should be aware of its presence in their patients [12, 29].  
There are a variety of deleterious effects associated with presence of depression in 
RA patients.  Research using National Databank for Rheumatic Diseases (NDB) data 
showed that RA patients followed for a median of 4.9 years were at an increased risk for 
mortality (HR=2.2; 95% CI: 1.2-3.9) [6].  Other longitudinal research using Veterans 
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Administration data showed RA patients classified as having depression were at an 
increased risk (HR=1.4; 95% CI: 1.1-1.8) of experiencing MI [7].  Also, the presence of 
depression among RA patients creates an increased propensity for work disability and 
need for health care resources, and estimates intimate that in RA patients suffering from 
comorbid depression have up to a 60% higher probability of experiencing work disability 
compared to those without depression [8].  In addition, the adjusted annual difference in 
direct medical costs due to comorbid depression between RA patients with and without 
depression has been estimated to be approximately 7.2% ($12,225 vs. $11,404) per 
patient per year [9]. 
Clinical recommendations advise that RA patients with major depressive disorder 
receive prompt treatment for it; however, among RA patients, depression is not 
adequately recognized, and nor does it receive the attention and management it requires 
[10-12].  When co-existing together, medical management of depression and a chronic 
physical disease becomes complex, and depression generally results in poorer response to 
the treatment of the chronic condition [14].[15] Researchers have posited that the 
treatment of either condition should result in improvements in both; yet, a of review 
interventional study data indicated that a unimodal treatment approach will not lead to 
improvements in both conditions.  More importantly, when specifically treating 
depression, patients will sometimes have a poor clinical response to the depression 
treatment [15].  Therefore, understanding how depression interacts with RA is paramount 
due to the gap between current medical practice and the present state of the content 
knowledge.  
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1.3 Evolution of RA Treatment 
In the last two decades there have been immense changes in the available 
pharmacological treatment for RA; specifically, biologic disease modifying anti-
rheumatic drugs (DMARDS).  The medications became available for RA in 1998, and 
their utilization in some populations was estimated to be 13.5% in 1999, which tripled in 
7 years to 41.4% [30].  In addition, the proportion of patients initiating a biologic agent 
who also have comorbid depression is approximately 19% [31].  These agents have 
revolutionized the treatment of RA because they not only increased within-patient 
clinical response, but also provided viable therapeutic options for the many patients who 
do not respond to conventional DMARDS.  There is research that was performed before 
the innovation of biologic DMARDS that examines associations between RA disease 
progression and depression and allows for temporal associations.  Although, research 
conducted prior to their availability, or with data containing only outcomes before this 
time period, is much less relevant to current RA patient populations because of the drastic 
changes in treatment strategies that are employed in the clinical setting. 
 
1.4 Bi-directional Effects 
  The mechanisms and interactions of depression and RA disease progression are 
still relatively unclear, but the association between the conditions is bi-directional [11, 
16].  Researchers have posited that depression is inflammatory condition, and thus may 
be pathologically linked to the etiological mechanisms in RA disease activity through 
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proinflammatory cytokine pathways [16, 17].  Evidence has demonstrated that major 
depression is accompanied by the activation of cell-mediated immunity.  Meta-analyses 
of cross-sectional studies have consistently demonstrated positive correlations between 
various cytokines and the presence and severity of depression.[18, 32].   
 Depression and RA disease activity may also be connected by way of 
psychological processes.  Depression researchers have argued that MDD is a mental 
process characterized by perpetual negative thinking [19].  This process of repetitive 
negative thinking, known as preservative thought, has been shown to be predictive of 
poor response to experimental challenges, as well as the presence and severity of major 
depressive disorder [33].  Thus, the association between depression and RA disease 
activity could be due to patients’ cognitive frame of mind, whereby depression acts a 
response shift.  This response shift may cause RA patients to react by choosing the most 
negative response option available concerning subjective self-reported subjective disease 
activity measures.   
Alternatively, depression has an impact on physical behavior, particularly 
peoples’ functional independence and engagement in activities of daily living [21, 34, 
35].  The act of moving less due to a lack of motivation or negative thinking may cause a 
deconditioning of the body and loss of natural endorphins, which in turn can influence 
pain and depression [24, 36, 37].  Despite such evidence, there is little longitudinal 
research regarding depression and rheumatoid arthritis disease progression that allows for 
temporal interpretations.  Due to the bi-directional effects, studies examining independent 
and dependent variables at the same measurement time point, or interventions that 
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simultaneously impact both depression and RA, cannot provide evidence and estimates of 
temporal associations.   
 
1.5 Temporal Influence of RA Disease Progression on Depression 
 Certainly, it is plausible that RA symptoms lead to the development or changes in 
depression.  The few relevant cohort studies conducted focused on the association of 
functional status with the presence of future depression or depressive symptoms [38-43].  
Functional status is not a sensitive marker of RA disease activity, and the derived 
findings from this body of research have been rather conflicting.  Some observational 
studies have found no temporal association between functional status and depression [38, 
43].  Conversely, other research has demonstrated a link between functional status and 
future depression [39, 39, 42].  Only two studies have examined RA disease activity 
measures other than functionality, with one showing an association of pain and future 
depression, and the other finding no association between composite disease activity 
scores and future depression [42, 43].  It should be noted some, or all of these studies, 
had inadequate adjustment for confounders, short follow-up durations, and small sample 
sizes.   
 Interventional studies (e.g., DMARDS) using RA treatments also permit causal 
interpretations, because theoretically, in subjects receiving a treatment that solely impacts 
RA symptoms, the observed longitudinal effect on depression should be due to reductions 
in RA disease activity.  Quasi-experimental and Randomized Clinical Trial (RCT) 
research among RA subjects receiving a variety of clinical therapies, such as short-term 
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corticosteroid pulse treatment or a combination of methotrexate (MTX) and etanercept 
(ETN), showed that reductions in RA disease activity measures were accompanied by 
corresponding decreases in depressive symptoms [44, 45].  These results suggest that 
through alleviating RA disease activity, it is possible to ameliorate depressive symptoms, 
which implies a temporal link between the symptomology of RA and depressive 
symptoms.  Despite such potential evidence, using such research to evaluate this 
relationship leaves it entirely unclear what specific RA disease activity characteristics are 
associated with the observed intervention effects on depression.   
1.6 Temporal Influence of Depression on RA Disease Activity 
The diametrically opposing counterpoint, depression may influence longitudinal 
changes in RA disease activity, but only a small number of pertinent studies that have 
examined temporal associations [46-49].  These studies have primarily examined patient 
reported-pain, and depression or depressive symptoms as a moderator of the 
psychological factors related to this outcome.  Research has demonstrated baseline 
depressive symptoms to be predictive of elevations in future pain, and data also suggests 
that prior depressive episodes are a predisposing risk factor for elevated pain responses 
[46, 49].  However, other evidence intimates that a history of depression is not associated 
with pain when accounting for concurrent depressive symptomology [48].   
Only one study examined disease activity outcomes other than pain, which 
included the physician global assessment and tender joint count.  It suggests depression 
moderates changes in disease activity associated with stress, but this effect did not appear 
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to be related to cell-mediated immunity.[47].  All of the described studies had substantial 
methodological limitations, but more importantly, there is no evidence regarding 
depression and its direct temporal impact on functionality, joint counts, acute phase 
reactants, composite indices, and other standard markers of RA disease progression.  
Consequently, it is unclear if depression has a substantive effect on joint symptoms and 
inflammation or merely influences how patients respond to the subjective self-reported 
measures of RA disease activity.   
 
1.7 Depression as a Moderator of RA Treatment Persistence and Response 
The detrimental influence of depression may also extend to RA treatment, and not 
many studies have investigated the association of depression with DMARD persistence 
and response, of which have mixed results and methodological constraints.  Research has 
demonstrated that depression increases patients’ risk (HR=1.68; CI 1.08-2.60) for 
DMARD discontinuation [50].  Other data suggests that comorbid depression, is not 
related to DMARD persistence [51, 52].  However, DMARD discontinuation for any 
reason is not the most appropriate outcome, and could explain why some research has 
derived null findings.  Discontinuations due to such reasons as adverse events or provider 
preference are not related to depression, and a more appropriate outcome is 
discontinuation strictly due to inefficacy.   
Studies have also assessed the direct moderating effect of depression on DMARD 
treatment outcomes [53, 54].  One determined baseline depression to have no moderating 
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effect on long-term DAS 28 response to anti-TNF therapy [53].  Conversely, other 
research has revealed significant moderating effects of baseline depression on long-term 
DMARD response to a variety of different RA disease activity measures [54].  Persistent 
depression may also decrease short-term anti-TNF efficacy [53].  Although, the impact of 
depression could vary by patients’ clinical remission status [54].  Depression may 
significantly decrease clinical response to DMARD therapy, but current findings are 
limited and based on no or little adjustment for confounders, highly restricted patient 
populations, and do not methodically assess how depression moderates response to 
treatment. 
 
1.8 Conceptual Framework 
Researchers have posited the 
relationship between RA disease 
activity and depression to be bi-
directional, and this forms the basis of 
the conceptual framework for this 
dissertation [10, 11, 16].  A bi-
directional association implies that RA disease activity has a temporal influence on 
longitudinal changes in depression, and vice versa, that depression has an effect on the 
prospective manifestation or perception of RA disease activity (Figure 1).  Observational 
studies utilizing similar bi-directional conceptualizations in other arthritic patient 
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populations, such as early inflammatory arthritis (EIA) and psoriatic arthritis (PsA), 
which focused on the pain and depression, have previously been conducted [55, 56].  It is 
believed that the presence of depression worsens the experience of future RA disease 
activity, be it due to a biological, psychological, or behaviorally mediated process, or 
some combination thereof, and that RA disease activity confers a temporal risk for the 
presence of depression.  In addition, we hypothesize that depression has a moderating 
influence on response to biologic DMARD therapy among patients with RA, where 
depression significantly decreases clinical response to biologic DMARD treatment. 
 
1.9 Summary 
The proposed research will quantify the burden of depression in a large RA 
cohort, the bi-directional association of an array of different RA clinical measures with 
depression, and the moderating influence of depression on clinical response to biologic 
agents.  There is little empirical evidence describing the extent that depression is 
recognized in routine rheumatology, and using patient-reported and physician-reported 
measures will be used to compare and quantify depression rates and agreement between 
RA patients and their treating rheumatologists..  In addition, an estimation of the bi-
directional association between RA symptoms and depression has never been examined 
regarding temporality and the multi-factorial nature of disease activity.  Through the 
application of the appropriate methodologies, estimations of the bi-directional effects can 
be obtained.  Also, the moderating effect of depression on biologic DMARD response 
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has never been assessed in a large observational RA cohort with adequate adjustment for 
confounders.   
This research will build upon prior work and has several implications.  Foremost, 
it will determine the extent to which depression is recognized in rheumatology practice 
by treating physicians.  More importantly, the derived findings will be used to inform 
rheumatologists of how depression impacts RA disease outcomes, including disease 
activity and treatment. Conversely, it will also generate data that can aid practicing 
clinicians in their understanding of the specific aspects of RA disease progression that 
confer a risk for depression.  The findings from the research will create an overarching 
causal framework that can be used for all subsequent investigations into the specific 
mediating biological, psychological, and behavioral factors between depression and RA.  
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CHAPTER II: 
A COMPARISON OF PATIENT AND RHEUMATOLOGIST REPORTED 
DEPRESSION MEASURES IN AN AMERICAN RHEUMATOID ARTHRITIS 
REGISTRY POPULATION 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
 
2.1 Abstract 
Background: Depression is a common comorbidity in individuals with rheumatoid 
arthritis (RA), which may be under-recognized by treating rheumatologists.  The study 
aim was to compare and contrast rates of depressive symptoms and their associations 
with RA disease activity using measures reported from patients and rheumatologists.  
Methods: The Consortium of Rheumatology Researchers of North America (CORRONA) 
registry is an observational cohort with data on more than 33,000 RA patients.  Using 
depression measures reported separately by patients and physicians, lifetime prevalence, 
12-month prevalence, and annualized incidence rates (IR) were estimated.  Measurement 
concordance and disagreement between patient and rheumatologist reports of depression 
were also examined.  Additionally, baseline cross-sectional associations between RA 
disease and a history of depressive symptoms were assessed.   
Results: Lifetime prevalence estimates of 26.5% and 12.9% were reported by patients and 
rheumatologists, respectively.  Similar findings were observed for 12-month prevalence 
rates, and the magnitude of the difference in reporting increased.  The annualized IR from 
the self-reported depression measure was approximately 7.8 per 100 patient-years, 
compared to 0.4 per 100 patient-years reported by their rheumatologists.  There was 
moderate to little measurement agreement, which appeared to depend on the time of 
onset, and the depression prevalence and incidence rates were significantly different 
between patients and rheumatologists.  Lastly, increased disease activity at enrollment 
was associated with a higher probability of reporting a history of depressive symptoms.  
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Conclusions: RA patients have a high likelihood of experiencing depression, and there 
were discrepancies between reports from patients when compared to their treating 
physicians.  Rheumatologists appeared to under-report depression, particularly when 
occurring more recently in time, implying they may not be aware of the presence of 
depressive symptoms among their RA patients.  Thus, estimates of prevalence and the 
impact of these symptoms need to be interpreted based on the source of the diagnosis.  
Collectively, the findings suggest that depressive symptoms are an important comorbidity 
that practicing rheumatologists should be aware of during clinical encounters. 
 
2.2 Background 
Depression is a common psychiatric comorbidity in patients with rheumatoid 
arthritis (RA), the most common autoimmune inflammatory arthritis, affecting 1.29 
million American adults 18 years or older [1, 40].  Studies using the Diagnostic and 
Statistical Manual of Mental Disorders (DSM) diagnosis criteria has estimated the point 
prevalence of major depressive disorders (MDD) in RA patients to be between 10%-23% 
[3, 57-59].  Furthermore, a meta-analysis determined that depression status is more 
common in RA patients when compared to healthy controls, independent of 
sociodemographic characteristics [5].  Comparatively, the 12-month prevalence of 
depression in the American adult population has been estimated to be only 6.6%, which is 
approximately half, or less, than the rate observed in the RA population [27].      
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 The ramifications of depression in RA patients are numerous and far reaching.  
Depression likely influences RA symptoms, treatment persistence, and clinical outcomes 
from therapy [46, 47, 50, 53, 54].  Research has shown that depression is temporally 
associated with future increases in patient-reported pain and increased moderating effects 
on disease activity as measured by physician global ratings and tender joint counts [46, 
47].  Depression may also influence disease modifying anti-rheumatic drug treatment and 
could result in an increased risk for discontinuation and poor therapeutic response [50, 
53, 54].  Moreover, depression exacerbates the impact of RA on overall health and 
function and is associated with higher mortality, an increased risk for myocardial 
infarction, greater work disability, and elevated healthcare expenditures [6-9].  Despite 
the potential consequences, researchers suggest that among RA patients depression is 
often under-recognized [10, 11].            
 Given the high frequency of occurrence and its association with unfavorable RA 
outcomes, depression is an important comorbidity that practicing rheumatologists should 
be aware of in their patients.  Health care management for RA is chronic, and patients 
commonly have more visits with their rheumatologists as compared to their primary care 
provider (PCP), while some patients may not even have a PCP [60].  However, a study 
examining communication about depression revealed that among RA patients classified 
with moderate to severe depression, only 19% discussed depression during visits with 
their rheumatologists, and more importantly, in every instance, the conversation was 
initiated by the patient [61].  In contrast, research has demonstrated that in the primary 
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care setting, where depression is discussed during 25% of visits, patients will begin the 
dialogue approximately 55% of the time [62].  
No research has assessed symptoms of depression using patient and physician 
depression measures reported separately from patients and rheumatologists in a large RA 
registry population.  The study objectives were to: (1) calculate depressive symptom rates 
and assess measurement concordance and disagreement using patient- and 
rheumatologist-reported depression measures and (2) examine the cross-sectional 
association of RA disease activity with a history of depression symptoms, using a 
national RA registry.  We postulated there would be a high burden of prevalent and 
incident reports of depressive symptoms and that greater RA disease severity would be 
associated with a higher likelihood of prior manifestation. 
 
2.3 Methods 
Data Source 
 The data for this study were an existing longitudinal cohort, the Consortium of 
Rheumatology Researchers of North America (CORRONA) registry.  The operation and 
funding mechanisms for the CORRONA registry have been published previously [63].  
Patients enrolled in the CORRONA registry are recruited during routine clinical visits 
from academic and community rheumatology practices and are followed as often as every 
three months.  Data collection began in 2001 and as of August 2012, data had been 
collected on >33,000 RA patients from 150 academic and community rheumatology 
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practices across the United States (US).  Data are gathered from patients and clinicians 
using standardized enrollment and follow-up survey forms and capture information on 
demographics, disease activity, disease severity, medication use, adverse events, and 
comorbidity.  CORRONA data collected up until August 2012 were used for the present 
analyses.  Patients are approved for enrollment into the CORRONA registry through the 
Institutional Review Boards (IRB) of institutions or a central IRB for academic and 
community rheumatology practices, respectively. 
Study Population 
 RA patients (N=15,604) enrolled between July 1, 2008 and August 13, 2012, the 
time period where both patient-reported and rheumatologist-reported depression 
measures were available, were used for the analyses (Figure A.1).  This sample was 
restricted to those with no missing self-reported or rheumatologist-reported depression 
data at study entry (N=14,755), and it was used to evaluate the lifetime prevalence of 
depression symptoms.  To examine the 12-month prevalence, participants (N=14,594) 
with reported depression data at the time of enrollment but no symptom onset 
information (n=161) were restricted.  For incident reports of depressive symptoms, 
patients were limited to a sample (N=7,555) where those with a history of prior 
manifestation at enrollment (n=4,190) and no follow-up visits (n=3,010) were excluded.  
The cross-sectional analysis was conducted using the primary analytic cohort 
(N=14,755), among patients with no missing data on possible confounders (N=11,506), 
and the primary factor of missing information was antidepressant medication use 
(N=1,519).   
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Measures 
 The depression symptom measures were single-item assessments.  CORRONA 
data collection forms obtain information on ever having depression symptoms at 
enrollment, the time of onset, and the presence of depressive symptoms at follow-up 
visits.  Patient enrollment surveys instruct participants to, “Please fill a ‘NO’ or ‘YES’ 
circle for each of the following conditions you have EVER had,”  including “Depression 
(Feeling Blue).”  This measure incorporates a component for the time of comorbidity 
onset where patients can indicate “YES” in the context of categorical indicators (e.g., 
“YES 1 – 5 years ago”).  Rheumatologist enrollment forms collect comorbidity data, 
including the time of onset, and rheumatologists are instructed to do the following: “If the 
patient has or has had any of the following,” which contains an item for “Depression” and 
the “MM/YY” time of onset.  Follow-up forms ask participants to indicate any “Medical 
condition or symptom you have had SINCE YOU LAST FILLED OUT THIS FORM,” 
and has an item for “Depression (Feeling Blue).” The rheumatologist follow-up surveys 
collect data on all new comorbities and have the same instructions and items as the 
enrollment forms.   
Depression as described in this study does not imply MDD as diagnosed using 
DSM criteria.  However, self-reported depressive symptoms, including questions about 
being “depressed,” are what are commonly used to assess the condition during routine 
clinical care [64].  Single-item patient-reported depression symptom measures have been 
used in prior research in a RA registry population and have demonstrated adequate 
reliability and convergent validity, and meta-analysis data suggests a high level of 
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sensitivity but low specificity [65].  Our process reflects the current American health care 
system, where patients are often the source of medical information and responsible for 
communicating between different providers when electronic medical records are not 
available.  PCPs do not regularly send clinical updates to specialists, and research has 
shown that general practitioners have a greater accuracy in reporting medical problems 
when compared to specialists [66].  Rheumatologists must ask patients about diagnoses 
and care they received from other physicians, and the rheumatologist measure is a 
reflection of whether they communicate with them about depression during clinical visits.    
Disease activity was assessed using composite indices, joint counts, global 
assessments, pain, and functional status.  The clinical disease activity index (CDAI) is a 
summary score of the tender joint count based on 28 counts (TJC), swollen joint count 
based on 28 counts (SJC), patient global assessment of disease activity (PGA; visual 
analogue scale (VAS) 0-10 cm), and physician global assessment of disease activity 
(EGA; VAS 0-10 cm) [67].  The 28 joint count disease activity score (DAS28) is 
calculated from the TJC, SJC, PGA, and the erythrocyte sedimentation rate (ESR) using a 
formula [68].  The other measures that were used included the core component 
assessments previously described: TJC, SJC, PGA, and EGA; and patient pain (VAS 0-
10 CM) and the health assessment questionnaire score (HAQ), converted from the 
modified HAQ (mHAQ) values [69, 70].          
Self-reported demographic variables included gender, age, race/ethnicity, 
education, marital status, employment, and health insurance.  Race/ethnicity was reported 
as one the following: White, Black, Asian, Other, or Hispanic.  Patients’ age at 
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enrollment was categorized: 18-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75-84, and 85+.  
Education level was captured as one of four categories: primary, high school, 
college/university, and don’t remember.  Marital status was coded into 4 groups: single, 
married/partnered, widowed, and divorced/separated; and employment was characterized 
using the following categories: full time, part time, unemployed, student, disabled, and 
retired.  Lastly, health insurance was organized into four mutually exclusive groups 
groups: none, Medicaid, Medicare, and private.      
Other covariates were smoking, alcohol use, exercise habits, body mass index 
(BMI), antidepressant use, comorbidity, disease duration, and the clinical disease activity 
index (CDAI).  Smoking and alcohol were binary measures (yes vs. no), and exercise was 
one of five categories: not at all, 1-2 times per week, 3-4 times per week, 5-6 times per 
week, and daily.  Comorbidity was measured as a composite index (0-9) based on reports 
of past or present conditions from either the patient or physician that included myocardial 
infarction, stroke, hypertension, other cardiovascular disorders, diabetes mellitus, 
pulmonary disease, cancer, peptic ulcer, other gastrointestinal disorders, and fractures 
[25].  Antidepressant use was captured as the current utilization of any medications 
reported by patients.   
Statistical Analysis 
The analyses were conducted in the common sample restricted to where both 
depression measures were available.  Lifetime prevalent depression was defined as a 
history depression at study enrollment; the 12-month prevalence of depression was 
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operationalized as having both a history of depression at enrollment and a reported onset 
occurring in the last year; and incident depression as the first longitudinal report of 
depression in patients with no prior depression.  Associations with the previously 
described covariates were examined separately for the two different baseline depression 
measures, using t-tests, chi-square tests, and Wilcoxon rank sum tests, between those 
reporting and not reporting a history of depression.  Lifetime prevalence, 12-month 
prevalence, and annualized incidence rates were calculated overall by gender, race, 
ethnicity, and baseline age grouping.  Measurement agreement for prevalent and incident 
reports of depression between the patient and rheumatologist measures was quantified 
using Cohen’s kappa and % agreement [71].  In addition, agreement estimates were 
calculated in patient subsets for prevalent depression stratified by the time of reported 
onset, being “< 1 Year” and “>= 1 Year.”  Also, the direction of measurement 
disagreement was assessed using McNemar’s Test of Homogeneity for paired data.  
Gender and age standardized lifetime depression prevalence estimates were 
calculated two ways: (1) standardizing CORRONA rates to gender and age distributions 
given in publications using nationally representative samples; and (2) standardizing 
estimates obtained from a nationally representative sample to the CORRONA RA 
population.  They were calculated two ways to illustrate the impact of patient 
demographics on depression prevalence estimates.  Demographic data in manuscripts was 
given by gender and by age groups, and thus the calculations assumed that age 
distributions were equal between genders.  CORRONA estimates were standardized to 
2000 U.S. census data used in Kessler et al. and the National Epidemiologic Survey on 
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Alcohol and Related Conditions (NESARC) population distribution provided in Grant et 
al. [27, 72].  To apply estimates from NESARC data in Hasin et al. given by age and by 
gender, age specific depression rates within each gender had to be generated [73].  The 
NESARC estimates given by age and by gender were assumed to have a constant ratio of 
the rates by age group within each gender.  Using the known NESARC population 
distribution, age specific prevalence rates were calculated within each gender, and then 
standardized to the CORRONA RA population. 
Mixed-effects logistic regression was used to examine the cross-sectional 
association of RA disease activity with prior depressive symptoms at study entry.  There 
were two outcomes: a history of (1) patient-reported and (2) rheumatologist-reported 
symptoms of depression.  CORRONA data is structured such that patients are nested 
within rheumatologists, and rheumatologists are clustered in clinical sites.  Patient 
outcome models were clustered by site as standard error estimates were similar to the 
fully nested model, and there was a low within-rheumatologist correlation after 
accounting for within site correlations.  Rheumatologist outcome models were clustered 
by rheumatologists because the measure was reported by the treating medical specialist, 
and standard error estimates were comparable to the fully nested models.  Predictor 
variables included the previously described RA disease activity measures, and to compare 
each of the different disease activity measures across multivariable models, they were 
coded as categorical quintiles.  Unadjusted associations were evaluated and models 
adjusting for possible confounders that were selected a priori. 
Sensitivity analyses utilized two composite depression definitions: combining (1) 
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the patient-reported and clinician-reported depression data, and (2) patient-reported 
depression and anti-depressant use information, which were used to create two types of 
composite definitions.  These composite depression criteria were applied to the 
prevalence and incidence analyses.   
 
2.4 Results 
Patient Characteristics 
The primary common measurement sample comprised 14,755 RA patients (Table 2.1).  
Participants were predominantly middle-aged females, and there were significant 
differences for all baseline covariates by reported depression history, for every variable 
except education.  The associations of patient attributes with prior depression were 
similar for the two depression measures.  Those with prior depression at study entry were 
more likely to be female, younger, divorced or separated, and not have full time 
employment.  In addition, in patients with a history of depression there was a higher 
frequency of smoking, lower levels of exercise, and increased disease duration, disease 
activity, BMI, comorbidity, and antidepressant use.  
Lifetime Prevalence of Depression 
The lifetime prevalence of depression reported by patients was 26.5%, compared 
to 12.9% by rheumatologists (Table 2.2).  The patterns by patient demographics were 
uniform between the two measurement sources.  Prior depression was most common in 
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females, those white or other and middle aged, while lower among males, Asians, the 
young, and elderly.  A marked feature was that the history of depression reported by RA 
patients was consistently twice that of rheumatologists, evidenced by the lack of strong 
measurement agreement (kappa=0.46) and statistically significant test of homogeneity 
(Table A.1).  The measurement disagreement was in one direction; the providers did not 
report prior depression in a large number of patients who indicated having a history of 
depression at study entry.  The age and gender standardized CORRONA patient-reported 
rates were approximately 22% (Table 2.3), lower than the original estimate, yet still 
higher than the comparators in Kessler et al. (16.2%) and Hasin et al. (13.2%).  A similar 
effect was observed when standardizing NESARC rates to the CORRONA RA 
population. The estimate increased from 13.2% to 15.0%.  Results from sensitivity 
analyses using composite depression measures were lower than estimates obtained from 
the patient measure, but did not noticeably differ in any other regard (Table A.2).     
12-Month Prevalence of Depression 
The 12-month prevalence of depression was estimated to be approximately 11.7% 
and 1.0%, reported by patients and rheumatologists, respectively (Table 2.4).  In general, 
the prevalence trends between the measurement sources concerning gender, 
race/ethnicity, and age grouping persisted, with some slight differences in the higher age 
categories.  Also of note, was the growth in the magnitude of the measurement 
discordance, which increased by more than five-fold, and relative differences were all > 
80%.  When stratified by the reported time of depression onset (< 1-year and > 1 year), 
the crude measurement agreement suggested less congruence for depression that had 
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occurred more recently in time: kappa=0.07 for depression with an onset of < 1-year; and 
kappa=0.37 for depression with a reported onset of > 1-year (Table A.1).  Similarly, tests 
of symmetry were statistically significant and the measurement incongruence was again 
in one direction, being driven by rheumatologists not reporting depression in many 
patients who indicated having prior depression at study enrollment.   
Incident Reports of Depression 
The annualized depression incidence rate (IR) reported by RA patients was 7.8 
per 100 patient-years, considerably higher than the rheumatologist-reported rate of 0.4 
per 100 patient-years (Table 2.5).  IR trends were similar across gender, race/ethnicity, 
and age groups, but in some subgroups, comparisons could not be made because of a lack 
of clinician-reported events.  Reports of depression were more common in females and 
Hispanics, but did not display any particular patterns by baseline age group.  The most 
prominent attribute was the discrepancy in IRs between the measurements sources, which 
again increased as the proximal time from depression onset decreased (mean inter-visit 
time=5.4 months), as indicated by relative differences in IRs overall and by every 
category of > 90%.  There was little longitudinal measurement agreement (kappa=0.03), 
and the test of homogeneity for paired data was statistically significant (Table A.1), 
suggesting very limited concordance; however, this in part is due to the high expected 
agreement (96.6%) driven by the large number of follow-up visits with no reports of 
depression.  Data from sensitivity analyses using a composite definition of longitudinal 
reports from patients and rheumatologists were extremely low because of very few events 
(N=26) (Table A.3).  Conversely, when patient-reports of depression and antidepressant 
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medication use measures were combined the IRs were still substantially higher than the 
rheumatologist based estimates.   
Cross-Sectional Associations 
In unadjusted models, every measure of disease activity was positively associated 
with prior depressive symptoms for both outcome measures (Table 2.6 and A.4).  Higher 
disease activity at study entry was associated with an increased likelihood of reporting 
past symptoms of depression, and unadjusted effect sizes were comparable between the 
two outcome measures.  Of the predictors associated with a history of manifestation, the 
strongest in magnitude were the PGA, patient pain, and HAQ.  Adjustment for possible 
confounders attenuated the associations, and this decrease in risk was greater when using 
the rheumatologist-reported outcome measure.  For the patient-reported outcome, the 
DAS28 and SJC lost statistical significance, compared to the DAS28, SJC, and EGA, 
regarding the rheumatologist-reported outcome.  Sensitivity analyses using composite 
depression outcomes variables were similar to the primary findings (data not shown). 
 
2.5 Discussion 
In this RA registry, there were high patient-reported levels of prevalent 
depression, greater than the general population [27, 73].  Conversely, the rheumatologist-
reported prevalence estimates were consistently equal to, or lower than, national 
estimates [27, 73].  CORRONA patient-reported depressive symptom IRs were higher 
compared to estimates from the National Databank for Rheumatic Diseases (NDB) and 
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rates for healthy individuals from studies using community based samples, while those 
reported from their treating rheumatologists were lower [25, 74].  Moreover, there 
appeared to be a trend in the measurement disagreement, whereas the time from onset 
decreased, the greater the level of discordance.  The cross-sectional results parallel other 
studies demonstrating that disease activity is associated with symptoms of depression, yet 
the adjusted effect sizes and number of significant associations was greater for the 
patient-reported outcome [22, 75].  The findings suggest a high frequency of depression 
among CORRONA RA patients, under-reporting by rheumatologists, and that increased 
disease activity is associated with its past manifestation.    
If the patient-reported estimates were extrapolated, they imply one-fourth of RA 
patients may have past depression, and the age and gender standardized CORRONA 
lifetime prevalence estimate of 22% is substantially higher than comparator rates from 
U.S. general population (13%-16%) [27, 73].  In 50% of these instances, rheumatologists 
reported disparate information; yet, prior research would suggest no significant 
differences in patient-proxy responses when assessing medical history [76].  These data 
are similar to results from the Medical Outcomes Study, in which upwards of 50% of 
patients with current MDD, the condition went unrecognized when visiting a PCP [77].  
There are three plausible explanations: rheumatologists’ under-report depression; they 
differ from patients in their definitions and thresholds for defining depression; or patients 
and clinicians differ in their knowledge of the patient’s depression history.  If clinicians 
under-report depression then this comorbidity maybe under-recognized, but the lifetime 
prevalence reported by patients could be an overestimation as they are not DSM 
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diagnoses.  The lifetime prevalence in normal individuals is between 13-16%, and thus 
the rheumatologist rate (12.8%) would indicate a similar likelihood of ever having 
depression when compared to the general population [27, 73].  Moreover, the point 
prevalence of MDD in RA patients has consistently been estimated to be > 10%, 
compared to 6.6% in the general population, and therefore, it is unlikely the risk among 
RA patients is equal to or lower than that in healthy individuals [3, 27, 57-59]. 
The 12-month prevalence rates of 11.7% and 1.0% indicated a stronger 
disagreement for more recently occurring depression, and patients and rheumatologists 
did not merely differ in their knowledge of the patient’s depression history.  The 
agreement statistics stratified by time of onset also suggested greater congruence for 
depression reported to manifest > 1-year prior to study entry.  The 12-month patient-
reported value is within the spectrum of estimates for the point prevalence of MDD in 
RA patients (10%-23%), but still higher than the general population (6.7%) [3, 27, 57-
59]. In contrast, the 12-month clinician-reported estimate is much lower (> 6x) than what 
would be expected in normal individuals [27].  This difference in reporting could be 
affected by response bias, defined as a systematic over- or underreporting by an external 
rater, and the more subjective the construct, e.g. mental illness, the higher the likelihood 
there will be discrepancies between the self- and external ratings [78].  Although, for 
depression and psychological well-being, the literature suggests proxies tend to report 
more symptoms and problems compared to patients, particularly clinicians [79, 80].  
Thus, in this scenario, theoretically any patient-proxy respondent bias would cause an 
underestimation of the true disagreement.  Another potentially complicating factor is 
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state-dependent recall bias, but a prohibitive amount of misclassification would be 
necessary to alter or account for the immense differences [81].   
The self-reported IRs were much larger than the rheumatologist-reported IRs, 
evidenced by the measurement disagreement, a ratio of approximately 20:1 (7.8 per 100 
patient-years vs. 0.4 per 100 patient-years).  The patient rates are within or outside the 
upper limit of the range of estimates for the incidence of MDD in the general population, 
while the rheumatologist-reported rate is less than one–fourth of the lowest observed 
incidence rate of MDD in normal individuals (1.8-7.5 per 100 patient-years) [74].  These 
findings may be partially explained by the single-item patient measure, likely 
representing the presence of depressive symptoms rather than clinical depression, and 
thus resulting in inflated IR estimates.  However, the more similar and simplistic the 
measure, the greater the level of response-precision, and studies have demonstrated 
greater agreement for simple questions asking the presence and absence of symptoms, 
when compared to scales assessing symptom intensity [78].  The crude depression 
measures may lead to over-reporting by patients, but they should also facilitate a 
comparison of the measures.  Current National Institute for Health and Clinical 
Excellence (NICE) guidelines recommend that physicians be aware of depression in 
patients with chronic physical disease [28].  Notably, the magnitude of the incongruence 
at follow-up visits was larger compared to study entry, where data collection is more 
comprehensive and the average time since depression onset greater.     
Prior symptoms of depression were associated with every RA disease activity 
measure, but these predictors had a stronger correlation with the patient-reported 
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outcome.  Many studies have examined cross-sectional associations between prevalent 
depressive symptoms and RA disease activity, and pain and functional status have been 
consistently linked to their presence [22, 57, 75, 82].  These variables were amongst the 
most strongly associated with past depressive symptoms; however, the CDAI, TJC, and 
PGA were also associated with the outcomes.  The difference in the magnitude and 
number of adjusted significant associations between the outcomes parallels the 
descriptive data and could explain the lower adjusted effect sizes for the rheumatologist-
reported outcome.  Given that disease activity displayed the hypothesized associations 
that are similar to data from prior cross-sectional studies [22, 75, 82-85], but also 
corresponded to the observed differences in the CORRONA population rates, these 
results further confirm the validity of the patient-reported measure of depressive 
symptoms to identify this comorbidity. 
Strengths and Limitations 
The primary strengths of this study include the large population based registry 
sample, physician diagnosed RA case ascertainment, and patient and provider reported 
data sources.  This study also has some limitations.  The single-item depressive symptom 
measures are not indicative of MDD as diagnosed by DSM criteria, and neither the 
frequency nor severity of the symptoms was assessed. Also, there were slight differences 
between the patient and rheumatologist depression metrics, which may have influenced 
the results.  The patient-reported measure is more an assessment of symptoms of 
depression, which represents the core expression of the disorder, rather than a measure of 
clinical depression.  This could have resulted in a degree of overestimation regarding the 
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patient-reported rates, but when the results of this study were contrasted to prior research, 
the presence of such bias seemed very minimal.  Moreover, feeling “depressed” is a 
critical symptom of MDD and is what is typically used in routine clinical practice to 
identify patients with this comorbidity [64]. 
2.6 Conclusions 
There are several implications from this research.  The data revealed high patient-
reported depression symptom rates in a large registry sample, and conversely, 
rheumatologist-reported comorbidity rates that were much lower than what their patients 
indicated.  Additionally, cross-sectional analyses demonstrated strong associations 
between multiple domains of disease activity and prior symptoms of depression that 
paralleled the descriptive results.  Based on the known depression rates in RA patients 
and the general population, the rheumatologist-reported estimates are implausibly low 
and likely represent under-reporting.  Current literature would suggest the cause is a lack 
of awareness about depression among rheumatologists, and studies have shown that 
medical specialists are not attentive to depressive disorders [61, 64].  This gap in clinical 
care needs to be addressed because depression in RA is associated with worse overall 
health, increased disease activity, decreased medication persistence, lower therapeutic 
response, and difficulties in medical management [6-9, 15, 29].  Consequently, and in 
accordance with NICE guidance, rheumatologists need to regularly assess for the 
presence of affective symptoms in their patients to provide the best care possible and 
address any challenges due to depression [28].  To better understand the epidemiology 
and severity of depressive symptomology in their RA patients, rheumatologists should 
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regularly ask patients about the condition or utilize 1- or 2-item ultra-brief symptom 
measures, such as the Patient Health Questionnaire-2 item scale, which have high 
sensitivity and specificity and been validated in patients with chronic physical disease 
[86, 87]. 
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Table 2.1 Descriptive data in CORRONA RA patients for the primary analytic cohort by lifetime prevalent 
depression status concerning each of the two depression measures. 
  Measurement Source 
Variable Patient-Reported Depression Clinician-Reported Depression 
  
Yes  
(N=10,852) 
No 
(N=3,903) 
P Yes  
(N=12,849) 
No 
 (N=1,906) 
P 
Female 3,313 (85.01%) 8,012 (73.88%) <0.001 1,634 (85.73%) 9,691 (75.50%) <0.001 
Race/Ethnicity       
White 3,274 (84.34%) 8,983 (83.03%) <0.001 1,687 (88.60%) 10,570 (82.60%) <0.001 
Hispanic 234 (6.03%) 635 (5.87%)  93 (4.88%) 776 (6.06%)  
Black 275 (7.08%) 873 (8.07%)  93 (4.88%) 1,055 (8.24%)  
Asian 36 (0.93%) 214 (2.02%)  4 (0.21%) 246 (1.92%)  
Other 63 (1.62%) 114 (1.05%)   27 (1.42%) 150 (1.17%)   
Age1 (yrs) 56.9 + 12.8 58.1 + 14.0 <0.001 57.1 + 12.7 57.9 + 13.8 0.03 
Education       
Primary  87 (2.30%) 283 (2.69%) 0.38 52 (2.83%) 318 (2.55%) 0.26 
High School 1,518 (40.17%) 4,320 (41.07%)  771 (41.92%) 5,067 (40.67%)  
College/University 2,153 (56.97%) 5,862 (55.73%)  1,011 (54.98%) 7,004 (56.22%)  
Don’t Remember 21 (0.56%) 54 (0 50%)   5 (0.27%) 69 (0.55%)   
Insurance        
None 93 (2.40%) 259 (2.40%) <0.001 47 (2.48%) 305 (2.39%) <0.001 
Medicaid 185 (4.78%) 249 (2 31%)  82 (4 33%) 352 (2.76%)  
Medicare 804 (20.78%) 2,074 (19.24%)  429 (22.64%) 2,449 (19.20%)  
Private 2,788 (72.04%) 8,200 (76.05%)   1,337 (70.55%) 9,651 (75.65%)   
Marital Status       
Single 446 (11.70%) 1,290 (12.20%) <0.001 203 (10.88%) 1,533 (12.24%) <0.001 
Married/Partnered 2,345 (61.52%) 7,188 (67.96%)  1,157 (62.0%) 8,376 (66.88%)  
Widowed 361 (9.47%) 971 (9 18%)  194 (10.40%) 1,138 (9.09%)  
Divorced/Separated 660 (17.31%) 1,128 (10.66%)   312 (16.72%) 1,476 (11.79%)   
Employment       
Full Time 1,230 (31.59%) 4,529 (41.80%) <0.001 588 (30.88%) 5,171 (40.32%) <0.001 
Part Time 325 (8.35%) 945 (8.72%)  141 (7.41%) 1,129 (8.80%)  
Unemployed 522 (13.41%) 1,088 (10.04%)  255 (13.39%) 1,355 (10.57%)  
Student  29 (0.74%) 109 (1.01%)  12 (0.63%) 126 (0.98%)  
Disabled 806 (20.70%) 837 (7.73%)  384 (20.17%) 1,259 (9.82%)  
Retired 982 (25.22%) 3,326 (30.70%)   524 (27.52%) 3,784 (29.51%)   
Disease Duration1 
(yrs) 8.4 + 9.6 8 2 + 9.4  0.22 8.8 + 9.7 8.2 + 9.4 0.02 
Alcohol Use 1,829 (47.73%) 5,195 (48.71%) 0.30 864 (46.01%) 6,160 (48.82%) 0.02 
Smoking 704 (18.40%) 1,493 (13.99%) <0.001 352 (18.78%) 1,845 (14.61%) <0.001 
Exercise       
None 1,427 (37.73%) 3,409 (32.33%) <0.001 745 (39.86%) 4,101 (32.87%) <0.001 
1-2 times/week 1,209 (31.97%) 3,073 (29.14%)  606 (32.42%) 3,679 (29.49%)  
3-4 times/week 688 (18.19%) 2,244 (21.28%)  300 (16.20%) 2,632 (21.10%)  
5-6 times/week 168 (4.44%) 699 (6.63%)  79 (4 27%) 888 (6.32%)  
Daily 290 (7.67%) 1,121 (10.63%)   135 (7 29%) 1,276 (10.23%)   
BMI (kg/m^2) 30.8 + 7.5 28.9 + 6.7 <0.001 30.9 + 7.4 29.1 + 6.9 <0.001 
Comorbidity2 1 (0-2) 1 (0-2) <0.001 1 (1-2) 1 (0-2) <0.001 
Antidepressant Use 2,153 (59.96%) 871 (9 18%) <0.001 1,192 (66.52%) 1,832 (16.24%) <0.001 
1Continuous value given as the mean value and standard deviation; 2Contiunous value given as the median and IQR.  
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Table 2.2 Gender, race/ethnicity, and age group lifetime depression prevalence estimates by depression 
measurement modality.  
  ¶ Patient-Reported Depression ¶ Clinician-Reported Depression   
Group N Events Prevalence  Events Prevalence Absolute ∆ aRelative ∆ 
Overall 14,755 3,903 26.45% [25.74-27.16] 1,906 12.92% [12 38-13.46] 13.53% 51.17% 
Male 3,417 584 17.09% [15.83-18.35] 272 7.96% [7.05-8.87] 9.13% 53.42% 
Female 11,325 3,313 29.25% [28.42-30.09] 1,634 14.43% [13.78-15.08] 14.83% 50.68% 
White 12,257 3,274 26.71% [25.93-27.50] 1,687 13.76% [13 15-14.37] 12.95% 48.47% 
Hispanic 869 234 26.93% [23.98-29.88] 93 10.70% [8.65-12.76] 16.23% 60.26% 
Black 1,148 275 23.95% [21.49-26.43] 93 8.10% [6.52-9.68] 15.85% 66.18% 
Asian 250 36 14.40% [10.04-18.76] 4 1.60% [0.04-3.16] 12.80% 88.89% 
Other 177 63 35.59% [28.52-42.68] 27 15.25% [9.94-20.57] 20.34% 57.14% 
18-24 153 25 16.34% [10.46-22.18] 14 9.15% [4 57-13.73] 7.19% 44.00% 
25-34 698 174 24.93% [21.72-28.14] 89 12.75% [10 27-15.23] 12.18% 48.85% 
35-44 1,630 452 27.73% [25.56-29.90] 212 13.01% [11 37-14.64] 14.72% 53.10% 
45-54 3,243 929 28.65% [27.09-30.20] 417 12.86% [11.71-14.01] 15.79% 55.11% 
55-64 4,227 1,276 30.19% [28.80-31.57] 649 15.35% [14 27-16.44] 14.83% 49.14% 
65-74 3,209 739 23.03% {21.57-24.49] 382 11.90% [10.78-13.03] 11.12% 48.31% 
75-74 1,301 246 18.91% [16.78-21.04] 118 9.07% [7 51-10.63] 9.84% 52.03% 
85+ 272 54 19.85% [15.10-24.60] 25 9.19% [5.75-12.63] 10.66% 53.70% 
¶ Restricted to patients enrolled after July of 2008, among those with no missing data for either patient-reported or clinician-
reported depression at baseline. 
aRelative differences were calculated as the % decrease in prevalence rates of the clinician-reported rate from the patient-
reported rate, relative to the patient-reported estimate. 
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Table 2.3 Lifetime depression prevalence rates standardized by gender and by age. 
Paper 
Publication 
Population 
Standard 
Population 
Crude 
Prevalence 
Standardized 
Prevalence 
Comparator 
Prevalence 
Standardized CORRONA Lifetime Depression Prevalence 
Kessler et al., 
2003 
National Comorbidity 
Survey 
2000 U.S. 
Census Data 
• 26.29% 21.53% [20.30-22.76] † 16.2% [15.1-17.3] 
Grant et al., 
2004 & Hasin 
et al., 2005 
National 
Epidemiologic Survey 
on Alcohol and 
Related Conditions 
NESARC 
Participants 
• 26.29% 21.63% [20.42-22.84] ¥ 13.2% [12.6-13.8] 
Standardized NESARC Lifetime Depression Prevalence 
Grant et al., 
2004 & Hasin 
et al., 2005 
National 
Epidemiologic Survey 
on Alcohol and 
Related Conditions 
CORRONA 
RA Patients 
□ 13.23% 15.04% [14.58-15.51] ‡ 26.5% [25.7-27.2] 
• Crude lifetime prevalence is from the CORRONA RA population. 
□ Crude lifetime prevalence is from the NESARC population. 
† Comparator lifetime prevalence is from Kessler et al. using the NCS. 
¥ Comparator lifetime prevalence is from Hasin et al. using the NESARC. 
‡ Comparator lifetime prevalence is from the CORRONA RA population.  
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Table 2.4 Gender, race/ethnicity, and age group 12-month depression prevalence estimates by depression measurement 
modality.  
  ¶ Patient-Reported Depression ¶ Clinician-Reported Depression   
Group N Events Prevalence Events Prevalence Absolute ∆ aRelative ∆ 
Overall 14,594 1,714 11.74% [11.22-12.27] 145 0 99% [0.83-1 16] 10.75% 91.54% 
Male 3,393 253 7.46% [6 57-8.34] 30 0.88% [0.57-1 20] 6.57% 88.14% 
Female 11,193 1,461 13.05% [12.43-13.68] 115 1.03% [0.84-1 21] 12.03% 92.13% 
White 12,130 1,449 11.95% [11.37-12.52] 127 1.05% [0.87-1 23] 10.90% 91.24% 
Hispanic 862 99 11.48% [9.36-13.62] 7 0.81% [0.21-1.41] 10.67% 92.93% 
Black 1,133 115 10.15% [8.39-11.91] 9 0.79% [0.28-1 31] 9.36% 92.17% 
Asian 247 14 5.67% [2.78-8.56] 0 0.00% - - 
Other 174 26 14.94% [9.63-20.26] 2 1.15% [-0.44-2.74] 13.79% 92.31% 
18-24 142 8 5.63% [1.83-9.44] 1 0.70% [-0.68-2.09] 4.93% 87.50% 
25-34 675 74 10.96% [8.60-13.32] 9 1 33% [0.47-2 20] 9.63% 87.84% 
35-44 1,616 195 12.07% [10.48-13.66] 24 1.49% [0.90-2.08] 10.58% 87.69% 
45-54 3,217 412 12.81% [11.65-13.96] 37 1 15% [0.78-1 52] 11.66% 91.02% 
55-64 4,192 558 13.31% [12.29-14.40] 38 0 91% [0.62-1 20] 12.40% 93.19% 
65-74 3,175 348 10.96% [9.87-12.05] 26 0.82% [0.51-1 13] 10.14% 92.53% 
75-74 1,290 94 7.29% [5.87-8.71] 9 0.70% [0.24-1 15] 6.59% 90.43% 
85+ 270 23 8.52% [5.18-11.86] 1 0.37% [-0.36-1.10] 8.15% 95.65% 
¶ Restricted to patients enrolled after July of 2008, among those with no missing data for either patient-reported or clinician-
reported depression at baseline. 
aRelative differences were calculated as the % decrease in prevalence rates of the clinician-reported rate from the patient-
reported rate, relative to the patient-reported estimate. 
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Table 2.5 Gender, race, and age specific annualized incidence rates by depression measurement modality. 
  ¶ Patient-Reported Depression ¶ Clinician-Reported Depression     
  
N Events 
Person 
Time 
(years) 
aIncidence Rate Events 
Person 
Time 
(years) 
aIncidence Rate Absolute 
∆ 
bRelative 
∆ 
Overall 7,555 914 11,764 7.77 [7.28 - 8.29] 46 12,572 0.37 [0.27 - 0.49] 7.40 95.24% 
Male 1,972 195 3,114 6.26 [5.44 -7.21] 12 3,287 0.37 [0.21 - 0.64] 5.89 94.09% 
Female 5,581 719 8,646 8.32 [7.73 - 8.95] 34 9,281 0.37 [0.26 - 0.51] 7.95 95.55% 
White 6,296 751 9,913 7.58 [7.05 - 8.14] 41 10,586 0.39 [0.28 - 0.53] 7.19 94.85% 
Hispanic 393 56 508 11.03 [8.49 - 14.33] 3 550 0.55 [0.18 - 1.69] 10.48 95.01% 
Black 626 87 937 9.28 [7.52 - 11.45] 2 1,009 0.20 [0.05 - 0.79] 9.08 97.84% 
Asian 147 11 261 4.21 [2.33 - 7.60] 0 274 - - - 
Other 74 8 130 6.15 [3.08 - 12.30] 0 138 - - - 
18-24 89 13 118 11.02 [6.40 - 18.98] 0 127 - - - 
25-34 345 44 498 8.83 [6.58 - 11.87] 2 541 0.37 [0.09 - 1.48] 8.46 95.81% 
35-44 808 96 1,268 7.57 [6.20 - 9.25]  12 1,348 0.89 [0.51 - 1.57] 6.68 88.24% 
45-54 1,678 249 2,626 9.48 [8.38 - 10.74] 10 2,861 0.35 [0.19 - 0.65] 9.13 96.31% 
55-64 2,075 260 3,291 7.90 [6.99 - 8.92] 10 3,533 0.28 [0.15 - 0.53] 7.62 96.46% 
65-74 1,710 162 2,694 6.01 [5.16 - 7.01] 10 2,834 0.35 [0.19 - 0.66] 5.66 94.18% 
75-74 706 76 1,072 7.09 [5.67 - 8.88] 2 1,124 0.18 [0.05 - 0.71] 6.91 97.46% 
85+ 138 13 189 6.86 [3.98 - 11.82] 0 195 - - - 
¶ Restricted to patients enrolled after July of 2008, among those with no missing data or reports of prevalent depression for either the 
patient or clinician depression measures at baseline 
aIncidence rates (IR) are reported per 100 patient-years of observation 
bRelative differences were calculated as 100% times the absolute difference dived by the patient-reported estimate. 
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Table 2.6 Unadjusted and adjusted associations of RA disease activity with the patient-reported lifetime prevalence 
of depression in the CORRONA registry. 
    † Unadjusted † Adjusted 
Variable N OR 95% CI P OR 95% CI P 
CDAI           
Quintile 1 2,353 - - <0.001 - - <0.001 
Quintile 2 2,189 1.59 [1.37-1.84]   1.36 [1.14-1.61]  
Quintile 3 2,273 1.81 [1.57-2.10]   1.40 [1.18-1.66]  
Quintile 4 2,303 2.21 [1.92-2.56]   1.66 [1.39-1.97]  
Quintile 5 2,232 2.64 [2.28-3.06]   1.67 [1.39-1.99]   
DAS28          
Quintile 1 1,175 - - <0.001 - - 0.31 
Quintile 2 1,175 1.32 [1.08-1.60]  1.09 [0.86-1.38]  
Quintile 3 1,175 1.56 [1.29-1.90]  1.22 [0.97-1.55]  
Quintile 4 1,174 1.87 [1.54-2.27]  1.21 [0.96-1.53]  
Quintile 5 1,174 1.96 [1.61-2.38]   1.26 [0.99-1.61]   
TJC           
Quintile 1 3,961 - - <0.001 - - <0.001 
Quintile 2 1,179 1.14 [0.97-1.33]   1.11 [0.92-1.34]  
Quintile 3 1,917 1.41 [1.24-1.61]   1.32 [1.13-1.54]  
Quintile 4 2,340 1.50 [1.32-1.69]   1.22 [1.05-1.42]  
Quintile 5 2,094 2.02 [1.78-2.28]   1.45 [1.24-1.68]   
SJC           
Quintile 1 4,085 - - 0.002    0.40 
Quintile 2 1,110 1.08 [0.93-1.26]   1.16 [0.96-1.39]  
Quintile 3 1,916 1.03 [0.90-1.17]   1.07 [0.91-1.24]  
Quintile 4 2,169 1.23 [1.09-1.39]   1.13 [0.97-1.31]  
Quintile 5 2,210 1.22 [1.08-1.38]   1.11 [0.95-1.28]   
PGA          
Quintile 1 2,746 - - <0.001 - - <0.001 
Quintile 2 1,843 1.23 [1.05-1.43]  1.18 [0.98-1.41]  
Quintile 3 2,285 2.07 [1.80-2.38]  1.68 [1.43-1.98]  
Quintile 4 2,594 2.50 [2.19-2.85]  1.75 [1.49-2.06]  
Quintile 5 1,966 3.33 [2.89-3.83]   2.03 [1.71-2.41]   
EGA          
Quintile 1 2,736 - - <0.001 - - <0.001 
Quintile 2 2,634 1.26 [1.10-1.44]  1.10 [0.94-1.28]  
Quintile 3 1,855 1.44 [1.25-1.66]  1.14 [0.96-1.36]  
Quintile 4 1,932 1.47 [1.27-1.69]  1.23 [1.04-1.45]  
Quintile 5 2,266 1.95 1.71-2.24]   1.44 [1.22-1.70]   
Patient-Pain VAS          
Quintile 1 2,438 - - <0.001 - - <0.001 
Quintile 2 2,397 1.31 [1.13-1.52]  1.14 [0.96-1.36]  
Quintile 3 2,153 2.04 [1.77-2.36]  1.53 [1.29-1.81]  
Quintile 4 2,558 2.53 [2.21-2.90]  1.67 [1.42-1.97]  
Quintile 5 1,884 3.11 [2.69-3.61   1.83 [1.53-2.18]   
HAQ           
Quintile 1 2,306 - - <0.001 - - <0.001 
Quintile 2 2,210 1.38 [1.17-1.61]   1.04 [0.85-1.27]  
Quintile 3 2,256 2.18 [1.85-2.53]   1.41 [1.18-1.69]  
Quintile 4 2,261 2.82 [2.44-3.27]   1.74 [1.45-2.09]  
Quintile 5 2,253 4.07 [3.52-4.71]   2.05 [1.69-2.48]   
† Indicates mixed effects models were clustered by data collection site. 
Confounders: age, gender, race, ethnicity, marital status, education, employment, health insurance, disease duration, BMI, 
composite comorbidity, smoking, alcohol consumption, and exercise. 
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CHAPTER III: 
TEMPORAL ASSOCIATIONS BETWEEN RHEUMATOID ARTHRITIS 
DISEASE ACTIVITY AND THE ONSET OF PATIENT REPORTED 
DEPRESSIVE SYMPTOMS 
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3.1 Abstract 
Background: Depression is a common disorder in patients with rheumatoid arthritis (RA).  
Research into the temporal relationships regarding its onset has primarily focused on 
functional status.  The study aim was to examine temporal associations of the diverse 
measures of RA disease activity with incident and successive self-reports of depression.  
Methods: The Consortium of Rheumatology Researchers of North America (CORRONA) 
registry is an observational cohort with longitudinal data on more than 34,000 RA 
patients.  Cox regression was used to assess the lagged association of RA disease activity 
with the incident onset of depressive symptoms.  Predictor variables included joint 
counts, global assessments, pain, function, serum biomarkers, and composite disease 
activity.  Hazard ratios (HRs) comparing categorical quintiles were estimated with 95% 
confidence intervals.    
Results: Every disease activity measure, except inflammatory markers, was significantly 
associated with the self-reported onset of depressive symptoms.  Adjusted HRs 
comparing 5th quintiles to 1st quintiles were the following: clinical disease activity index 
= 2.3 [2.1-2.7]; patient-reported pain = 2.3 [2.0-2.6]; physician-assessed swollen joints = 
1.4 [1.4-1.6].  When examining successive self-reports of depression (two consecutive), 
the magnitude of the associations increased: clinical disease activity index = 3.6 [2.5-5.0].     
Conclusions: Results suggest depression onset in RA patients is related to measures 
reported by the patient: pain, functional status, and global disease activity; and measures 
reported by providers, rather than biological factors.  The magnitude of the associations, 
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however, were greater for the patient-reported measures compared to physician 
assessments, implying that patients’ experience of their disease activity may be a 
precipitating factor of depression onset. 
  
3.2 Background 
Major depressive disorder (MDD) is a common condition within rheumatoid 
arthritis (RA) patients, with an estimated point prevalence of 16.8% that is significantly 
higher than the general population [5, 26].  This comorbidity negatively impacts RA 
patients in a variety of ways and is associated with more healthcare costs, greater work 
disability, higher morality, and an increased risk for myocardial infarction [6-9].  Despite 
the many deleterious consequences, research would suggest that MDD is under-
recognized by rheumatologists in the routine rheumatology practice, even though RA 
patients have the majority of their healthcare encounters with their rheumatologists and 
sometimes do not even have a primary care provider (PCP) [60, 61].  Moreover, the 
relationship between RA disease activity and depression is still rather unclear [10, 11].        
 The interrelationships of RA disease activity and depression encompass a diverse 
array of constituents and possible causal pathways [88].  Researchers have asserted the 
association between these two conditions is bi-directional, and it is plausible that 
components of RA disease activity, such as impaired physical function or high levels of 
pain, put RA patients at an increased risk for depression [10, 11].  Some have argued this 
mood disorder is a mental process distinguished by uncontrollable repetitive negative 
thinking, a process known as perseverative thought, which is associated with the presence 
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and severity of MDD [19, 33].  Stress arising from patients’ RA disease activity status 
may influence cognitive perceptions, creating an increased risk for perseverative 
cognitions, thus resulting in a higher likelihood for MDD.  Perseverative thought and 
clinical depression are accompanied by the activation of cell-mediated immunity that 
includes proinflammatory cytokine pathways [20, 89].  Consequently, it is also possible 
the heightened immunological activity and corresponding processes associated with RA 
disease activity influences the onset of depression.               
 The link between RA disease activity and depression has been well replicated 
among cross-sectional studies [22, 75, 83-85]. Although, there are few longitudinal 
studies that allow for temporal interpretations concerning disease activity and the onset of 
depression [38, 39, 41-43, 90].  Most have focused on the association between patient 
function and future depression, yet functionality is not a sensitive marker of disease 
activity, and the results have been discordant.  Some observational studies have 
demonstrated a link between patient function and future depression [39, 42, 91, 92], 
while others have found no such temporal association [38, 41, 43].  Only two studies 
have evaluated indicators of disease activity other than functionality; one suggests that 
increased pain is predictive of future depression [42]; and another found no association 
between composite disease activity and subsequent depression [43].  Some, or all of these 
studies, had inadequate adjustment for confounders, short overall follow-up durations, 
long inter-visit times, and small sample sizes.     
 There is a paucity of research literature examining the temporal association 
between RA disease activity and the onset of depression among RA patients.  Given the 
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high risk for MDD in patients with RA, the impact on overall health and quality of life, 
and potential effects on RA symptoms, treatment persistence, and clinical outcomes; 
understanding how the multifactorial nature of RA disease progression is associated with 
depression onset is paramount [5-9, 29].  The objective of this study was to temporally 
predict the onset of depressive symptoms using the different domains of RA disease 
activity: localized inflammation, global disease activity, pain, functionality, acute phase 
reactants, and composite disease activity.   
 
3.3 Methods  
Study Data 
 The Consortium of Rheumatology Researchers of North America (CORRONA) 
database is an existing longitudinal cohort that was designed for the purpose of collecting 
prospective information on patients from community practices with rheumatic diseases.  
The details regarding the operation and funding sources for the CORRONA have been 
published previously [63].  Data collection began in October 2001, and as of August 
2012, more than 33,000 RA patients had been enrolled.  Patients are recruited during 
clinical encounters from both private and academic rheumatology clinics, and data 
collection generally occurs every three to six months at routine clinical visits [63].  
Information is captured from patients and their rheumatologists using standardized 
enrollment and follow-up surveys that gather data on demographics, disease activity, 
disease severity, medication use, adverse events, and comorbidity.  All study participants 
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provide written informed consent, and are approved for enrollment through the 
Institutional Review Boards (IRB) of institutions or a central IRB for academic and 
private rheumatology clinics, respectively. 
Patient Population   
 The study population consisted of all patients (N=33,743) with physician 
diagnosed RA enrolled into the CORRONA registry between October 2001 and August 
2012 (Figure A.2).  Patients with missing data on prior depression (n=1,681) or a self-
reported history of depression at study entry (n=8,141) were excluded.  Additionally, we 
excluded participants with no clinical follow-up visits after study enrollment (n=4,920).  
The primary analytic cohort comprised 19,001 RA patients with no self-reported history 
of depression who also had observed follow-up visits after study entry.  This population 
meeting the pre-specified cohort criteria was used to evaluate the temporal association 
between the different domains of RA disease activity and the onset of self-reported 
depressive symptoms.  Within the overall sample, further exclusions were made as 
necessary for the various analyses based on the availability of disease activity and 
covariate data.  
RA Disease Activity Predictors 
Model based disease activity predictors included composite indices, joint counts, 
global assessments, pain, function, and acute phase reactants.  Two composite scales 
were used: the clinical disease activity index (CDAI) and 28 joint count disease activity 
score (DAS28) [67, 68].  The CDAI is a summary score of the tender joint count (TJC) 
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based on 28 counts, the swollen joint count (SJC) based on 28 counts, patient global 
assessment (PGA; visual analogue scale (VAS) 0-10 cm), and physician global 
assessment (EGA; VAS 0-10 cm) [67].  The DAS28 is a numerical score calculated from 
the TJC, SJC, PGA, and the erythrocyte sedimentation rate (ESR), using a mathematical 
formula [68].  Other predictor variables included the core component measures of RA 
disease activity, which were previously described: TJC, SJC, PGA, EGA, and ESR; in 
addition to: patient pain (VAS 0-10 cm), C-reactive protein (CRP), and health assessment 
questionnaire score (HAQ), converted from modified HAQ scores [69, 70].  Of note, 
laboratory measures are not collected at every clinical visit and have higher proportions 
of missing data.     
Depression Outcome Measures 
 The primary depression measure was a single item collected from patient follow-
up forms.  CORRONA follow-up surveys gather information on all new comorbidities 
patients experience from the time of their last clinical visit, which includes a measure for 
depression.  The follow-up survey item instructs study participants to do the following: 
“Fill in each box for medical condition or symptom you have had SINCE YOU LAST 
FILLED OUT THIS FORM”; and contains a measure for “Depression (feeling blue).”  
Using this measure, two outcomes were operationalized and included the following 
endpoints: (1) first incident self-report of depression and (2) successive self-reports of 
depression, defined as the first two consecutive follow-up visits with reports of 
depression.  Similar approaches have been used when evaluating the impact of depression 
on response to biologic DMARD treatment [53].  These outcomes were not intended to 
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be representative of clinical depression as diagnosed using with DSM criteria, but rather a 
measure of the core symptom of depression.  Single-item measures assessing depressive 
symptoms have been used in prior research among RA registry populations  and validated 
against the Beck Depression Inventory and yielded sensitivity and specificity estimates of 
65.3% [0.50-0.58] and 87.3% [0.77-0.94], respectively, suggesting a modest ability to 
identify patients with probable MDD [25, 93].      
Covariates 
 Demographic variables included the following self-reported measures: gender, 
age, race, ethnicity, marital status, employment, and health insurance.  Race and ethnicity 
were reported separately and combined into four categories: White, Black, Asian, 
Hispanic, and Other.  Age was categorized into the following groups: 18-24, 25-34, 35-
44, 45-54, 55-64, 65-74, 75-84, and 85+.  Patients’ level of attained education was 
measured as one of four groups: primary, high school, college/university, and don’t 
remember; and marital status was characterized as single, married/partnered, widowed, 
and divorced/separated.  Work status was measured using six categories: full time, part 
time, unemployed, student, disabled and retired; and health insurance as one of the 
following: none, Medicaid, Medicare, and private.  Gender and race/ethnicity were time-
invariant, while age group, education, marital status, employment, and insurance type 
were time-varying.  
 Additional study variables were disease duration, BMI, medical comorbidity, 
antidepressant use, smoking, alcohol use, and exercise.  Physician-reported disease 
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duration was coded into categorical quintiles due to non-linear hazard trends, and BMI 
(kilograms/meters²) was a continuous variable.  Patient comorbidity was the number of 
comorbidities calculated using reports of past or present conditions from either patients or 
rheumatologists: included myocardial infarction, stroke, hypertension, other 
cardiovascular disorders, diabetes mellitus, pulmonary disease, cancer, peptic ulcer, other 
gastrointestinal disorders, and fractures [25].  Antidepressant use was collected as the 
current use of any medications from a patient-reported single-item measure.  Both 
smoking and drinking were captured as binary exposures (ever vs. never); more 
comprehensive data are restricted to later CORRONA survey version forms.  Exercise 
was an ordinal measure with five categories: not at all, 1-2 times per week, 3-4 times per 
week, 5-6 times per week, and daily.  Disease duration, BMI, comorbidity, antidepressant 
use, exercise, smoking, and alcohol use were all time-varying covariates. 
Statistical Analysis     
 Our goal was to assess associations of RA disease activity domains with the time 
to onset of depressive onsets.  The primary analytic method used was Cox Proportional 
Hazards modeling.  The depression endpoints included the previously described incident 
and successive self-reported depression measures, and patients with no observed 
depression were censored at the time of their last clinical visit.  The primary predictor 
variables of interest were RA disease activity measures, which were categorized into 
quintiles for two reasons: (1) disease activity variables displayed non-linear trends 
regarding their associations with the depression outcomes and (2) categorization provided 
a way to compare the magnitude of the associations across the different measures.  
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Unadjusted and multivariable models adjusting for all possible covariates that were 
associated with at least one of the outcomes were examined.  The basic unadjusted model 
form is shown in the equation below. 
h(t)  h0(t)exp((1(DiseaseActivity)i, j1  Xi, j ...))  
  The focus of the analysis was the impact of a RA disease activity predictor 
modeled as a lagged time-varying variable, where in the above equation, the parameter 
DiseaseActivityi, j-1 corresponds to a measure from a previous clinical visit.  However, this 
assumption is not implicit as the effect of concurrent measures of disease activity was not 
assessed in these analyses because they represent disease activity measured at a given 
clinical visit, while reports of depression by patients correspond to its presence during a 
period in the interval from the prior data collection point to the present one.   This lagging 
was intended to cause the exposure, RA disease activity, to precede the depression 
outcomes.  The associated coefficient 1 represents the lagged effect of RA disease 
activity on an incident or persistent report of depressive symptoms.  Unadjusted and 
adjusted models incorporating the previously described covariates were used to estimate 
hazard ratios (HRs) with 95% confidence intervals, and the proportional hazards 
assumption was evaluated using Schoenfield’s global test [94].  
 Sensitivity analyses were conducted to explore the interval censored nature of the 
outcomes, differential follow-up time patterns, hierarchical data structure, and missing 
laboratory data.  In the primary analyses, clinical visit dates were used for estimating the 
time of onset. Strictly speaking, however, the outcome endpoints are interval censored 
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data, meaning the occurrence of an event is only known to have occurred between two 
given clinical visits.  Consequently, analyses were also performed using interval censored 
survival regression with an appropriate parametric distribution that adequately fit the data 
[95].  A caveat of all of registry databases is differential follow-up time patterns, where 
there is between person variability concerning patient’s inter-visit times, which could 
potentially result in response bias.  To further test robustness, survival models were 
analyzed in a patient subset with equidistant follow-up intervals (N=4,566), in individuals 
whose time between visits was approximately 4 months (+/- 2).  CORRONA data is 
hierarchical, where patients are clustered within physicians, amongst data collection sites.  
To investigate cluster correlations regarding the results, sensitivity analyses were 
conducted using semi-parametric gamma shared frailty models [96].  Lastly, in a manner 
of assessing missing laboratory values, survival models were tested using composite 
disease activity data at only clinical visits where laboratory measures were available. 
 
3.4 Results 
Patient Characteristics 
 Patient characteristics and the associations of these attributes with the depression 
outcomes from the primary analytic cohort were assessed (Tables 3.1 and A.5).  Patients 
at the highest risk for prospective self-reports of incident or successive depressive 
symptoms were non-white individuals, younger, and widowed or divorced/separated; and 
individuals of a lower socioeconomic status, evidenced by the higher hazards among 
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patients with a lower education level, lacking health insurance, and without full time 
employment.  Prior smoking and decreased physical activity were associated with a 
greater probability of experiencing the outcomes, while previous alcohol exposure was 
protective against reporting depression.  Additionally, lower disease duration, higher 
BMI, more comorbidity, and lagged anti-depressant use were all associated with a greater 
risk for patient-reports of depression.  Overall, the patient attributes exhibited the 
anticipated risk trends that would be expected based on prior research.    
Composite Disease Activity     
Both groups of categorical quintile indicators for the CDAI and DAS28 were 
collectively associated with incident and successive self-reports of depressive symptoms 
(Table 3.2).  There were dose-response trends, where as a patient’s lagged time-varying 
disease activity quintile increased, so did their risk for the onset of depressive symptoms. 
Although, the increased risk was greater for the CDAI when compared to the DAS28; 
evidenced by adjusted HRs comparing 5th quintiles to 1st quintiles: 2.34 [2.06-2.66] vs. 
1.70 [1.47 vs. 1.99], respectively.    Adjustment for potential confounders attenuated the 
HRs, but the adjusted multivariable model results did not change otherwise.  The 
magnitude of the risk was higher for successive depressive symptoms than for incident 
symptomatic onset, especially for the upper categorical quintiles (Figure 3.1).  
Results from the sensitivity analyses were generally similar (Tables A.6-A.8).  
When using interval censored survival regression, the magnitude of the estimates 
increased, but the previously noted trends did not change otherwise.  To ensure the 
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duration between visits was not influencing the results, the HRs were estimated among 
patients with equidistant follow-up visits (N=4,566).  The estimates slightly increased for 
the CDAI, but decreased for the DAS28, which was not significantly associated with the 
successive depression outcome.  Accounting for the patients’ data collection site using 
shared frailty models did not change the results and associated variance estimates, 
evidenced by the very low within cluster tau correlation coefficients. 
Patient-Reported Disease Activity Measures 
   Every self-reported measure of disease activity, as categorical quintiles, was 
associated with the depression outcomes (Table 3.3).  They all displayed “dose-
response” trends, similar to the composite indices, and the magnitude of these estimates 
closely resembled the CDAI.  Again, adjustment attenuated the observed associations, 
and the magnitude of the point estimates increased when using the successive outcome.  
However, after adjustment the magnitude of the effect sizes were similar across each of 
the patient-reported disease activity measures; demonstrated by adjusted HRs for incident 
self-reports comparing 5th quintiles to 1st quintiles for patient pain, function, and global 
assessment: 2.28 [2.03-2.56], 2.55 [2.22-2.92], and 2.47 [2.18-2.80], respectively.   
Results from the sensitivity analyses were essentially the same as the primary findings 
(data not shown).   When using interval censored survival regression or patients with 
equidistant follow-up visits, the effect sizes slightly increased, and the estimates from 
frailty models clustered by clinical site did not noticeably differ in any regard.  
Physician-Reported Disease Activity Measures 
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Among the physician-reported metrics, each was significantly associated with the 
onset of depressive symptoms (Table 3.4).  The “dose-response” trends remained, 
adjustment for possible confounders reduced the magnitude of the point estimates, and 
the effect sizes were larger for the successive outcome.  The strength of the associations 
slightly varied for the physician reported measures; the weakest to the strongest in 
magnitude was the SJC, TJC, and EGA, respectively; shown by adjusted HRs for incident 
self-reports comparing 5th quintiles to 1st quintiles: 1.42 [1.29-1.57], 1.61 [1.47-1.76], and 
1.77 [1.57-1.98], respectively.  Similar to the other measures, the findings from the 
sensitivity analyses did not alter the interpretation of the primary results (data not 
shown).  Results from interval-censored survival regression models or a sample of 
patients with equidistant follow-up visits had marginally greater risk estimates for all of 
the predictors.  Clustering by practice site in shared frailty models did not alter the 
results, and the within-site correlations were very low. 
Laboratory-Reported Disease Activity Measures  
In unadjusted survival models, both CRP and ESR were significantly associated 
with incident reports and successive depressive symptoms (Table 3.5).  The ESR risk 
estimates quintiles trended by quintile, while the CRP HR trends were non-linear.  
However, after multivariable adjustment neither predictor was collectively associated 
with incident depressive symptoms, and the majority of the point estimates trended to the 
null.  Concerning the successive depression outcome, only CRP was significantly 
associated with the outcome and again the trends were non-linear.  Risk estimates by 
ESR grouping were negligible.  Adjustment for confounders attenuated the CRP 
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estimates, and it was no longer associated with the successive depression outcome.  
Sensitivity analyses using CDAI and DAS28 values at only clinical visits where lab 
measures were available showed the same results as the primary composite disease 
activity findings (data not shown).  Model based HRs using interval censored survival 
regression showed increased effect sizes for the CRP but not the ESR, and the CRP 
quintiles were collectively associated with the incident outcome.  Model based 
estimations from the other sensitivity analyses were also generally the same as the main 
results (data not shown). 
 
3.5 Discussion 
This is the first study to systematically evaluate the temporal relationship between 
the different domains of RA disease activity and the onset of depression in RA patients.  
Greater disease activity, assessed by the core component measures, conferred a higher 
risk for incident self-reports of depressive symptoms, and the hazard trends only 
strengthened when using a stricter definition of “caseness.”  The composite indices 
calculated using the individual metrics displayed similar patterns.  However, acute phase 
reactants were not associated with self-reported depressive symptoms after multivariable 
adjustment, corresponding to the differences in effect sizes between the CDAI and 
DAS28.  While both the patient-reported and physician-reported measures of disease 
activity were significantly associated with depression onset, the magnitudes of the 
associations were larger for the patient-reported metrics.  Our results suggest that RA 
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disease activity is temporally associated with the onset of depressive symptoms, and not 
simply just related to functional status.   
Every patient- and physician-reported disease activity measure was significantly 
associated with depression onset, but not the laboratory-reported acute phase reactants 
indicative of serum inflammation.  Interventional studies have demonstrated a clear 
temporal link between disease activity and depression [44, 45].  Patients receiving 
clinical treatment for RA, showing reductions in disease activity, have had corresponding 
decreases in their depressive symptoms.  Theoretically, any changes in depression should 
be due to the effect of therapy on disease activity [44, 45].  Although, from such research, 
it is entirely unclear what disease activity domains are temporally associated with 
changes in depression.  Researchers have posited depression is an inflammatory disease 
and that MDD and RA may be pathologically linked via such mechanisms, and meta-
analytic evidence has shown that in normal individuals major depression is positively 
associated with CRP, tumor necrosis factor, and an array of different cytokines [16-18, 
32, 97].  Furthermore, proof-of-concept research in RA patients has drawn a causal link 
between cytokine regulated events and brain function, but our results imply that the onset 
of depressive symptoms in RA patients is not related to shared inflammatory processes 
[98].  However, the outcomes were not indicative of case-level mood disorder, which is 
the circumstance regarding prior research, and consequently, the clinical end points may 
not have been representative of the necessary severity required to detect a lagged 
association between biomarkers and depression. 
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There was between-source measurement variation regarding the risk estimates, 
and the effect sizes for the patient-reported measures were consistently greater than those 
reported by the physicians.  Among the few studies conducted among RA patients 
permitting temporal interpretations [38-43], most suggest that patient-reported function is 
an important determinant of downstream depression [39, 40, 42, 92], less understood, is 
the influence of the other RA disease activity domains.  Research has shown that pain is 
also temporally associated with future depression [42], but not composite disease activity 
calculated using the ESR and Thompson’s joint score ratings [43].  Our results parallel 
existing data in that patient-reported disease activity measures were consistently 
predictive of future depression. Yet, the findings also demonstrated that physician-
reported measures were also temporally associated with depression onset.  Previous 
studies have generally used cohorts with long inter-visit times (1-5 years).  Conversely, 
the mean inter-visit time among the CORRONA analytic cohort was 5.45 months (95% 
CI: 5.43-5.48).  Given the short inter-visit times and interval censored nature of the data, 
there may have been a close proximal ordering between the measurement of disease 
activity and the onset of depressive symptoms.  These design characteristics could 
explain the detectable signals regarding the physician-reported disease activity measures, 
increased effect sizes for the patient-reported disease activity measures, and persistent 
dose response trends. 
Strengths and Limitations 
The strengths of this study include the longitudinal design with temporal lagging, 
comprehensive RA disease activity measurement, large national registry sample, and 
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extremely robust study finding that were consistent across a range of different sensitivity 
analyses.  However, there are also limitations to this study.  The depression measures that 
were utilized are not representative of clinical depression as evaluated by using DSM 
criteria, and consequently, there was the possibility of measurement error when assessing 
the incident onset of depressive symptoms.  Information bias in the context of prevalent 
or incident self-reports of depression, when identifying the study population and outcome 
endpoints, could have potentially influenced the results.  Nonetheless, simple questions 
about feeling “depressed,” “blue,” or “sad,” are commonly employed in routine clinical 
practice to assess for the presence of comorbid depression and given the strain even short 
screeners can place on patients and support staff in busy clinical practices, these “ultra-
brief” measures are important tools that can provide valuable and important information 
[99, 100].  Moreover, when validated against external raters, chart abstractions, and 
laboratory results, patients have consistently shown a strong ability to recall the 
occurrence of previous comorbid conditions [76, 101, 102].  
3.6 Conclusions  
Collectively, the results imply that in RA patients, increases in global disease 
activity, pain, function, and joint swelling and tenderness are temporally related to the 
onset of self-reported depressive symptoms.  The findings of this study, however, provide 
no evidence that the inflammatory processes associated with the etiology of RA are 
involved with depression onset.  Thus, these data would suggest that the onset of 
depression among RA patients is more likely related to other potential causal 
mechanisms.  The difference in the magnitudes of the HR trends between the patient- and 
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physician-reported metrics indicate a stronger relationship with the patient-reported 
global assessment, pain, and function, when compared to disease activity as assessed by 
physicians.  Given the strong and consistent associations concerning the patient-reported 
metrics, patients’ experience of their arthritis may be more sensitive to the onset of 
depressive symptoms, while the lower effect sizes for the physician-reported measures 
suggest that the RA symptoms of joint swelling and pain are more distal determinants.  
Future research in this area, among patients with chronic physical disease, should focus 
on evaluating and identifying the specific determinants and mechanisms that may be 
responsible for the mediating the observed relationships.  
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Table 3.1. Baseline characteristics of RA patients in the primary survival analysis analytic 
cohort. 
Variable N % 95% CI 
Female 13921 73.3 [72.7-73.9] 
Race/Ethnicity    
White 15866 83.9 [83.4-84.5] 
Hispanic 1073 5.7 [5.3-6.0] 
Black 1328 7.0 [6.7-7.4] 
Asian 354 18.7 [1.7-2.1] 
Other 284 15.0 [1.3-1.7] 
Age    
18-24 184 1.0 [0.8-1.1] 
25-34 698 3.7 [3.4-3.9] 
35-44 1851 10.0 [9.3-10.2] 
45-54 3979 21.0 [20.4-21.6] 
55-64 5302 28.0 [27.3-28.6] 
65-74 4401 23.2 [22.6-23.8] 
75-84 2166 11.4 [11.0-11.9] 
85+ 2166 2.1 [1.9-2.3] 
Education    
Primary  885 4.8 [4.5-5.2] 
High School 7441 40.7 [40.0-41.4] 
College/University 9787 53.5 [52.8-54.2] 
Don’t Remember 184 1.0 [0.9-1.2] 
Insurance     
None 326 1.9 [1.7-2.1] 
Medicaid 372 2.2 [2.0-2.4] 
Medicare 3542 20.9 [20.3-21.5] 
Private 12685 74.9 [74.3-75.6] 
Marital Status    
Single 2180 11.5 [11.0-11.9] 
Married/Partnered 12878 67.9 [67.2-68.5] 
Widowed 2014 10.6 [10.2-11.1] 
Divorced/Separated 1903 10 [9.6-10.5] 
Employment    
Full Time 7356 38.7 [38.1-39.4] 
Part Time 1903 10.0 [9.6-10.5] 
Unemployed 2317 12.2 [11.7-12.7] 
Student  129 0.7 [0.6-0.8] 
Disabled 1699 8.9 [8.5-9.4] 
Retired 5583 29.4 [28.8-30.1] 
Disease Duration    
Quintile 1 7660 40.5 [39.8-41.2] 
Quintile 2 2660 14.1 [13.6-14.6] 
Quintile 3 3128 16.5 [16.0-17.1] 
Quintile 4 2890 15.3 [14.8-15.8] 
Quintile 5 2575 13.6 [13.1-14.1] 
Alcohol Use 8002 43.1 [42.4-43.8] 
Smoking 2583 13.7 [13.2-14.2] 
Exercise    
None 5809 30.7 [30.1-31.4] 
1-2 times/week 5566 29.5 [28.8-30.1] 
3-4 times/week 4085 21.6 [21.0-22.2] 
5-6 times/week 1308 6.9 [6.6-7.3] 
Daily 2129 11.3 [10.8-11.7] 
BMI1 18685 28.7 [28.6-28.8] 
Comorbidity2 19001 1 [0-1] 
Antidepressant Use 1413 7.7 [7.3-8.1] 
1Indicates summary measure is given as a mean value; 2Indicates summary measure is reported 
as a median with the associated interquartile range. 
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Table 3.2. Unadjusted and adjusted temporal associations (HR) of patients' lagged time-
varying CDAI and DAS28 quintiles with incident and successive self-reports of 
depressive symptoms. 
Variable N Hazard Ratio P Value Hazard Ratio P Value 
  Unadjusted Incident Symptoms Adjusted Incident Symptoms 
CDAI Quintile 17,567   <0.001   <0.001 
Quintile 1   - - - - 
Quintile 2   1.49 [1.29-1.71] <0.001 1.44 [1.25-1.65] <0.001 
Quintile 3   1.83 [1.60-2.09] <0.001 1.69 [1.47-1.93] <0.001 
Quintile 4   2.14 [1.88-2.43] <0.001 1.88 [1.65-2.15] <0.001 
Quintile 5   2.91 [2.58-3.30] <0.001 2.34 [2.06-2.66] <0.001 
DAS28 Quintile 12,101    <0.001    <0.001 
Quintile 1   - - - - 
Quintile 2   1.22[1.03-1.44] 0.02 1.17 [0.99-1.39] 0.06 
Quintile 3   1.29 [1.01-1.52] 0.002 1.18 [1.01-1.40] 0.046 
Quintile 4   1.69 [1.45-1.97] <0.001 1.49 [1.27-1.74] <0.001 
Quintile 5   2.17 [1.87-2.51] <0.001 1.70 [1.46-1.99] <0.001 
  Unadjusted Persistent Symptoms Adjusted Persistent Symptoms 
CDAI Quintile 17,859   <0.001   <0.001 
Quintile 1   - - - - 
Quintile 2   1.77 [1.24-2.52] 0.002 1.69 [1.18-2.40] 0.004 
Quintile 3   2.21 [1.58-3.10] <0.001 2.01 [1.43-2.83] <0.001 
Quintile 4   3.26 [2.37-4.50] <0.001 2.79 [2.01-3.86] <0.001 
Quintile 5   4.71 [3.45-6.42] <0.001 3.60 [2.62-4.96] <0.001 
DAS28 Quintile 12,688   <0.001   <0.001 
Quintile 1   - - - - 
Quintile 2   1.14 [0.79-1.64] 0.50 1.14 [0.79-1.65] 0.50 
Quintile 3   1.21 [0.84-1.73] 0.31 1.16 [0.80-1.67] 0.44 
Quintile 4   1.64 [1.17-2.29] 0.004 1.48 [1.05-2.09] 0.03 
Quintile 5   2.39 [1.75-3.27] <0.001 1.84 [1.31-2.57] <0.001 
Adjusted for the following confounders: gender, race, ethnicity, age group, education, health 
insurance, marital status, employment, disease duration, alcohol use, smoking, exercise, BMI, 
comorbidity, and antidepressant use. 
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Figure 3.1. Adjusted CDAI quintile hazard ratio estimates for 
incident and successive reports of depressive symptoms.
Incident Reports
Successive Reports
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Table 3.3 Unadjusted and adjusted temporal associations (HR) of the patient-reported 
measures of disease activity as lagged time-varying quintiles with incident and successive 
self-reports of depressive symptoms. 
Variable N Hazard Ratio P Value Hazard Ratio P Value 
    Unadjusted Incident Symptoms Adjusted Incident Symptoms 
Patient Pain  17,615  <0.001  <0.001 
Quintile 1  - - 
- 
- - 
Quintile 2  1.24 [1.09-1.41] 0.001 1.22 [1.07-1.39] 0.003 
Quintile 3  1.58 [1.40-1.80] <0.001 1.52 [1.33-1.72] <0.001 
Quintile 4  1.96 [1.75-2.20] <0.001 1.74 [1.55-1.96] <0.001 
Quintile 5   2.88 [2.58-3.22] <0.001 2.28 [2.03-2.56] <0.001 
Patient Function  17,591  <0.001  <0.001 
Quintile 1  - - - - 
Quintile 2  1.30 [1.13-1.48] <0.001 1.31 [1.12-1.53] 0.001 
Quintile 3  1.53 [1.34-1.75] <0.001 1.52 [1.32-1.75] <0.001 
Quintile 4  2.36 [2.09-2.67] <0.001 2.17 [1.90-2.48] <0.001 
Quintile 5   3.04 [2.70-3.42] <0.001 2.55 [2.22-2.92] <0.001 
Patient Global  17,614  <0.001  <0.001 
Quintile 1  - - - - 
Quintile 2  1.20 [1.05-1.39] 0.01 1.19 [1.04-1.37] 0.01 
Quintile 3  1.67 [1.47-1.89] <0.001 1.58 [1.40-1.80] <0.001 
Quintile 4  2.28 [2.02-2.57] <0.001 2.00 [1.77-2.26] <0.001 
Quintile 5   3.10 [2.74-3.50] <0.001 2.47 [2.18-2.80] <0.001 
  Unadjusted Persistent Symptoms Adjusted Persistent Symptoms 
Patient Pain  17,895  <0.001  <0.001 
Quintile 1  - - - - 
Quintile 2  1.32 [0.95-1.83] 0.10 1.28 [0.92-1.77] 0.14 
Quintile 3  1.41 [1.01-1.98] 0.04 1.34 [0.95-1.87] 0.09 
Quintile 4  2.63 [1.98-3.49] <0.001 2.32 [1.74-3.09] <0.001 
Quintile 5   5.12 [3.93-6.66] <0.001 3.87 [2.94-5.09] <0.001 
Patient Function  17,863  <0.001  <0.001 
Quintile 1  - - - - 
Quintile 2  1.14 [0.81-1.60] 0.47 1.31 [0.90-1.91] 0.16 
Quintile 3  1.64 [1.20-2.24] 0.002 1.83 [1.32-2.54] <0.001 
Quintile 4  2.66 [1.99-3.55] <0.001 2.65 [1.95-3.62] <0.001 
Quintile 5   4.09 [3.10-5.39] <0.001 3.66 [2.68-5.02] <0.001 
Patient Global  17,895  <0.001  <0.001 
Quintile 1  - - - - 
Quintile 2  1.26 [0.90-1.77] 0.18 1.22 [0.87-1.72] 0.25 
Quintile 3  1.39 [0.99-1.93] 0.05 1.29 [0.93-1.80] 0.13 
Quintile 4  2.82 [2.11-3.77] <0.001 2.43 [1.81-3.27] <0.001 
Quintile 5   5.20 [3.92-6.88] <0.001 3.91 [2.92-5.23] <0.001 
Adjusted for the following confounders: gender, race, ethnicity, age group, education, health 
insurance, marital status, employment, disease duration, alcohol use, smoking, exercise, BMI, 
comorbidity, and antidepressant use. 
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Table 3.4 Unadjusted and adjusted temporal associations (HR) of the physician-reported measures of disease 
activity as lagged time-varying quintiles with incident and successive self-reports of depressive symptoms. 
Variable N Hazard Ratio P Value Hazard Ratio P Value 
    Unadjusted Incident Symptoms Adjusted Incident Symptoms 
‡ TJC 17,702  <0.001  <0.001 
Quintile 1  - - - - 
Quintile 3  1.25 [1.11-1.41] <0.001 1.20 [1.07-1.36] 0.003 
Quintile 4  1.51 [1.37-1.66] <0.001 1.38 [1 26-1.52] <0.001 
Quintile 5   1.98 [1.81-2.16] <0.001 1.61 [1.47-1.76] <0.001 
‡ SJC 17,699  <0.001   <0.001 
Quintile 1  - - - - 
Quintile 3  1.24 [1.13-1.37] <0.001 1.20 [1.09-1.33] <0.001 
Quintile 4  1.30 [1.18-1.44] <0.001 1.21 [1.09-1.33] <0.001 
Quintile 5   1.60 [1.45-1.76] <0.001 1.42 [1 29-1.57] <0.001 
EGA 17,702  <0.001   <0.001 
Quintile 1  - - - - 
Quintile 2  1.17 [1.03-1.32] 0.002 1.14 [0 99-1.29] 0.05 
Quintile 3  1.43 [1.27-1.62] <0.001 1.35 [1 19-1.53] <0.001 
Quintile 4  1.65 [1.46-1.86] <0.001 1.48 [1 31-1.68] <0.001 
Quintile 5   2.15 [1.92-2.41] <0.001 1.77 [1 57-1.98] <0.001 
    Unadjusted Persistent Symptoms Adjusted Persistent Depression 
‡ TJC 17,952  <0.001   <0.001 
Quintile 1  - - - - 
Quintile 3  1.04 [0.78-1.40] 0.78 0.99 [0.74-1.35] 0.99 
Quintile 4  1.63 [1.32-2.01] <0.001 1.44 [1 17-1.79] 0.001 
Quintile 5   2.45 [2.03-2.97] <0.001 1.86 [1 52-2.26] <0.001 
‡ SJC 17,952  <0.001   <0.001 
Quintile 1  - - - - 
Quintile 3  1.26 [1.01-1.57] 0.04 1.22 [0 98-1.52] 0.07 
Quintile 4  1.38 [1.11-1.72] 0.003 1.28 [1.03-1.60] 0.03 
Quintile 5   1.88 [1.52-2.32] <0.001 1.65 [1 33-2.06] <0.001 
EGA 17,952  <0.001   <0.001 
Quintile 1  - - - - 
Quintile 2  1.32 [0.99-1.76] 0.06 1.27 [0 95-1.70] 0.11 
Quintile 3  1.38 [1.03-1.85] 0.03 1.28 [0 95-1.71] 0.09 
Quintile 4  1.89 [1.43-2.51] <0.001 1.64 [1 23-2.18] 0.001 
Quintile 5   2.86 [2.21-3.71] <0.001 2.22 [1.70-2.89] <0.001 
‡ Due to a high frequency of 0 values for the joint counts at follow-up visits, these measures could be not 
categorized into five groups. 
Adjusted for the following confounders: gender, race, ethnicity, age group, education, health insurance, marital 
status, employment, disease duration, alcohol use, smoking, exercise, BMI, comorbidity, and antidepressant use. 
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Table 3.5 Unadjusted and adjusted temporal associations (HR) of the laboratory-
reported measures of disease activity as lagged time-varying quintiles with incident and 
successive self-reports of depressive symptoms. 
Variable N       Hazard Ratio P Value Hazard Ratio P Value 
    Unadjusted Incident Symptoms Adjusted Incident Symptoms 
CRP Quintile 9,327  0.003   0.10 
Quintile 1  - - - - 
Quintile 2  1.14 [0.95-1.38] 0.16 1.13 [0.94-1.37] 0.19 
Quintile 3  1.03 [0.85-1.25] 0.76 1.02 [0.84-1.24] 0.86 
Quintile 4  1.03 [0.84-1.26] 0.81 0.96 [0.78-1.18] 0.67 
Quintile 5   1.37 [1.14-1.65] 0.001 1.20 [0.99-1.45] 0.07 
ESR Quintile 12,143  0.01   0.85 
Quintile 1  - - - - 
Quintile 2  1.02 [0.84-1.20] 0.86 0.94 [0.80-1.12] 0.50 
Quintile 3  1.09 [0.92-1.30] 0.31 0.95 [0.80-1.13] 0.56 
Quintile 4  1.17 [0.99-1.38] 0.06 0.97 [0.82-1.15] 0.74 
Quintile 5   1.29 [1.10-1.52] 0.002 1.03 [0.87-1.23] 0.74 
   Unadjusted Persistent Symptoms Adjusted Persistent Symptoms 
CRP Quintile 10,059  0.04   0.22 
Quintile 1  - - - - 
Quintile 2  1.24 [0.82-1.86] 0.31 1.24 [0.82-1.86] 0.32 
Quintile 3  0.89 [0.57-1.41] 0.63 0.89 [0.57-1.41] 0.63 
Quintile 4  1.10 [0.71-1.72] 0.67 1.06 [0.67-1.67] 0.81 
Quintile 5   1.60 [1.07-2.39] 0.02 1.39 [0.92-2.11] 0.12 
ESR Quintile 12,708  0.54   0.62 
Quintile 1  - - - - 
Quintile 2  0.81 [0.56-1.17] 0.26 0.80 [0.55-1.15] 0.23 
Quintile 3  0.86 [0.59-1.25] 0.42 0.81 [0.55-1.19] 0.28 
Quintile 4  0.84 [0.58-1.21] 0.34 0.76 [0.52-1.13] 0.17 
Quintile 5   1.06 [0.74-1.50] 0.76 0.91 [0.62-1.32] 0.61 
Adjusted for the following confounders: gender, race, ethnicity, age group, education, health 
insurance, marital status, employment, disease duration, alcohol use, smoking, exercise, BMI, 
comorbidity, and antidepressant use. 
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CHAPTER IV: 
TEMPORAL ASSOCIATIONS OF DEPRESSION WITH THE DIFFERENT 
DOMAINS OF RHEUMATOID ARTHRITIS DISEASE ACTIVITY 
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4.1 Abstract 
Background: Depression is a common psychiatric comorbidity of rheumatoid arthritis 
(RA), yet little is known of its temporal effect on disease activity and symptoms.  The 
aim was to evaluate how prevalent depression and the incident onset of depressive 
symptoms impacted longitudinal changes in the different domains of RA disease activity. 
Methods: RA patients with depression data and follow-up time were identified from a 
national observational cohort of > 34,000 individuals (The Consortium of Rheumatology 
Researchers of North America; CORRONA).  Linear mixed models estimated the 
association between the prevalence and incident onset of depression influenced changes 
in disease activity over 2-years.  Outcomes were the clinical disease activity index 
(CDAI), tender and swollen joint counts (TJC and SJC), patient and physician global 
assessment (PGA and EGA), patient-reported pain, health assessment question (HAQ), 
C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR).  To account for 
potential confounders, patients with and without depression were matched using a 
propensity score.  Model based estimates of disease activity were generated and trends 
over time between the two groups tested.  
Results: Rates of disease activity change by lifetime depression status were significantly 
different for the CDAI, PGA, EGA, pain, and HAQ; however, for incident depressive 
symptoms, only pain reached statistical significance.  The presence of depression was 
associated with slower rates of disease activity decline, and this effect varied by the time 
of onset.  Model based estimations of disease activity (CDAI) change at 1 year by 
lifetime prevalent depression status: -2.98 [-3.33 - - 2.64] and -3.97 [-4.31 - -3.63] in 
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those with and without a self-reported history of depression.  Similar results were 
obtained when defining “caseness” using incident depressive symptoms, but the 
magnitude of the effect was much lower.  Also, the depressive effect was greater for the 
patient-reported measures of disease activity compared to the physician assessed metrics.  
Conclusions: The results suggest that the presence of depression in RA impacts 
prospective changes in metrics reported by the patient: pain, functional status, and global 
assessment; and to some extent measures reported by providers, but not the number of 
swollen joints or acute phase reactants.  Moreover, this depressive effect varied by the 
time of onset, indicating effect modification, and that a greater case severity may be 
associated with a stronger temporal impact on RA disease activity. 
 
4.2 Background 
   Rheumatoid arthritis (RA), the most prevalent autoimmune arthritic disorder, is 
characterized by a plethora of comorbid conditions that comprise somatic and 
psychosocial impairments with a dizzying array of complex expressions and relations [1, 
103].  Despite innovations in RA treatment, specifically, the evolution of disease 
modifying anti-rheumatic drugs (DMARDs) regarding biologic response modifiers, there 
is still an immense gap in our understanding and clinical care of comorbidity in patients 
suffering from chronic physical disease [15, 103].  With an estimated meta-analytic point 
prevalence of 16.8%, from studies using diagnostic assessment criteria, major depressive 
disorder (MDD) is one of the most common co-occurring illnesses among RA patients 
68 
 
 
[26].  National Institute for Health and Care Excellence (NICE) guidelines recommend 
for the routine screening of depression in patients with chronic physical conditions; 
however, psychiatric comorbidities are under-recognized in specialty practices [28, 61, 
66]. 
 The etiological relationship between RA disease activity and MDD is diverse and 
constitutes a multitude of potential determinants and complex interrelationships [17, 19, 
88, 104].  This relationship is likely bi-directional, where each condition simultaneously 
influences the manifestation of the other, and studies among individuals with psoriatic 
arthritis (PsA) and early undifferentiated inflammatory arthritis (EIA) have demonstrated 
significant bi-directional effects between the two disorders [10, 11, 55, 56].  The possible 
mechanisms linking RA and MDD include biological, psychological, and behavioral 
factors, as well as the interaction of processes among these different domains [18, 20, 23, 
33, 35, 40, 98, 105].  Cross-sectional studies have consistently demonstrated a strong 
association between MDD and RA symptoms, suggesting positive correlations with 
composite disease activity, pain, function, global assessments, and acute phase reactants 
[22, 57, 84, 106].  Yet, the intrinsic lack of temporality in such research inhibits any 
ability to make causal interpretations. 
Of importance, and unfortunately a poorly studied area, is the impact of MDD on 
the evolution of RA disease activity.  There is a dearth of research literature that has 
examined the temporal association between depression and RA disease activity.  Studies 
have primarily focused on patient-reported pain, or depression as a moderator of 
psychological factors related to patient-reported pain [46-49].  Research suggests both 
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present and past depression is predictive of elevations in future pain, but that concurrent 
depressive symptoms are the predominant causal factor of this relationship [46, 48, 49].  
Evidence would also intimate that depression is a moderator of stress-associated disease 
activity changes, measured using tender joint counts and physician global ratings, but the 
effect did appear to be related to cell-mediated immunity [47].  Existing studies have 
issues with adjustment for confounders, small samples, and limited follow-up, but more 
importantly, none evaluated the direct temporal effect of depression on functionality, 
joint counts, acute phase reactants, and composite disease activity. 
Despite the high prevalence of MDD in RA patients, and the difficulties it creates 
with regard to medical management when co-occurring with chronic physical illness, 
there is a prohibitive gap in our current understanding of how MDD interacts with RA 
disease activity and influences the trajectory of the illness [15, 26, 29].  The aim of this 
study was to temporally predict longitudinal changes in RA disease activity among 
patients with and without reported depression to determine whether rates of change over 
time are different between the two groups. 
 
4.3 Methods 
Study Design and Populations 
 Two separate longitudinal studies were conducted using RA patients participating 
in the Consortium of Rheumatology Researchers of North America (CORRONA) 
registry.  This database is an extant prospective cohort that was created with the intention 
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of collecting longitudinal data on patients with rheumatic diseases from community based 
clinical practice sites [63].  Institutional Review Boards (IRB) of academic entities or a 
centralized IRB for participating private rheumatology clinics approve individuals for 
entry into the study, and all patients provide written informed consent at enrollment.  
Information is gathered from patients and their treating rheumatologists using standard 
enrollment and follow-up surveys that gather data on demographics, disease activity, 
disease severity, medication use, adverse events, and comorbidity.  The specific operating 
and funding mechanisms for the CORRONA registry have been previously published 
[63].  
Analytic samples were drawn from RA Patients (N=33,743) enrolled into the 
CORRONA registry between October 2001 and August 2012.  First, to examine the 
temporal impact of the self-reported baseline lifetime prevalence of depression on 
subsequent changes in RA disease activity, rates of disease activity change from study 
entry over follow-up were assessed by patients self-reported depression status at 
enrollment.  Patients without self-reported depression data at study entry (n=1,681), no 
observed clinical follow-up visits (n=7,530), or missing baseline data on disease activity 
and covariate measures (n=7,525), were excluded (Figure A.3).  The analytic sample 
comprised CORRONA RA patients (N=17,006) with observed self-reported depression 
at study entry and observed follow-up time with baseline data on disease activity and 
possible confounders.  A single propensity score (PS) matched (1:1) population of 
patients with and without lifetime prevalent depression at baseline (N=8,282) was created 
from this primary analytic cohort.  This work was replicated in secondary analyses 
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substituting the physician-reported lifetime depression indicator for the patient self-
report.  
Second, among patients without prevalent depression at study entry, patient with 
incident self-reports of depression who were compared to randomly matched controls 
with no observed longitudinal self-reports.  From the overall RA population (N=33,743), 
those with a self-reported history of depression (n=8,141) or missing prevalence data 
(n=1,681) at study entry and patients without follow-up visits (n=4,920) were excluded 
(Figure A.4).  Depressed patients were defined as those with an incident self-report of 
depression and were compared regarding their changes in RA disease activity to controls, 
defined as patients with no self-reports of depression during follow-up.  The visits where 
incident self-reports occurred (depressed) were assigned as the index date among 
depressed participants, which were then matched to a randomly selected follow-up visit 
from a patient with no prospective reports of depressive symptoms (controls).  Eligible 
index visits were required to have relevant disease activity and covariate data and 
observed follow-up time.  A total of 2,372 and 10,073 possible depressed and randomly 
selected controls, respectively, were available for inclusion.  Similar to the prevalence 
analysis, depressed patients (n=2,108) were PS matched (1:2) to potential controls 
(n=4,216).  This process was replicated in secondary analyses using an alternative case 
definition, successive depression, defined as the first two consecutive self-reports of 
depression. 
Depression Predictor Variables 
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 The depression measures were single-item evaluations collected from enrollment 
and follow-up survey forms.  Patient-reported depression measures were used for the 
primary study, while the clinician-reported measures were only used in secondary 
analyses.  CORRONA surveys capture data on a history of depression at enrollment, 
associated time of onset, and the existence of depression during follow-up.  Patient 
enrollment questionnaires ask participants to do the following: “Please fill a ‘NO’ or 
‘YES’ circle for each of the following conditions you have EVER had,” including 
“Depression (Feeling Blue),” as well as the categorized time of comorbidity onset (e.g., 
“YES Less than 1 year ago”).  Physician forms collect comorbidity data from enrollment 
surveys that ask them to indicate, “If the patient has or has had any of the following, fill 
in the box,” and an item for “Depression” is included.  Follow-up forms ask patients to 
acknowledge any, “Medical condition or symptom you have had SINCE YOU LAST 
FILLED OUT THIS FORM,” which contains an item for “Depression (Feeling Blue).” 
 The CORRONA depression measures do not represent MDD as assessed using 
the DSM.  Nonetheless, patient-reported depressive symptoms are frequently employed 
to evaluate the presence of the condition in everyday clinical care and have been used in 
prior RA registry research [25, 64, 99, 100].  Single-item depression symptom measures 
have been developed and validated as screening tools for use in patients with chronic 
physical, and evidence would suggest a high sensitivity but lower specificity with regards 
to case ascertainment [65, 87, 93].  Ultra-brief depression measures are valuable tools 
that provide important clinical information, and moreover, when validated against chart 
73 
 
 
abstractions or laboratory measures patients have consistently proven a strong capacity to 
recall prior comorbid conditions [86, 100-102].      
RA Disease Activity Outcomes 
 Outcome variables for the analysis comprised composite disease activity, joint 
counts, global assessments, pain, function, and acute phase reactants.  Composite disease 
activity measures included the clinical disease activity index (CDAI) and 28 joint disease 
activity score (DAS28) [67, 68].  The CDAI is a score calculated by summing the tender 
joint count (TJC), the swollen joint count (SJC), patient global assessment (PGA; visual 
analogue scale (VAS) 0-10 cm), and physician global assessment (EGA; VAS 0-10 cm) 
[67].  The DAS28 is a continuous value computed from the TJC, SJC, PGA, and 
erythrocyte sedimentation rate (ESR) with a mathematical formula.  Additional outcome 
measures were the previously described core components disease activity metrics: TJC, 
SJC, PGA, EGA, and ESR; and the following: patient-reported pain (VAS 0-10 cm), C-
reactive protein (CRP), and health assessment questionnaire score (HAQ) converted from 
modified HAQ values [69]. 
Covariate Measures 
For the prevalence analysis, covariate data was obtained from the time of their 
entry into the CORRONA registry, and thus all pertinent measures were from study 
baseline and time-invariant factors.  Conversely, in the incidence study that used follow-
up visits as the index time points, covariate data was obtained from both time-invariant 
and -varying measures.    
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 Self-reported demographic and socioeconomic measures included the following: 
gender, age, race, ethnicity, education, marital status, employment, and health insurance.  
Race and ethnicity were combined into categories: White, Black, Asian, Hispanic, and 
Other; and age was categorized into groupings: 18-24, 25-34, 35-44, 45-54, 55-64, 65-74, 
75-84, and 85+.  Patients’ education was captured as primary, high school, 
college/university, and don’t remember.  Marital status included the following 
characterizations: single, married/partnered, widowed, and divorced/separated; and 
employment was measured using six groups: full time, part time, unemployed, student, 
disabled and retired.  Lastly, health insurance was captured as one of the following: none, 
Medicaid, Medicare, and private.  Age group, education, marital status, employment, and 
insurance type were all obtained as a time-varying measure at patients’ index dates in the 
incidence study.   
 Behavioral and clinical characteristics were the following measures: smoking, 
alcohol use, exercise, disease duration, BMI (kilograms/meters²), and medical 
comorbidity.  Smoking and drinking were both collected as binary variables (ever vs. 
never); more complex measures are only captured on newer CORRONA survey forms.  
Exercise was captured as one of five categories: not at all, 1-2 times per week, 3-4 times 
per week, 5-6 times per week, and daily.  Comorbidity was measured using a composite 
score calculated from reports of past or present conditions from either patients or 
rheumatologists: included myocardial infarction, stroke, hypertension, other 
cardiovascular disorders, diabetes mellitus, pulmonary disease, cancer, peptic ulcer, other 
gastrointestinal disorders, and fractures [25].  Disease duration, BMI, comorbidity, 
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exercise, smoking, and alcohol use were all also time-varying covariates at patients’ 
index time points for the incidence analysis.    
Concomitant RA treatment factors, all of which were time-varying measures and 
only considered as possible confounders in the incidence analysis, included biologic 
DMARDs, biologic history, combination therapy, no DMARD utilization, prednisone, 
and methotrexate from patients assigned index date.  Biologic DMARD use at patients’ 
assigned index dates included the initiation of any of the commercially available agents: 
Enbrel, Humira, Remicade, Cimzia, Simponi, Actemra, Orencia, Kineret, and Rituxan.  
Biologic history (experienced vs. naïve) was defined as a reported utilization of any 
biologic DMARD prior to the index time point.  Combination therapy was characterized 
as utilization of biologic response modifier in addition to a non-biologic DMARD: 
Arava, Azulfidine, Imuran, Methotrexate, Plaquenil, Minocin, Ridaura, Cuprimine, and 
Cyclosporine.  No therapy was defined as not having any currently prescribed DMARD 
medications at patients’ assigned index date.  Prednisone and Methotrexate use were the 
current utilization of these therapies at the selected index visit.           
Confounding 
 PS matching was used to account for possible confounding factors and patients 
classified as depressed (prevalent or incident) were matched to controls [107].  In the 
lifetime prevalence study, RA patients with a self-reported history of depression were 
matched to patients with no prior depression at the time of their enrollment into the 
CORRONA registry.  For the incidence analysis, patients with incident self-reports of 
76 
 
 
depressive symptoms were matched in stratified blocks of yearly calendar time to 
controls with no prior depression or self-reports of depression during follow-up.  The 
block matching approach was used to account for the potential influence of changes in 
RA treatment patterns on the evolution of disease activity during follow-up.  Data were 
stratified into 1-year incremental blocks of time, and within each calendar year of time, 
visits for patients with incident reports of depressive symptoms were matched to visits for 
randomly selected controls with a probability score using random number generation.  
The likelihood of a patient-reported history of depression at study entry or 
incident depressive symptoms during follow-up was estimated with logistic regression 
models conditioned on covariates that were associated with the exposures.  For the 
prevalence study, propensity score model variables were the following: CDAI, patient 
pain, HAQ, gender, age group, race, ethnicity, health insurance, marital status, 
employment, BMI, comorbidity, smoking, drinking, and exercise.  The incorporation of 
the CDAI, patient pain, and HAQ were used to balance baseline differences in disease 
severity for all the outcome measures simultaneously.  In the incidence analysis, 
covariates included the same variables used in the prevalence model except alcohol use 
because it was not associated with incident depressive symptoms, in addition to education 
and concomitant treatment factors: prior biologic DMARD use, no current DMARD 
prescriptions, and prednisone use.  Depressed patients were then matched to controls at 
ratio of 1:1 and 1:2 for the prevalence and incidence analyses, respectively, using nearest 
neighbor matching and caliper of 0.05 without replacement [107].       
Statistical Analysis 
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The objective was to predict longitudinal changes in RA disease activity by 
prevalent or incident depressions status and determine whether the longitudinal rate of 
change significantly differed by the exposures.  The primary method of analysis was 
linear mixed effects models, which are appropriate for repeated measures and other 
clustered data [108].  The outcome variables constituted the previously described 
composite and core component measures of RA disease activity [67, 68, 70].  These are 
all continuous repeated measures data; however, the acute phase reactants (CRP and 
ESR) were log transformed due to highly skewed multivariate distributions.  Follow-up 
time, from study entry and index dates for prevalence and incidence analyses, 
respectively, was restricted to two years because this provided enough time to observe 
changes in disease activity, and the median time to recovery from a depressive episode is 
generally between 6 and 12 months [109].  Evaluation using Lowess curves showed non-
linear longitudinal trends for most outcomes, and thus time was modeled as a quadratic 
function in all analyses, and random effects were incorporated regarding intercepts and 
slopes for follow-up time.  CORRONA data is hierarchical, where patients are nested 
within physicians, which are clustered by practice sites.  Mixed effects models were 
clustered by patients, within data collection sites, because of low within-physician cluster 
correlations and standard error estimates that were comparable to the fully nested models.  
The basic unadjusted model form is below. 
DiseaseActivityi, j 0  1(Depression) 2(Time) 3(Time
2 ) 4 (Depression Time) 5(Depression Time
2 )
 The estimate of interest was the depression by follow-up time interaction, which 
tested whether the evolution of disease activity was significantly different by prevalent or 
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incident depression status.  The coefficients 3 + 4 represent the difference in the rates of 
disease activity change between those with and without reports of depression.  
Multivariable model fit was assessed using maximum likelihood ratio testing, and 
residual plots were used to evaluate for outlier data points.  To account for any remaining 
differences in baseline disease activity due to a poorer within-outcome measure matching 
precision in the PS matched samples, we further adjusted for both the main effect of the 
baseline outcome (categorized quintiles), being study entry and index dates for 
prevalence and incidence analyses, respectively, and its interaction with follow-up time 
in multivariable mixed effects models.  Model based estimations of disease activity at 
baseline and changes at 1 and 2 years follow-up were calculated.  The described analyses 
were replicated using the physician-reported lifetime prevalence measure and successive 
case definition regarding the prevalence and incidence analyses, respectively.  Secondary 
analyses were also performed in the propensity score matched prevalence sample using 
patient’s self-reported time of depression onset, where depressed patients were further 
divided into two groups based on their lifetime depression status that was categorized as 
an “onset within the last year” or “onset equal to or greater than 1 year.” 
 
4.4 Results 
Propensity Score Matching 
 The full analytic patient-reported lifetime prevalence cohort comprised 17,006 
patients with and without a history of depression (12,307 vs. 4,303, respectively), and 
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from this group depressed patients (n=4,131) were matched to controls (1:1) (Table 4.1).  
The propensity score model C-statistic was 0.71, which is a measure of the area under the 
curve (AUC) for a receiver operator operating characteristic (ROC) curve, and over 96% 
of the depressed patients were retained in the matched sample.  In the full study 
population, those with prior depression were more likely to be of lower SES, female, 
younger, widowed or divorced/separated, smokers, and physically inactive and have a 
greater level of BMI, comorbidity and disease activity.   After propensity matching, there 
was a successful rebalancing of all characteristics that were associated with prior 
depression at study entry, including most baseline outcome measure of disease activity.  
Similar results were obtained when these analyses were replicated using the physician-
reported lifetime prevalence measure, restricted to data where the measure was available 
(Table A.9).   
 The incidence study sample was composed of 12,445 eligible patients meeting the 
pre-specified cohort criteria, of which 2,372 had incident self-reports of depression and 
10,073 did not.  Individuals with incident onset depression (n=2,108) were matched (1:2) 
to controls (n=4,216) with self-reported no history of depression or longitudinal reports 
during follow-up (Table 4.2).  Among all available study participants, there were similar 
patterns regarding their demographic, socioeconomic, behavioral, and clinical 
characteristics as observed for the full prevalence sample.  Similarly, depressed patients 
also had higher levels of baseline disease severity for every outcome measure (Table 
A.10).  Concerning concomitant treatment factors at patients’ assigned index date, 
patients with incident depressive symptoms were more likely to be biologic experienced 
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and using prednisone (Table A.11).  There was a successful rebalancing of all baseline 
variables, including most baseline disease activity outcomes and concomitant treatment 
variables.  The secondary analyses that utilized a stricter successive case definition of 
depression yielded analogous findings (data not shown).     
Prevalent Depression 
 The unadjusted associations of RA disease activity by patient-reported lifetime 
depression status generally suggested no difference in the rates of change (Table A.12).  
Patients with prior depression had higher predicted baseline levels of disease severity, but 
the longitudinal decrease that was present for every outcome was similar by depression 
history for every measure, except CRP, which showed a significantly slower decline in 
patients with a history of depression.  Similar results were obtained when using the 
rheumatologist-reported depression measure (Table A.13).  However, in the matched 
patient-reported prevalence sample patients with a history of depression had significantly 
slower rates of decline (Table 4.3), evidenced by the predicted 1- and 2-year CDAI 
changes: -3.97 [-4.31 - -3.63] and -3.67 [-4.24 - -3.11] in patients without prior 
depression; and -2.98 [-3.33 - - 2.64] and -2.87 [-3.46 - -2.28] in those with a self-
reported history of depression.  There was statistically significant depression by follow-
up time interactions for the following outcome variables: CDAI, TJC, PGA, EGA, Pain, 
and HAQ.  The matched physician-reported prevalence sample the results were 
comparable; although, the magnitude of the effect sizes were larger but only the PGA and 
Pain outcomes reached statistical significance (Table A.14).  When categorizing patients’ 
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depression status by the self-reported time of onset in the matched sample, the rates of 
disease activity decline were inversely associated with time since onset, where patients 
with more recent depression had larger decreases compared to those with a more distal 
onset (Table 4.4).                    
Incident Depressive Symptoms 
 Unadjusted analyses using all patients with self-reported incident depressive 
symptoms and available control comparators suggested a significantly different rate in 
the longitudinal course of disease activity between the two groups (Table A.15).  
However, these findings are not adjusted for potential confounding factors, particularly 
baseline differences in disease activity, as done using PS matching in this study.  The 
unadjusted results would imply patients with the incident onset of depressive symptoms 
have significantly faster decreases in their disease activity from the index date, which is 
demonstrated by 1- and 2-year CDAI models based estimations of change from baseline: 
-0.65 [-0.82 - -0.48] and -0.89 [-1.16 - -0.62] in the controls; and -2.19 [-2.55 - -1.84] and 
-2.13 [-2.64 - -1.84] in the depressed, respectively.  Among the propensity score matched 
patients, the results were drastically different from the unadjusted associations and 
displayed prospective trends analogous to the adjusted prevalence findings; although, the 
effect sizes were smaller in magnitude (Table 4.5).   For every disease activity outcome 
measure in the matched sample, there were smaller prospective decreases in those with 
depressive symptoms and only patient-reported pain reach statistical significance: -0.53 [-
0.60 - -0.46] vs. -0.32 [-0.42 - -0.20] at 1-year; and -0.33 [-0.45 - -0.21]  vs. -0.07 [-0.24 - 
-0.10]  at 2-years.  Similar findings were obtained for the “successive” self-reported 
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depression case definition, but the magnitude of the prospective differences were larger 
(Table A.15). 
 
4.5 Discussion 
 This research is the first of its kind to comprehensively examine the temporal 
impact of depressive symptoms on longitudinal changes in the different measurement 
domains of RA disease activity.  Among propensity score matched samples, these 
longitudinal analyses consistently demonstrated that symptoms of depression were 
associated with a slower rate of disease activity decline; yet notably, our findings suggest 
that depressive symptoms have no detectable impact on swollen joints and acute phase 
reactants.  There were also distinct differences between the influence of prevalent versus 
incident depressive symptoms, where the effect sizes and number of significant 
associations was greater for patients with prior symptomology.  Moreover, the magnitude 
of this depressive effect was greater for the patient-reported disease activity outcomes 
when compared to the physician reported measures.  Our results indicate that depression 
temporally influences the trajectory of RA symptoms, but the effect is limited to patient- 
and provider-reported disease activity measures and likely varies by the clinical case 
severity.          
 The disease activity measures affected by depressive symptoms included the 
CDAI, TJC, PGA, EGA, patient-reported pain, and HAQ, but not the more objective 
markers of localized swelling (SJC) and serum inflammation (ESR and CRP).  These 
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findings parallel previous studies that have consistently demonstrated temporal 
associations between depression and patient-reported outcomes; specifically, pain, among 
RA, PsA, and EIA patients [46, 48, 55, 110].  Prior research also indicates that depression 
moderates shifts in disease activity due to stress, measured using patient-reported pain, 
EGA, and TJC, but immune activation was not associated with these changes [47].  The 
results of our work has replicated prior data and further expanded upon them to show 
direct temporal associations between symptoms of depression and multiple domains of 
disease activity measurement.  Researchers have hypothesized that stress and the 
associated perseverative cognitions that characterize depression lead to the stimulation of 
pro-inflammatory cytokine pathways and bear a role in the etiology of chronic physical 
diseases [17, 20, 88].  Cross-sectional studies yielding significant positive correlations 
between depression and inflammatory biomarkers further support such assertions [18].  
However, the results of this research and prior longitudinal studies provide no support for 
the premise that depression and RA share biological mechanisms regarding serum 
inflammation.  Our findings suggest the temporal effect of depressive symptoms is 
limited to global assessments of disease activity and measures of pain and function. 
 The results also imply that there is effect heterogeneity concerning 
depression’s temporal effect on disease activity in the context of the time of onset, 
evidenced by the difference in the results between those reporting a history of depression 
versus individuals with the incident onset of symptoms.  Despite yielding similar 
depressive effects, when assessing temporal associations using prevalent and incident 
depressive symptom measures the magnitude and number of significant associations was 
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greater compared to the controls for those RA patients reporting a history of depression.  
Considering that research into affective disorders has shown that some of the strongest 
predictors of the frequency and severity of a depressive episode are age of onset and 
stressful lifetime events, the variation in effect by patient’s reported time of onset may 
simply be a crude proxy for their case severity [111, 112].  This is further supported by 
the prevalence analyses that trended by the self-reported time of depression onset, and the 
evaluations using the physician-reported measure (awareness by the provider may be 
representative of case level mood disorder) and successive case definition that showed a 
stronger temporal effect compared to the results from the primary patient-reported 
prevalence and incidence analyses, respectively.  These findings suggest that the greater 
the severity of the depressive symptomology, the larger the difference in the longitudinal 
trajectory of disease activity it will create concerning the outcome measures that it 
impacts, which is certainly plausible given research has shown strong linear relationships 
between depression and future disease activity [46, 48]. 
 Depressive symptoms were temporally associated with changes in patient-
reported pain, function, and global assessment of disease activity; and physician-reported 
tender joints and global assessment of disease activity; however, the magnitude of the 
difference in the longitudinal rates of change in these outcomes between the groups were 
greater for the patient-reported outcome measures.  Prior studies in RA patients have 
primarily focused on patient-reported pain, and thus provide few relevant inferences 
when examining all RA disease activity simultaneously [46-49].  Research among 
patients with EIA and PsA have demonstrated a temporal link between depression and 
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pain, but not disease activity as measured using swollen joints [55, 56].  Clearly, 
depression is temporally related to prospective changes in disease activity; although, the 
impact on disease progression varies depending on the type of measure; and the 
mechanisms that mediate these associations are not understood.  Evidence suggests that 
potential causal explanations for this relationship include measurement response shift 
created from perseverative cognitions, cell-mediated processes that affect inflammation, 
or a confluence of psychological, behavioral, and biological factors which impact pain.  
The stronger associations regarding the patient-reported measures of disease activity, in 
addition to the lack of any significant temporal effects on joint swelling and serum 
inflammation, indicate that shared immunological mechanisms are likely not a common 
causal underpinning that connects these two conditions. 
Strengths and Limitations 
The strengths of this study include the full array of RA disease activity measures, 
longitudinal design using a national RA registry sample, rigorous statistical adjustment, 
and robust study findings that exhibited consistent patterns across a multitude of different 
assessments.  Likewise, these studies have several limitations.  The metrics for prevalent 
and incident depression were indicators for the presence and absence of the core 
condition symptomology, rather than measures of major depressive disorder as assessed 
using diagnostic criteria in the clinical setting.  Also of note, the temporal ordering 
between depression and the longitudinal impact on the different domains of RA disease 
activity is not well known.  Given that the utilized propensity score matching 
methodology simultaneously balanced all baseline disease activity measures, this crude 
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approach may have resulted in an over-adjustment and a corresponding underestimation 
of the true differences between patients with and without depressive symptoms.  Lastly, 
multivariable mixed effects model did not control for time-varying factors that may have 
changed after the index time points, which could potentially influence the evolution of 
disease activity, if highly correlated with patient’s depression status.   
 
4.6 Conclusions  
 There are several important implications of these results.  Foremost, the temporal 
impact of depressive symptoms extends beyond self-reported measures of pain and 
includes global assessments of disease activity, functionality, and tender joints, even after 
rigorous statistical adjustment.  Moreover, the findings suggest this depressive effect 
increases with the level of depression case severity; still, these data would indicate 
symptoms of depression have no appreciable impact on measures of localized and serum 
inflammation.  Through concurrently assessing the temporal influence of depression on 
every measurement domain of RA disease activity, our studies have also contributed 
essential knowledge to the understanding of the fundamental mechanisms that may be 
responsible for mediating this relationship.  Previous work has proposed two pertinent 
hypotheses that fit into the collective meaning of the study results: the negative affect and 
associated repetitive thinking that typifies major depression leads to a response tendency 
concerning patient-reported disease activity measures; and depressive symptomology 
creates changes in behavioral patterns and a corresponding reduction in physical activity 
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and loss of natural endorphins that causes increases in musculoskeletal pain [29].  
Accordingly, future research must be conducted to ascertain how the presence of 
depression is related to the subjective measurement responses of RA disease activity as 
well as changes in behavior, engagement in activities of daily living, and endorphins 
among patients with chronic physical disease.            
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Table 4.1 Descriptive data by patient-reported lifetime depression status for the full study population and 
propensity score matched sample. 
Variable Full Study Population Matched Sample 
  
No Depression 
(N=12,703) 
Depression  
(N=4,303) 
P No Depression 
(N=4,141) 
Depression  
(N=4,141) 
P 
Female 9,295 73.17% 3,652 84.87% <0.001 3,491 84.30% 3,480 84.04% 0.74 
Race/Ethnicity           
White 10,749 84.62% 3,718 86.40% <0.001 3,546 85.63% 3,563 86.04% 0.97 
Hispanic 589 4.64% 204 4.74%  205 4.95% 201 4.85%  
Black 934 7.35% 270 6.27%  278 6.71% 268 6.47%  
Asian 267 2.10% 42 0.98%  41 0.99% 43 1.04%  
Other 164 1.29% 69 1.60%   71 1.71% 66 1 59%   
Age1 (yrs) 58.2 13.6 56.5 12.2 <0.001 56.8 12.5 56.8 12.4 0.79 
Education           
Primary  529 4.16% 175 4.07% 0.44 198 4.78% 159 3.84% <0.001 
High School 5,003 39.38% 1,650 38.35%  1,765 42.62% 1,586 38.30%  
College/University 7,042 55.44% 2,441 56.73%  2,129 51.41% 2,362 57.04%  
Don’t Remember 129 1.02% 37 0.86%   49 1.18% 34 0.82%   
Insurance            
None 238 1.87% 110 2.56% <0.001 110 2.66% 106 2 56% 0.69 
Medicaid 266 2.09% 199 4.62%  168 4.06% 152 3.67%  
Medicare 2,439 19.20% 834 19.38%  796 19.22% 775 18.72%  
Private 9,760 76.83% 3,160 73.44%   3,067 74.06% 3,108 75.05%   
Marital Status           
Single 1,410 11.10% 471 10.95% <0.001 453 10.94% 455 10.99% 0.88 
Married/Partnered 8,689 68.40% 2,643 61.42%  2,579 62.28% 2,609 63.00%  
Widowed 1,231 9.69% 446 10.36%  448 10.82% 433 10.46%  
Divorced/Separated 1,373 10.81% 743 17.27%   661 15.96% 644 15.55%   
Employment           
Full Time 5,337 42.01% 1,390 32.30% <0.001 1,418 34.24% 1,422 34.34% 0.96 
Part Time 1,254 9.87% 397 9.23%  401 9.68% 411 9 93%  
Unemployed 1,247 9.82% 594 13.80%  580 14.01% 583 14.08%  
Student  113 0.89% 27 0.63%  27 0.65% 26 0.63%  
Disabled 969 7.63% 911 21.17%  736 17.77% 704 17.00%  
Retired 3,783 29.78% 984 22.87%   979 23.64% 995 24.03%   
CDAI 12.7 12.4 16.5 13.7 <0.001 16.1 13.5 15.9 13.5 0.56 
Disease Duration1 (yrs) 8.7 9.6 8.9 9.8 0.13 9.3 9.9 8.9 9.8 0.07 
Alcohol Use 6,176 48.62% 1,955 45.43% <0.001 1,901 45.91% 1,899 45.86% 0.97 
Smoking 1,769 13.93% 791 18.38% <0.001 740 17.87% 721 17.41% 0.58 
Exercise           
None 3,927 30.91% 1,560 36.25% <0.001 1,521 36.73% 1,473 35.57% 0.71 
1-2 times/week 3,841 30.24% 1,404 32.63%  1,326 32.02% 1,340 32.36%  
3-4 times/week 2,735 21.53% 804 18.68%  757 18.28% 799 19.29%  
5-6 times/week 844 6.64% 205 4.76%  208 5.02% 200 4.83%  
Daily 1,356 10.67% 330 7.67%   329 7.94% 329 7 94%   
BMI (kg/m^2) 28.8 6.8 30.6 7.7 <0.001 30.2 7.6 30.3 7.5 0.64 
Comorbidity2 1 [0-2] 1 [0-2] <0.001 1 [0-2] 1 [0-2] 0.59 
1Continuous value given as the mean value and standard deviation; 2Contiunous value given as the median and IQR.  
 
89 
 
 
Table 4.2 Descriptive characteristics by incident depression status among the full study population and propensity 
score matched sample. 
  Full Study Population Matched Sample 
Variable 
No Depression 
(N=10,073) 
Depression 
 (N=2,372) 
P 
Value 
No Depression 
(N=4,216) 
Depression 
 (N=2,108) 
P 
Value 
Female 7,214 71.62% 1,881 79.30% <0.001 3,299 78.25% 1,649 78.23% 0 98 
Race/Ethnicity     <0.001     0 27 
White 8,596 85.34% 1,967 82.93%  3,523 83.56% 1,782 84.54%  
Hispanic 485 4.81% 168 7.08%  245 5.81% 135 6.40%  
Black 655 6.50% 159 6.70%  302 7.16% 127 6.02%  
Asian 198 1.97% 34 1.43%  69 1.64% 26 1.23%  
Other 139 1.38% 44 1.85%   77 1.83% 38 1.80%   
Age1 (yrs) 60.7 13.3 59.1 13.5 <0.001 59.8 13.4 59.7 13.4 0.81 
Education     0.004     0 99 
Primary  413 4.10% 126 5.31%  212 5.03% 107 5.08%  
High School 4,057 40.28% 1,009 42.54%  1,774 42.08% 894 42.41%  
College/University 5,506 54.66% 1,216 51.26%  2,187 51.87% 1,087 51.57%  
Don’t Remember 97 0.96% 21 0.89%   43 1.02% 20 0.95%   
Insurance      <0.001     0.82 
None 130 1.29% 59 2.49%  77 1.83% 33 1.57%  
Medicaid 131 1.30% 65 2.74%  81 1.92% 45 2.13%  
Medicare 2,179 21.63% 491 20.70%  874 20.73% 442 20.97%  
Private 7,633 75.78% 1,757 74.07%   3,184 75.52% 1,588 75.33%   
Marital Status     <0.001     0.80 
Single 1,042 10.34% 252 10.62%  450 10.67% 214 10.15%  
Married/Partnered 7,032 69.81% 1,538 64.84%  2,788 66.13% 1,398 66.32%  
Widowed 1,080 10.72% 275 11.59%  513 12.17% 250 11.86%  
Divorced/Separated 919 9.12% 307 12.94%   465 11.03% 246 11.67%   
Employment     <0.001     0.68 
Full Time 3,916 38.88% 786 33.14%  1,482 35.15% 741 35.15%  
Part Time 958 9.51% 253 10.67%  448 10.63% 218 10.34%  
Unemployed 993 9.86% 305 12.86%  549 13.02% 250 11.86%  
Student  57 0.57% 12 0.51%  21 0.50% 8 0.38%  
Disabled 692 6.87% 336 14.17%  461 10.93% 248 11.76%  
Retired 3,457 34.32% 680 28.67%   1,255 29.77% 643 30.50%   
CDAI 8 9 10.0 14.0 12.7 <0.001 12.5 11.6 12.3 11.4 0.65 
Disease Duration1 (yrs) 11.2 9.8 11.2 10.3 0.85 11.8 9 9 11.2 10.3 0.02 
Alcohol Use 4,731 46.97% 1,040 43.84% 0.006 1,840 43.64% 930 44.12% 0.72 
Smoking 1,173 11.64% 400 16.86% <0.001 633 15.01% 319 15.13% 0 90 
Exercise     <0.001     0 99 
None 2,823 28.03% 823 34.70%  1,360 32.26% 684 32.45%  
1-2 times/week 3,036 30.14% 710 29.93%  1,272 30.17% 646 30.65%  
3-4 times/week 2,325 23.08% 488 20.57%  912 21.63% 452 21.44%  
5-6 times/week 808 8.02% 109 4.60%  217 5.15% 106 5.03%  
Daily 1,081 10.73% 242 10.20%   455 10.79% 220 10.44%   
BMI (kg/m^2) 28.5 6.5 29 6.9 <0.001 28.9 6 9 28.9 6.7 0.71 
Comorbidity2 1 [0-1] 1 [0-2] <0.001 1 [0-2] 1 [0-2] 0.78 
1Continuous value given as the mean value and standard deviation; 2Contiunous value given as the median and IQR.  
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Table 4.3 Disease activity data by patient-reported lifetime depression status at the time of 
patient enrollment in the full population and propensity score matched sample. 
Full Study Population 
Variable Range 
No 
Depression 
Depression P Value SD Standardized 
Difference 
CDAI 0-76 12.68 16.46 <0.001 12.85 0.29 
DAS  0-10 3.48 3.91 <0.001 1.60 0.27 
TJC 0-28 3.73 5.46 <0.001 5.91 0.29 
SJC 0-28 4.03 4.36 <0.001 5.48 0.06 
PT Global 0-100 27.47 38.99 <0.001 26.50 0.43 
MD Global 0-100 21.67 26.70 <0.001 20.98 0.24 
PT Pain 0-100 29.98 41.81 <0.001 27.61 0.43 
HAQ 0-3 0.77 1.10 <0.001 0.64 0.52 
CRP (mg/L) 0-200 13.10 13.55 0.87 88.78 0.01 
ESR (mm/hr) 0-300 22.9 22.99 0.86 21.31 0.00 
Matched Sample  
Variable Range 
No 
Depression 
Depression P Value SD Standardized 
Difference 
CDAI 0-76 16.09 15.92 0.56 16.01 0.01 
DAS  0-10 3.94 3.84 0.04 3.89 0.03 
TJC 0-28 4.94 5.23 0.04 5.08 0.06 
SJC 0-28 4.85 4.35 <0.001 4.6 0.11 
PT Global 0-100 36.8 37.35 0.36 37.08 0.01 
MD Global 0-100 26.31 26 0.53 26.16 0.01 
PT Pain 0-100 40.45 40.09 0.56 40.27 0.01 
HAQ 0-3 1.06 1.06 0.61 1.06 0.00 
CRP (mg/L) 0-200 12.27 13.59 0.49 12.93 0.10 
ESR (mm/hr) 0-300 25.03 22.84 <0.001 23.95 0.09 
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Table 4.4 Model based estimates of disease activity by patient-reported lifetime depression status at baseline and the 
corresponding change at 1 year and 2 years follow-up among propensity score matched sample.   
Depression Outcome N Scale ● Baseline  ● Year 1 ∆ ● Year 2 ∆   
No CDAI 4,141 0-76 15.70 [15.30-16.10] -3.97 [-4.31 - -3.63] -3.67 [-4.24 - -3 11]   
Yes CDAI*** 4,141 0-76 15.59 [15.91-15.99] -2.98 [-3.33 - -2.64] -2.87 [-3.46 - -2 28]   
No DAS28 2,091 0-10 3.89 [3.84-3.94] -0.36 [-0.41 - -0.30] -0.43 [-0.53 - -0 34]   
Yes DAS28 2,062 0-10 3.91 [3.86-3.96] -0.27 [-0.33 - -0.22] -0.34 [-0.44 - -0 24]   
No TJC 4,141 0-28 4.90 [4.70-5.11] -1.42 [-1.60 - -1.25] -1.38 [-1.67 - -1.09]   
Yes TJC** 4,141 0-28 4.92 [4.72-5.13] -1.06 [-1.24 - -0.88] -0.91 [-1.22 - -0.61]   
No SJC 4,141 0-28 4.39 [4.16-4.61] -1.30 [-1.45 - -1.16] -1.25 [-1.48 - -1.02]   
Yes SJC 4,141 0-28 4.29 [4.07-4.51] -1.17 [-1.31 - -1.02] -1.26 [-1.50 - -1.02]   
No PGA 4,141 0-10 3.69 [3.62-3.76] -0.53 [-0.61 - -0.45] -0.36 [-0.49 - -0 22]   
Yes PGA*** 4,141 0-10 3.69 [3.62-3.75] -0.16 [-0.24 - -0.08] -0.03 [-0.17 - 0.11]   
No EGA 4,141 0-10 2.67 [2.59-2.75] -0.74 [-0.80 - -0.69] -0.68 [-0.78 - -0 59]  † 
Yes EGA** 4,141 0-10 2.64 [2.55-2.72] -0.62 [-0.67 - -0.56] -0.53 [-0.62 - -0.43]   
No Pain 4,141 0-10 4.01 [3.94-4.09] -0.56 [-0.65 - -0.48] -0.32 [-0.46 - -0 17]   
Yes Pain*** 4,141 0-10 4.01 [3.93-4.08] -0.20 [-0.28 - -0.12] -0.05 [-0.20 - 0.09]   
No HAQ 4,141 0-3 1.05 [1.04-1.07] -0.09 [-0.11 - -0.08] -0.07 [-0.09 - -0.04]   
Yes HAQ*** 4,141 0-3 1.06 [1.04-1.07] -0.02 [-0.04 - -0.01] 0.01 [-0.02 - -0.04]   
No Log CRP 1,395 N/A 0.71 [0.69-0.74] -0.07 [-0.09 - -0.04] -0.09 [-0.14 - -0.05]   
Yes Log CRP 1,380 N/A 0.71 [0.68-0.73] -0.03 [-0.06 - -0.01] -0.08 [-0.12 - -0.03]   
No Log ESR 2,099 N/A 1.24 [1.23-1.25] -0.02 [-0.03 - -0.01] -0.02 [-0.04 - 0.01]   
Yes Log ESR 2,070 N/A 1.24 [1.23-1.25] -0.02 [-0.03 - -0.01] -0.01 [-0.03 - 0.01]   
Prior depression by follow-up time interaction: * P <0.05; ** P <0.01; *** P <0.001   
● Indicates mixed effects models were further adjusted for both the main effect of the baseline outcome (categorized quintiles) 
and its interaction with follow-up time.   
N/A means the outcome measure was a continuous value with no definitive measurement scale.   
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Table 4.5 Model based estimates of disease activity by patient-reported depression status at baseline categorized by the time of 
reported of onset and the corresponding changes at 1-year and 2-years follow-up among the propensity score matched sample.  
Depression Outcome Scale N ● Baseline ● 1 Year ∆  ● 2 Years ∆  
P 
Value 
No CDAI 0-76 4,099 15.73 [15.32-16.13] -3.98 [-4.33 - -3.64] -3.73 [-4.29 - -3.16] <0.001 
< 1 YearA CDAI 0-76 1,429 15.78 [15.26-16.30] -3.26 [-3.86 - -2.66] -2.90 [-4.00 - -1.80]  
>= 1 YearA CDAI 0-76 2,670 15.55 [15.11-15.99] -2.81 [-3.23 - -2.38] -2.63 [-3.33 - -1.92]   
No DAS28 0-10 2,076 3.89 [3.84-3.94] -0.35 [-0.41 - -0.30] -0.43 [-0.53 - -0.33] 0.08 
< 1 Year DAS28 0-10 723 3.94 [3.88-4.01] -0.35 [-0.44 - -0.25] -0.37 [-0.56 - -0.18]  
>= 1 YearA DAS28 0-10 1,320 3.89 [3.83-3.95] -0.23 [-0.30 - -0.16] -0.32 [-0.44 - -0.19]   
No TJC 0-28 4,099 4.91 [4.70-5.12] -1.43 [-1.60 - -1.25] -1.40 [-1.69 - -1.10] 0.04 
< 1 Year TJC 0-28 1,429 5.03 [4.76-5.30] -1.09 [-1.40 - -0.78] -1.06 [-1.63 - -0.50]  
>= 1 YearA TJC 0-28 2,670 4.88 [4.65-5.10] -1.05 [-1.27 - -0.84] -0.85 [-1.21 - -0.48]   
No SJC 0-28 4,099 4.39 [4.17-4.61] -1.31 [-1.45 - -1.17] -1.27 [-1.50 - -1.04] 0 57 
< 1 Year SJC 0-28 1,429 4.26 [4.00-4.52] -1.26 [-1.51 - -1.00] -1.31 [-1.76 - -0.86]  
>= 1 Year SJC 0-28 2,670 4.32 [4.08-4.55] -1.12 [-1.30 - -0.95] -1.27 [-1.55 - -0.98]   
No PGA 0-10 4,099 3.70 [3.63-3.77] -0.54 [-0.62 - -0.42] -0.38 [-0.51 - -0.24] <0.001 
< 1 YearA PGA 0-10 1,429 3.71 [3.62-3.81] -0.21 [-0.35 - -0.07] -0.08 [-0.34 - 0 19]  
>= 1 YearA PGA 0-10 2,670 3.69 [3.61-3.77] -0.15 [-0.24 - -0.05] -0.02 [-0.18 - 0 15]   
No EGA 0-10 4,099 2.67 [2.59-2.75] -0.75 [-0.80 - -0.69] -0.69 [-0.78 - -0.60] 0.001 
< 1 Year EGA 0-10 1,429 2.65 [2.56-2.75] -0.64 [-0.74 - -0.54] -0.50 [-0.68 - -0.32]  
>= 1 YearA EGA 0-10 2,670 2.63 [2.55-2.72] -0.61 [-0.68 - -0.54] -0.54 [-0.66 - -0.43]   
No Pain 0-10 4,099 4.02 [3.95-4.09] -0.58 [-0.66 - -0.50] -0.33 [-0.47 - -0.19] <0.001 
< 1 YearA Pain 0-10 1,429 4.04 [3.95-4.14] -0.20 [-0.34 - -0.06] -0.20 [-0.47 - 0.07]  
>= 1 YearA Pain 0-10 2,670 4.02 [3.94-4.10] -0.22 [-0.32 - -0.12] -0.01 [-0.18 - 0 17]   
No HAQ 0-3 4,099 1.06 [1.04-1.07] -0.09 [-0.11 - -0.08] -0.07 [-0.10 - -0.04] <0.001 
< 1 YearA HAQ 0-3 1,429 1.06 [1.04-1.08] -0.04 [-0.06 - -0.01] -0.03 [-0.08 - -0.03]  
>= 1 YearA HAQ 0-3 2,670 1.06 [1.04-1.07] -0.02 [-0.04 - 0.01] 0.03 [-0.01 - 0.06]   
No Log CRP N/A 1,383 0.71 [0.69-0.74] -0.07 [-0.09 - -0.04] -0.10 [-0.14 - -0.05] 0 22 
< 1 YearA Log CRP N/A 531 0.70 [0.67-0.73] -0.01 [-0.05 - 0.03] -0.07 [-0.18 - 0.03]  
>= 1 Year Log CRP N/A 828 0.71 [0.68-0.74] -0.06 [-0.09 - -0.03] -0.09 [-0.15 - -0.33]   
No Log ESR N/A 2,084 1.24 [1.23-1.25] -0.02 [-0.03 - -0.01] -0.02 [-0.04 - 0.001] 0.69 
< 1 Year Log ESR N/A 728 1.24 [1.23-1.26] -0.03 [-0.05 - -0.01] -0.02 [-0.06 - 0.02]  
>= 1 Year Log ESR N/A 1,323 1.24 [1.23-1.25] -0.01 [-0.03 - 0.001] -0.01 [-0.03 - 0.02]   
AIndicates pairwise comparison versus those with no history of depression was statistically significant; BIndicates the pairwise 
comparison versus those with a history of depression with a reported onset within the last year was statistically significant. 
● Indicates mixed effects models were further adjusted for both the main effect of the baseline outcome (categorized quintiles) and its 
interaction with follow-up time. 
N/A means the outcome measure was a continuous value with no definitive measurement scale. 
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Table 4.6 Model based estimates of disease activity by incident depression status at baseline and the corresponding change at 1 year 
and 2 years follow-up among a propensity score matched sample. 
Depression Variable N Scale ● Baseline  ● Year 1 ∆ ● Year 2 ∆ 
No CDAI 4,216 0-76 12.24 [11.89-12.59] -1.90 [-2.18 - -1.63] -2.08 [-2.52 - -1.63] 
Yes CDAI 2,108 0-76 12.25 [11.84-12.66] -1.52 [-1.92 - -1.13] -1.62 [-2.25 - -0.99] 
No DAS28 2,912 0-10 3.46 [3.42-3.50] -0.15 [-0.19 - -0.11] -0.23 [-0.29 - -0.16] 
Yes DAS28 1,491 0-10 3.48 [3.43-3.53] -0.12 [-0.17 - -0.06] -0.15 [-0.24 - -0.06] 
No TJC 4,216 0-28 3.40 [3.21-3.60] -0.63 [-0.77 - -0.49] -0.78 [-0.99 - -0.56] 
Yes TJC 2,108 0-28 3.45 [3.23-2.67] -0.50 [-0.70 - -0.31] -0.48 [-0.78 - -0.18] 
No SJC 4,216 0-28 3.44 [3.23-3.65] -0.56 [-0.68 - -0.43] -0.73 [-0.93 - -0.53] 
Yes SJC 2,108 0-28 3.43 [3.20-3.66] -0.45 [-0.63 - -0.27] -0.77 [-1.06 - -0.49] 
No PGA 4,216 0-10 3.29 [3.24-3.35] -0.42 [-0.49 - -0.35] -0.18 [-0.30 - -0.07] 
Yes PGA 2,108 0-10 3.29 [3.22-3.36] -0.30 [-0.40 - -0.20] -0.09 [-0.26 - 0.07] 
No EGA 4,216 0-10 1.47 [1.37-1.57] -0.34 [-0.38 - -0.30] -0.33 [-0.40 - -0.25] 
Yes EGA 2,108 0-10 1.46 [1.36-1.57] -0.30 [-0.36 - -0.24] -0.34 [-0.44 - -0.23] 
No Pain 4,216 0-10 3.62 [3.56-3.67] -0.53 [-0.60 - -0.46] -0.33 [-0.45 - -0.21] 
Yes Pain** 2,108 0-10 3.64 [3.57-3.71] -0.32 [-0.42 - -0.22] -0.07 [-0.24 - 0.10] 
No HAQ 4,216 0-3 0.97 [0.96-0.08] -0.07 [-0.08 - -0.05] -0.03 [-0.06 - -0.01] 
Yes HAQ 2,108 0-3 0.97 [0.96-0.99] -0.05 [-0.07 - -0.03] -0.01 [-0.05 - 0.02] 
No Log CRP 1,765 N/A 0.56 [0.53-0.59] -0.04 [-0.06 - -0.02] -0.032 [-0.066 - 0.003] 
Yes Log CRP 877 N/A 0.61 [0.59-0.64] -0.04 [-0.07 - -0.01] -0.06 [-0.11 - -0.01] 
No Log ESR 2,965 N/A 1.23 [1.22-1.24] -0.004 [-0.012 - 0.05] 0.004 [-0.011 - 0.019] 
Yes Log ESR 1,509 N/A 1.22 [1.21-1.23] 0.001 [-0.012 - 0.013] 0.004 [-0.017 - 0.026] 
Incident depression by follow-up time interaction: * P <0.05; ** P <0.01; *** P <0.001   
● Indicates mixed effects models were further adjusted for both the main effect of the baseline outcome (categorized quintiles) and its 
interaction with follow-up time. 
N/A means the outcome measure was a continuous value with no definitive measurement scale. 
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CHAPTER V: 
THE MODERATING EFFECTS OF DEPRESSION ON BIOLOGIC DISEASE 
ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95 
 
 
5.1 Abstract 
Background: Depression is a common comorbid condition in rheumatoid arthritis (RA) 
patients that may influence the evolution of disease progression, and consequently, affect 
response to therapeutic treatments. 
Methods: RA patients initiating a biologic DMARD with a 6- or 12-months (+/- 2 
months) follow-up visit were identified.  Patients classified as depression were compared 
to controls with respect to achieving remission or low disease activity (LDA) based on 
the clinical disease activity index (CDAI).  To account for confounders, particularly 
differences in baseline disease severity, inverse probability weighting was used due to the 
high correlation between disease activity measures and their strong association with the 
outcomes.  Logistic regression was then used to estimate odd ratios (ORs) and 95% 
confidence intervals (CIs) and assess unadjusted and adjusted associations. 
Results: Response rates were significantly different between patients with and without 
reports of depression receiving biologic treatment at 6- and 12-months follow-up: 15.51% 
vs. 6.59, 16.71% vs. 9.52%, 36.99% vs. 27.15%, 35.84% vs. 25.24 for remission and 
LDA, respectively.  The corresponding ORs for remission and LDA in the depressed 
were 0.38 [0.25-0.58] and 0.64 [0.49-0.83] at 6 months and 0.53 [0.36-0.77] and 0.60 
[0.45-0.81] at 12 months, respectively.  The remission ORs from propensity score 
weighted models displayed similar patterns: 0.48 [0.30-0.77] at 6 months and 0.67 [0.44-
1.04] at 12-months.  Adjusted LDA effect estimates indicated only a slightly lower 
likelihood of response: 0.90 [0.66-1.22] at 6 months and 0.88 [0.63-1.23] at 12 months. 
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Conclusions: The findings indicate that depression is associated with a lower chance of 
response, particularly CDAI remission, but not LDA.  However, it is unclear whether this 
association with achieving clinical remission is related to a substantive impact on disease 
expression or is due to the effect on patient’s experience of their symptoms.     
 
5.2 Background 
Medical comorbidity is a significant problem in patients with rheumatoid arthritis (RA), 
the most prevalent inflammatory arthritic condition in the United States that affects an 
estimated 1.3 Americans [1, 103].  Psychiatric disorders are common in the RA 
population, particularly clinical depression, with an estimated point prevalence of 16.8% 
(10%-23%) that is significantly greater compared to the normal individuals [5, 26].  
Clinical guidelines recommend that physicians be aware of depression in those suffering 
from chronic physical illness, yet the condition is under-recognized in the primary care 
setting and specialty practices, and this is especially an issue in rheumatology clinics [28, 
61, 64, 77].  The presence of depression in RA may influence the evolution of disease 
activity, and correspondingly, the clinical outcomes of therapeutic treatment [29]. 
 Biologic disease modifying anti-rheumatic drugs (DMARDs) revolutionized RA 
care and not only increased within-patient clinical response but provided viable treatment 
options for patients not responding to conventional treatments.  In some populations, the 
utilization of these medications was estimated to have tripled in seven years from 13% to 
41% [30]. Nonetheless, despite such improvements, when depression co-occurs in the 
context of chronic physical disease medical management often becomes difficult, and 
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data suggests more than 20% of patients starting biologic therapy suffer from depression 
[15, 31].  More specifically, researchers have posited that a unimodal treatment approach 
will lead to improvements in the two together; however, interventional study data 
indicates the presence of depression results in poorer therapeutic response for both 
conditions when either one is treated individually [14, 15].  
 Existing data implies that the presence of comorbid depression therapy has a 
detrimental impact on treatment response [53, 54].  A post analysis of clinical trial data 
demonstrated that in patients starting biologic therapy there was a significantly lower 
likelihood of achieving remission and low disease activity as defined using the DAS28 at 
2 years follow-up [54].  Moreover, an observational study revealed similar findings of a 
decreased rate of disease activity decline among treated individuals suffering from 
chronic depression [53].  Depression may influence the longitudinal trajectory of RA 
disease activity, and accordingly, affect how patients’ respond biologic response 
modifiers, but it is unclear whether this is due to a tangible effect on RA symptoms or a 
consequence of depression’s impact on how patients respond to the self-reported 
measures of disease activity [29].  More importantly, extant methodologies of have 
utilized small and restricted study samples and inadequate statistical adjustment for 
potential confounders, particularly baseline differences in disease severity. 
 Depression in RA is associated with a higher risk for mortality, greater work 
disability, increased health care costs, and may influence the prospective course of 
disease acidity and clinical treatment [6, 8, 9, 29].  Notably, few studies have rigorously 
investigated how this important and highly prevalent comorbidity effects response to 
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biologic DMARDs, even though comparative effectiveness research (CER) concerning 
these treatments has been named as a top priority by the Institute of Medicine (IOM) 
[113].  The objective of this study was to evaluate the moderating effects of depressive 
symptomology on response to biologic agents using a large national RA registry. 
 
5.3 Methods 
Study Data 
 The Consortium of Rheumatology Researchers of North America is a national 
prospective cohort of American arthritis patients.  Patients are enrolled into the 
CORRONA registry at participating academic and community rheumatology clinics by 
their treating CORRONA physician, and more comprehensive regarding the database 
operation and funding mechanisms have been published elsewhere [63].  Institutional 
Review Boards (IRBs) of academic sites and a centralized IRB for universities and 
private rheumatology clinics, respectively, approve patients for enrollment into the 
CORRONA registry and informed consent is obtained from all patients prior to entry into 
the study.  Information is collected using survey questionnaires administered to both 
patients and their corresponding rheumatologists at routine clinical encounter that 
generally occur between 3 to 6 months [63].  Surveys gather data on demographics, 
behavioral characteristics, disease activity and severity, medical comorbidity, and 
medication utilization and history.  
Patient Selection 
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 Individuals with physician diagnosed RA (N=33,743) enrolled into the 
CORRONA registry during October 2001 to August 2012 were used to compare clinical 
responses rates to biologic DMARD treatment among patients with and without 
depression.  Eligible participants included all patients (N=4,592) initiating their first 
observed biologic agent at a follow-up encounter while in CORRONA, and these 
identified visits were assigned as the index dates.  Enrollment visits could not be used 
because at these time points there are only measures of prevalent depression, rather than 
assessments of recently occurring symptomatology.  Patients without relevant disease 
activity and covariate data (n=1,644) and an identifiable follow-up visit after treatment 
initiation (n=397) were further restricted.  Depressed patients were classified as those 
with symptoms at, or within, a follow-up visit 6 months prior to starting therapy.  A 
history of depression was defined as a reported prevalence at enrollment or the presence 
symptoms during follow-up before the stated window.  Control comparators were those 
without a concurrent and history of depression symptomology at and prior to treatment 
initiation.  Among patients starting biologic therapy during follow-up, 1,520 controls and 
496 patients with co-occurring depressive symptoms were identified for inclusion 
(Figure 5.1).    
Depression Measures 
 The depression measures used in this study were single-item assessments 
collected from a patient-reported comorbidity inventory list at study entry and subsequent 
follow-up visits.  CORRONA surveys capture data on ever having depression at 
enrollment, as well as information during follow-up on all medical comorbidities that 
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have occurred since the patient’s last clinical visit.  Patient follow-up surveys instruct 
study participants to report any “Medical condition or symptom you have had SINCE 
YOU LAST FILLED OUT THIS FORM,” which contains an item for “Depression 
(Feeling Blue).”  Enrollment forms instruct patients to, “Please fill a ‘NO’ or ‘YES’ 
circle for each of the following conditions you have EVER had,” which includes 
depression. These measures were used to assign patients present and past depression 
proximal to their assigned index dates; however, they were not intended to characterize 
clinical depression as evaluated using diagnostic criteria.  Nonetheless, ultra-brief 
symptomatic scale assessments of depression are routinely used to evaluate the condition 
in clinical practice and have been validated in patients with chronic physical disease [86, 
87, 100].  Given the burden that even short screening instruments can place in busy 
practices sites, these measures are feasible alternatives that provide invaluable clinical 
information [99, 100]. 
Clinical Outcomes 
The primary and secondary study outcomes were remission and low disease 
activity (LDA), respectively, defined using the clinical disease activity index.  The 
clinical disease activity index (CDAI) is a summary score (0-76) calculated by adding 
together the patient global disease of disease activity (PGA; visual analogues scale (VAS) 
0-10 cm)), physician global assessment of disease activity (EGA; VAS 0-10 cm), tender 
joint count (TJC) based on 28 counts, and swollen joint count (SJC) based on 28 counts 
[67].  CDAI remission and LDA are defined using respective cut point values of < 2.8 
and > 2.8 to < 10.  Response to treatment was assessed at 6 and 12 months (+/- 2 months) 
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follow-up visits after treatment initiation, and to account for adherence to therapy, 
medication discontinuation prior to either of the identified evaluation time points was 
imputed as non-response and carried forward as appropriate [114].  When assessing 
remission, patients classified with the outcome status at initiation were excluded, and 
similarly, while using the LDA outcome only patients in moderate-to-severe disease at 
baseline were included in the analysis.  A secondary outcome measure was the twenty 
eight joint count disease activity score (DAS28; 0-10), which is calculated from three of 
previously described measures (PGA, TJC, SJC) and the erythrocyte sedimentation rate 
(ESR) using mathematical formula: DAS28= 0.56 × √(TJC) + 0.28 × √(SJC) + (0.70 × 
lnESR) + 0.014 × PGA [68].   
Inverse Probability Weighting 
 To account for possible confounding factors, an inverse probability weighting 
(IPW) approach was utilized [107].   Briefly, IPW is implemented in the propensity score 
(PS) context to account for differences in the probability of exposure between two 
comparison groups, and the exposed and unexposed participants are weighted to 
represent the overall study sample [115].  This approach was used for two reasons: it 
allows for the entirety of the analytic cohort to be retained in the analysis; and to 
simultaneously control for patients’ baseline composite disease activity (CDAI or 
DAS28), pain, and function, all of which are highly correlated with each other and the 
study outcomes.  Logistic regression modeling was used to calculate a propensity score 
for each patient, the probability of self-reported depressive symptoms at treatment 
initiation, conditioned on factors selected a priori that were associated with the exposure 
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at baseline.  For the primary analyses, inclusion was based on statistical significance (i.e., 
p value), but for some secondary and sensitivity analyses standardized differences were 
used due to small sample sizes.  IPWs for the exposed and unexposed patients were then 
calculated as 1 ÷ PS and 1 ÷ (1-PS), respectively [107].  To reduce the potential unduly 
influence of outlier values on variance estimates, IPWs were truncated at the 95th 
percentile [115].  The IPWs were also sample normalized by multiplying the raw weights 
by a stabilizing factor (i.e., sum of all probability weights divided by the sample size).   
This process was conducted separately for patients with a 6 and 12 months follow-up 
visit and each of the different analytic cohorts.           
Confounders 
         Potential differences in key covariate measures associated with patient’s 
depression status, when starting therapy, that could influence clinical response to 
treatment, were of concern.  All possible confounding factors were measured from 
patients assigned index visit and used at the subsequent available follow-up time points.  
The biggest predictor of response to therapy during follow-up is a patient’s baseline level 
of disease severity.  Accordingly, baseline disease activity outcome measures (CDAI and 
DAS28) were considering potential confounders in addition to patient’s initial pain and 
functional status.  These attributes were measured using self-reported pain (VAS 0-10 
cm) and the health assessment questionnaire (HAQ) [69].   
Demographic and socioeconomic factors were also considered potential 
confounders and included self-reported measures of gender, age, marital status, race, 
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ethnicity, achieved education, employment, and health insurance.  Patients’ age at 
enrollment was coded as into categorical groupings due to a non-linear relationship with 
the likelihood of reporting concurrent depressive symptoms.  Marital status was captured 
as five categories: single, married/partnered, widowed, and divorced/separated.  Ethnicity 
and Race, reported as separate variables, were joined into a single measure with five 
categories: White, Black, Asian, Hispanic, and Other.  Level of attained education was 
characterized using three groups: primary, high school, and college/university; and 
employment status was collected as one of six groups: full time, part time, unemployed, 
student, disabled and retired. 
     Relevant clinical and behavioral attributes were exercise, alcohol use, 
smoking, disease duration, body mass index (BMI; kilograms/meters²), and comorbidity.  
Exercise habits were assessed using five groupings: not at all, 1-2 times per week, 3-4 
times per week, 5-6 times per week, and daily.  Previous alcohol and smoking exposure 
were measured as discrete (ever vs. never) binary variables because more comprehensive 
evaluations are restricted to the most recent CORRONA data collection forms.  Disease 
duration was categorized into quintiles, and BMI was classified according to standard 
WHO recommendations, due to non-linear associations with self-reported depressive 
symptomology.  Reports of prior and current medical conditions from either patients or 
rheumatologists were used to create a composite comorbidity index and included the 
following: myocardial infarction, stroke, hypertension, other cardiovascular disorders, 
diabetes mellitus, pulmonary disease, cancer, peptic ulcer, other gastrointestinal 
disorders, and fractures [25].  
104 
 
 
    DMARD treatment characteristics included in our assessment were biologic 
history, biologic type, combination therapy, methotrexate, prednisone, and number of 
prior biologics.  Biologic history (experienced vs. naïve) was the reported utilization of 
any biologic DMARD prior to the index time point, and medication type was 
characterized using two groups: ant-TNF and non-TNF.   Combination therapy was 
defined as the additional utilization of a non-biologic DMARD (Arava, Azulfidine, 
Imuran, Methotrexate, Plaquenil, Minocin, Ridaura, Cuprimine, and Cyclosporine) at 
treatment initiation.  Methotrexate and prednisone use were the concurrent prescription of 
these treatments individually when patients started therapy.  Number of prior biologic 
therapies was calculated as the frequency of reported usages for any of the nine 
commercially available therapies, but the variable was restricted to three due to small 
sample sizes in higher categorical stratums.         
Statistical Analysis 
 The objective was to examine differences in clinical response rates to biologic 
agents by patients self-reported depression status proximal to their treatment initiation.  
The primary method of analysis was logistic regression modeling and they were used to 
examine likelihood of achieving remission and LDA separately at 6 and 12 months 
follow-up visits.  The primary predictor variable was a binary indicator for the presence 
of concurrently occurring depressive symptomology at, or within, 6 months of the 
assigned therapy start date.  Unadjusted odds ratios (OR) with 95% confidence intervals 
(CI) were estimated, and models weighted using IPWs were used to examine adjusted 
associations.  The basic unadjusted model is shown is illustrated in the equation below. 
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𝐿𝑜𝑔𝑖𝑡(𝑝) = log (
𝑝
1−𝑝
) = 𝛽0 + 𝛽1(𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑣𝑒 𝑆𝑦𝑚𝑝𝑡𝑜𝑚𝑠)         
 The central parameter of the analyses was the indictor for co-occurring depressive 
symptoms contiguous to the time of biologic treatment initiation.  This parameter 
represents the moderating effects of depression on clinical response to biologic DMARDs 
and tests whether the probability of achieving remission and LDA differs between with 
and without individuals reporting the presence of the comorbidity.  Unadjusted and 
adjusted models using IPWs were developed and tested separately among patients at 6 
months and 12 months follow-up.  A secondary study intended to assess for potential 
response effect heterogeneity by the time of depressive symptomology onset was also 
conducted.  Among patients classified as depressed, participants with incident 
symptomatic onset were compared to those with concurrent depressive symptomology 
and prior history as defined in this study.  Further, three sensitivity analyses were 
performed: using the DAS28 to define clinical response among patients with available 
data; replicating the analyses using the CDAI in those in the DAS28 sample;  and 
restricting to patients with both a 6 and 12 months follow-up visit. 
 
5.4 Results 
Patient Characteristics 
 From the CORRONA RA registry, there were 2,551 patients who satisfied all of 
the pre-specific cohort inclusion and exclusion criteria: initiating a biologic DMARD 
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after study entry, available baseline disease activity and covariate data, and a follow-up 
visit within 12 months of starting therapy (Figure 5.1).  Of these individuals, there was 
1,520 potential controls with no self-reports of depressive symptoms when starting 
therapy or any visit prior to the assigned index date and 496 patients with co-occurring 
symptomology reported at, or within, 6 months of treatment initiation.   
RA patients (restricted to > LDA) initiating biologic therapy with concurrent 
symptoms of depression were more likely to be female and of lower socioeconomic 
status and had higher levels of prior smoking, low physical activity, BMI, comorbidity, 
and anti-depressant use (Table 5.1).  Concerning concomitant treatment attributes, 
depressed participants were more likely to be biologic experienced, initiating a non-TNF, 
and not using a non-biologic DMARD (Table 5.2).  Further, those with depressive 
symptomology had greater disease severity as measured by every metric, except the SJC, 
EGA, CRP, and ESR; and the differences were largest between the two groups for 
patient-reported measures as evidenced by the standardized differences (Table A.17).  
The attributes of those in the secondary and sensitivity analysis study samples 
were generally similar to the primary analytic cohort.  When restricting to patients with 
both a 6 and 12 months follow-up visit or those with available DAS28 disease activity 
data, the observed patterns were largely the same (data not shown).  Comparing 
depressed participants, specifically, those with the incident onset of depressive symptoms 
versus patients with a prior history and concurrent symptomology, the previously 
described differences in the distribution of patient characteristics were the same but lower 
in magnitude (Tables A.18-A.20).   In addition, patients with a history of depression and 
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co-occurring symptoms had higher baseline disease activity values for all measures, 
except the SJC and ESR, and the standardized differences were mostly comparable across 
the different metrics.       
 Remission      
 For CDAI remission, there were statistically significant unadjusted differences in 
the clinical response rates between controls and those reporting concurrent depressive 
symptoms at 6 and 12 months follow-up: 15.51% vs 6.59% and 16.71% vs. 9.52%, 
respectively (Table 5.3).  Patients with symptoms of depression were significantly less 
likely to achieve remission, and the corresponding ORs were 0.38 [0.25-0.58] at 6 
months and 0.53 [0.36-0.77) at 12 months.  Rates of medication discontinuation were 
comparable between the two groups.  Although, after statistical adjustment for potential 
confounders, particularly baseline differences in disease activity, the observed point 
estimates were attenuated to the null.  Adjusted ORs for remission were 0.48 [0.30-0.77] 
and 0.68 [0.44-1.05], and the difference in the likelihood of remission at 12 months was 
no longer statistically significant.  Moreover, of the patients not responding to therapy at 
6 months between the two groups, a higher proportion of the depressed moved into 
remission at 12 months compared to the controls (data not shown).  Restricting to 
patients with both a 6 and 12 months follow-up visit did not alter the results (data not 
shown).    
Sensitivity analyses using the DAS28 differed from the primary findings.  Patients 
with co-occurring depressive had a lower probability of achieving DAS28 remission 
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compared to controls: 24.51% vs. 17.54% at 6 months and 25.72% 17.48% at 12 months; 
and the differences were not statistically significant (Table 5.4).  The associated ORs 
were 0.66 [0.38-1.13] and 0.61 [0.34-1.07], respectively; however, after weighting using 
IPWs the depressive effect was nullified:  1.11 [0.60-2.05] at 6 months and 1.13 [0.61-
2.12] at 12 months.  Replicating the analyses using the CDAI to define response, 
restricted to patients with DAS28 data, resulted in identical findings to the primary 
analyses.  An examination in the primary remission sample of the individual CDAI and 
DAS28 core component measures at 6 and 12 months showed large standardized 
differences (> 0.1) for the TJC, PGA, and EGA; but not the SJC and ESR (Table A.21). 
Secondary analyses restricted to patients with depressive symptoms, comparing 
with those with an incident reports to participants with a prior history and concurrent 
symptomology, showed that the likelihood of remission varied by the time of onset.  
Unadjusted response rates at 6 months among patients with depressive symptoms were 
significantly higher in those without a prior history: 11.11% vs. 5.21% at 6 months; yet 
the same effect was not observed at 12 months: 11.11% vs. 9.03% (Table 5.5).  The 
corresponding ORs were 2.27 [1.03-5.03] at 6 months and 1.26 [0.58-2.72] at 12 months, 
and weighting using IPWs slightly attenuated the estimates:  2.05 [0.86-4.88] and 0.89 
[0.38-2.12].   Biologic discontinuation rates were comparable between the two groups at 
6 months, but slightly larger at 12 months. 
Low Disease Activity 
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 Similarly, between patients with and without co-occurring depressive symptoms, 
there were significant differences in the likelihood of achieving LDA.  The response rates 
concerning LDA were 36.99% and 27.15% at 6 months and 35.84% and 25.24% at 12 
months, and the analogous ORs were 0.64 [0.49-0.83] and 0.60 [0.45-0.81] (Table 5.3).  
Although, models weighted with IPWs largely attenuated the effect estimates to the null 
and the differences in the probability of response by depression status were negligible.  
Treatment persistence was also comparable between the two groups.  Sensitivity analyses 
restricting to patients with both follow-up assessments (data not shown) and using the 
DAS28 to define were (Table 5.4) were similar to the primary findings.  When 
examining response effect heterogeneity among patients with depressive symptoms, there 
was a significant difference in the LDA outcome at 12 months: 20.76% vs 39.73% (OR = 
2.52; 95% CI: 1.43-4.43); but not at 6 months: 25.72% vs 31.76% (OR = 1.34; 95% CI: 
0.79-2.28) (Table 5.5).  However, statistical adjustment highly weakened the observed 
associations, with corresponding ORs were 1.05 [0.58-1.89] at 6 months and 1.78 [0.95-
3.31] at 12 months. Also of note, when compared to the other analyses, there were larger 
differences in medication discontinuation.  The 6 ad 12 months discontinuation rates 
between those with an incident onset and patients with a prior history were 32.97% vs. 
24.71% and 49.58% vs. 39.73%, respectively. 
 
5.5 Discussion 
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This study is the first research to investigate the comparative effectiveness of 
biologic DMARDs in the presence of a highly prevalent psychiatric comorbidity in RA 
patients.  The presence of co-occurring depressive symptoms appears to significantly 
impact the likelihood of achieving of clinical remission as measured by the CDAI, but 
this moderating effect varied over patients’ follow-up and did not extend to LDA.  
Furthermore, when comparing the primary findings from the CDAI, to results from 
sensitivity analyses using the DAS28, there were incongruences regarding the observed 
data.  Concerning the moderating effect of concurrent depressive symptomology, the 
findings from this research also indicate the presence of effect modification in the context 
of the time of onset.  These data indicate that depression likely has a detrimental 
influence on clinical response to biologic response modifiers, yet this effect did not 
appear to be due to a substantive impact on the more objective metrics of disease activity.  
 Depressive symptoms contiguous to initiating a biologic agent were associated 
with a significantly lower probability of achieving clinical remission at 6 months follow-
up, and a similar, yet lesser effect was observed at 12 months.  However, after controlling 
for potential confounders, especially differences in baseline disease severity, this 
depressive effect did not extend to patients reaching LDA during follow-up.  Prior 
research has shown similar moderating effects on the likelihood of attaining both 
remission and LDA, but this work did not adjust for potential confounding factors [54].  
These data would suggest that after statistical adjustment, the impact of depression only 
extends to remission as defined using the CDAI.  Moreover, given that depressed patients 
not in remission at 6 months had a greater chance of moving into remission at 12-months 
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compared to controls, suggests that as time progresses patients with depressive symptoms 
may improve through the course of RA treatment.  This is not surprising, considering that 
randomized interventional studies have demonstrated that patients receiving RA 
treatment also have reductions in their depressive symptoms in addition to disease 
activity [44, 45].  The lack of an effect for LDA implies that depressive symptoms do not 
affect a less stringent definition of clinical response, which is likely because its presence 
does not impact every individual core component measure that comprise the composite 
indices.  Alternatively, the weak case definition used to assess depression may not have 
been representative of the necessary severity to detect a moderating effect on biologic 
DMARD treatment in the context of LDA. 
 When replicating the primary study using the DAS28 to discriminate patients’ 
level of disease activity, the results differed compared to defining clinical response with 
the CDAI.  This is in contrast to evidence that indicates depression has a significant 
impact on changes in disease activity due to clinical treatment measured using the 
DAS28 as both a numerical score and categorical groupings [53, 54].  Our findings 
showed significant unadjusted differences in disease activity as measured using the 
DAS28, but they were lower in magnitude compared to the CDAI, and statistical 
adjustment removed the observed depressive effect.  Two contributing factors likely 
explain the disparate results when defining disease activity using the two different 
composite scales.  First, the DAS28 incorporates the ESR, while the CDAI uses the EGA, 
and descriptive data revealed that at follow-up there was large standardized differences 
for the EGA but not the ESR [68].  This would suggest that the effect of depression on 
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RA disease activity extends to subjective assessments by external raters.  Second, the 
CDAI incorporates the raw value of each component measure in the calculation as a 
summary score, whereas the DAS28 uses a mathematical formula that differentially 
proportion the contribution of the different metrics [67, 68, 116].  Thus, the large 
disparity in the PGA and TJC between patients with and without depressive symptoms at 
follow-up may lead to greater measurable differences in disease activity using the CDAI 
because it combines the raw component measurement values [67]. 
 The secondary analyses demonstrated that among patients classified with 
depressive symptomology proximal to treatment initiation, there was response effect 
heterogeneity in terms of the time of symptom onset.  The incident onset of symptoms 
was strongly associated with an increased likelihood of achieving remission compared to 
those who had concurrent and a history of depressive symptomology, particularly at 6 
months follow-up; albeit, the effect was slightly attenuated and not significant after 
adjusting for potential confounders.  These findings parallel research that has 
demonstrated the presence of persistent depression at two adjacent follow-up visits is 
associated with a stronger moderating effect on response to therapy [53].  These results 
support the data showing depressive symptoms having a stronger impact on remission at 
6 months, and the lack of a statistically significant result after adjustment may purely be 
due to the small sample sizes.  The observed effect modification is likely a proxy for 
patients’ depressive symptom severity, as a history of depression is one of the strongest 
predictors of the severity and frequency of future episodes [112].  Conversely, when 
assessing LDA, the depressive effect was apparent at 12 months follow-up, rather than 6 
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months, and adjustment highly weakened the observed association.  This result could be a 
function of the much higher rate of medication discontinuation at 12 months in those with 
an earlier onset among the LDA sample (49.58% vs. 39.37%), and research has 
demonstrated a strong temporal association between depression and persistence to 
treatment [50].  If the presence of depression increases the risk of stopping biologic 
therapy because of issues with efficacy, this could potentially be another complication it 
creates concerning RA treatment and medical management. 
Strengths and Limitations 
 The strengths of this study include the large U.S. RA population based registry 
sample, comprehensive disease activity and medication utilization data, and rigorous 
statistical adjustment.  There are also several important limitations of this study.  First, 
the operationalization of the different depressive symptomology constructs was not 
equitable to depression as evaluated using diagnostic methods.  These measurements 
issues could have potentially impacted the observed results in several ways: the disparate 
findings between remission and LDA; differences in terms of the results between the 6 
and 12 months follow-up assessments; and the discrepancies in the data between the 
CDAI and DAS28.  In addition, there is the possibility of confounding from unmeasured 
factors not included in the analysis.  Lastly, the follow-up assessments were not 
conducted using a clinical protocol as mandated in clinical trials, and therefore, there is 
between-patient variation concerning the timing of their 6 and 12 months study visits. 
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5.6 Conclusions 
 In summary, the findings from this comparative effectiveness research indicate 
that the presence of depressive symptom at, or prior, to starting biologic treatment has a 
negative impact on clinical outcomes from therapy.  Symptoms of depression 
significantly decrease the likelihood of achieving remission at 6 months, and the effect 
persists even after 12 months of remaining on treatment.  However, what remains 
unclear, is the underlying mechanism responsible for the observed moderating effects.  
Depression may influence how patients and rheumatologists respond to subjective disease 
activity rating scales or have an impact on patients’ experience of pain through a 
combination of psychological, behavioral, and biological mechanisms [29].  In addition, 
the strength of the moderating effect probably increases with the degree of depression 
case severity, evidenced by the effect heterogeneity in the context of the time of symptom 
onset.  Collectively, the results suggest that depression is an important factor that 
practicing rheumatologists must consider when prescribing biologic medications in 
rheumatology practice because of the measureable impact on response, and consequently, 
the influence it can have on clinical decision making.  These data further underscore the 
need for regular screening, and future research should focus on examining this 
relationship using more sophisticated depression measurement methods, while retaining 
other rigorous epidemiological and statistical design characteristics.                
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Table 5.1 Baseline characteristics of patients initiating their first observed biologic DMARD 
in the CORRONA registry during follow-up with and without co-occurring depressive 
symptoms. 
Variable (n, %) 
¶ Controls 
(N=1,391) 
¶ Depressive Symptoms 
(N=482) 
P 
Female 1,036 74.48% 391 81.12% 0.003 
Race/Ethnicity     0.72 
White 1,187 85.33% 403 83.61%  
Hispanic 72 5.18% 33 6.85%  
Black 85 6.11% 29 6.02%  
Asian 22 1.58% 7 1.45%  
Other 25 1.80% 10 2.07%   
Age1 (yrs) 57.61 12.73 54.99 11.86 <0.001 
Education     0.64 
Primary  72 5.18% 20 4.15%  
High School 553 39.76% 190 39.42%  
College/University 766 55.07% 272 56.43%   
Insurance      0.008 
None 30 2.16% 9 1.87%  
Medicaid 27 1.94% 23 4.77%  
Medicare 234 16.82% 87 18.05%  
Private 1,100 79.08% 363 75.31%   
Marital Status     0.36 
Single 155 11.14% 59 12.24%  
Married/Partnered 972 69.88% 316 65.56%  
Widowed 104 7.48% 43 8.92%  
Divorced/Separated 160 11.50% 64 13.28%   
Employment     <0.001 
Full Time 599 43.06% 149 30.91%  
Part Time 132 9.49% 46 9.54%  
Unemployed 160 11.50% 59 12.24%  
Student  7 0.50% 4 0.83%  
Disabled 138 9.92% 132 27.39%  
Retired 355 25.52% 92 19.09%   
Disease Activity     <0.001 
Low 324 23.29% 75 15.56%  
Moderate 551 39.61% 169 35.06%  
Severe 516 37.10% 238 49.38%   
Disease Duration1 (years) 10.35 9.79 10.23 9.49 0.82 
Alcohol Use 846 44.64% 187 38.72% 0.02 
Smoking 315 16.62% 115 23.81% <0.001 
Exercise     0.002 
None 444 31.92% 197 40.87%  
1-2 times/week 417 29.98% 145 30.08%  
3-4 times/week 294 21.14% 78 16.18%  
5-6 times/week 89 6.40% 22 4.56%  
Daily 147 10.57% 40 8.30%   
BMI (kg/m^2) 28.79 6.81 30.82 8.0 <0.001 
Comorbidity2 1 [0-2] 1 [0-2] <0.001 
Antidepressant Use 108 7.76% 227 47.10% <0.001 
1Continuous value given as the mean value and standard deviation; 2Contiunous value given as the 
median and IQR.  
¶ Restricted to patients in low, moderate, and severe disease activity at treatment initiation. 
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Table 5.2 Concomitant treatment characteristics by depressive symptom 
status at the time of treatment initiation. 
Variable (n, %) 
¶  Controls 
(N=1,391) 
¶  Depressive 
Symptoms 
(N=482) 
P Value 
Biologic Naïve 756 54.35% 237 49.17% 0.05 
Anti-TNF 1,075 77.28% 350 72.61% 0.04 
Combination Therapy 1,132 81.38% 371 76.97% 0.04 
Prednisone Use 474 34.08% 184 38.17% 0.10 
Methotrexate Use 929 66.79% 298 61.83% 0.04 
Biologic Agent      
Enbrel 271 19.48% 106 21.99% 0.22 
Humira 446 32.06% 138 28.63%  
Remicade 256 18.40% 78 16.18%  
Cimzia 55 3.95% 11 2.28%  
Simponi 64 3.38% 17 3.52%  
Actemra 29 2.08% 15 3.11%  
Orencia 199 14.31% 77 15.98%  
Kineret 6 0.43% 3 0.62%  
Rituxan 82 5.90% 37 7.68%   
# Prior Biologics     0.02 
0 761 54.71% 237 49.17%  
1 422 30.34% 146 30.29%  
2 144 10.35% 63 13.07%  
>3 64 4.60% 36 7.47%   
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Table 5.3 Odds ratios for CDAI remission and low disease activity at 6 and 12 months after 
biologic DMARD initiation by self-reported depressive symptomology status.  
Depressive 
Symptoms 
Follow-up N Response 
Rate 
Discontinuation 
Rate 
Odds Ratio † Odds Ratio 
No ∆ 6 Months 1,244 15.51% 30.55% REF REF 
Yes ∆ 6 Months 425 6.59% 31.29% 0.38 [0.25-0.58] 0.48 [0.30-0.77] 
No ∆ 12 Months 1,101 16.71% 41.69% REF REF 
Yes ∆ 12 Months 378 9.52% 46.83% 0.53 [0.36-0.77] 0.68 [0.44-1.05] 
No □ 6 Months 957 36.99% 29.47% REF REF 
Yes □ 6 Months 361 27.15% 31.02% 0.64 [0.49-0.83] 0.90 [0.66-1.22] 
No □ 12 Months 837 35.84% 41.70% REF REF 
Yes □ 12 Months 309 25.24% 47.25% 0.60 [0.45-0.81] 0.88 [0.63-1.23] 
∆ CDAI Remission; □ CDAI Low Disease Activity; † Weighted using inverse probability weights  
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Table 5.4 Odds ratios for DAS remission and low disease activity at 6 and 12 months after biologic 
DMARD initiation by self-reported depressive symptomology status.  
Depressive 
Symptoms 
Follow-up N Response 
Rate 
Discontinuation 
Rate 
Odds Ratio † Odds Ratio 
No ∆ 6 Months 355 24.51% 26.76% REF REF 
Yes ∆ 6 Months 114 17.54% 26.32% 0.66 [0.38-1.13] 1.11 [0.60-2.05] 
No ∆ 12 Months 311 25.72% 39.87% REF REF 
Yes ∆ 12 Months 103 17.48% 42.72% 0.61 [0.34-1.07] 1.13 [0.61-2.12] 
No □ 6 Months 304 25.72% 26.32% REF REF 
Yes □ 6 Months 99 17.48% 25.25% 0.79 [0.49-1.29] 1.25 [0.72-2.18] 
No □ 12 Months 251 22.04% 38.87% REF REF 
Yes □ 12 Months 104 16.16% 42.22% 0.47 [0.26-0.85] 0.82 [0.43-1.56] 
∆ DAS28 Remission; □ DAS28 Low Disease Activity; † Weighted using inverse probability weights  
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Table 5.5 Odds ratios for CDAI remission and low disease activity at 6 and 12 months after 
biologic DMARD initiation comparing patients with depressive symptoms by their time of 
reported onset (incident onset vs. prior history and concurrent symptomology).  
Incident 
Onset 
Follow-up N Response 
Rate 
Discontinuation 
Rate 
Odds Ratio † Odds Ratio 
No ∆ 6 Months 326 5.21% 32.21% REF REF 
Yes ∆ 6 Months 99 11.11% 28.28% 2.27 [1.03-5.03] 2.05 [0.86-4.88] 
No ∆ 12 Months 288 9.03% 48.26% REF REF 
Yes ∆ 12 Months 90 11.11% 42.22% 1.26 [0.58-2.72] 0.89 [0.38-2.12] 
No □ 6 Months 276 25.72% 32.97% REF REF 
Yes □ 6 Months 85 31.76% 24.71% 1.34 [0.79-2.28] 1.05 [0.58-1.89] 
No □ 12 Months 236 20.76% 49.58% REF REF 
Yes □ 12 Months 73 39.73% 39.73% 2.52 [1.43-4.43] 1.78 [0.95-3.31] 
∆ CDAI Remission; □ CDAI Low Disease Activity; † Weighted using inverse probability weights  
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CHAPTER VI: 
DISCUSSION AND CONCLUSIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
122 
 
 
6.1 Summary 
 The purpose of this dissertation was examine the burden of comorbid depression 
among RA patients, quantify the bi-directional effects between the two conditions, and 
assess the moderating effects of depression on RA treatment.  Researchers have asserted 
that depression is under-recognized in rheumatology practice, yet no studies have 
assessed the presence of condition using measures reported separately from patients and 
their arthritis care providers [10-12].  The first study assessed depression rates and cross 
sectional associations with disease activity using depression metrics reported by RA 
patients and rheumatologists.  The link between these conditions is bi-directional, and 
there are mechanisms that can explain this relationship, but no research has examined this 
association in RA patients with the different disease activity measurement domains [10, 
11].  When evaluating the temporal bi-directional association between RA disease 
activity and depression; the research was separated out into two separate studies to assess 
each causal trajectory independently.  If depression influences the course of RA 
symptoms, then it may affect response to therapy, but extant research has an array of 
methodological limitations [53, 54].  The moderating effects of depression on biologic 
DMARD treatment were assessed using a national RA registry sample and rigorous 
statistical approaches.       
 The examination of depression rates and cross-sectional baseline associations 
with disease activity revealed a large burden of patient-reported depression, low 
rheumatologist-reported rates, and a strong correlation to disease activity.  The patient-
reported prevalence and incidence estimates of depression were greater than in the 
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general population, even after age and gender standardization.  Moreover, the counterpart 
rheumatologist-reported rates were equal to, or lower, compared to results from studies in 
healthy individuals.  There was poor agreement between the occurrence of patient- and 
rheumatologist-reported depression, and the magnitude of the disparity trended regarding 
the time of onset, where the level of disagreement increased for depression occurring 
more recently.   Prior depression at enrollment was associated with increased disease 
activity for every measured assessed; however, the associations were larger in magnitude 
for a history of depression reported by patients.  These data suggest a high frequency of 
depression in RA patients and under-reporting of this comorbidity by their treating 
rheumatologists, and consequently, a lack of clinical awareness regarding its occurrence, 
and cross-sectional analyses further support these findings.   
 The research assessing the temporal bi-directional effects between RA disease 
activity and depression yielded significant associations for both causal pathways.  
Patient- and provider-reported measures of RA disease activity were predictive of the 
incident onset of depressive symptoms.  Also, depression was temporally associated with 
slower rates of disease activity decline, but the magnitude the effects were stronger for 
prevalent depression and individuals with an earlier symptomatic onset, suggesting a 
stronger impact among those with a greater case severity.  The commonalities between 
the separate directional assessments were that (1) the magnitude of the temporal effects 
were largest for the patient-reported disease activity measures and (2) laboratory-reported 
acute phase reactants were neither associated with depression onset nor longitudinally 
influenced by its presence.  Collectively, the results imply the bi-directional effects 
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between these conditions are due to the cognitive aspects of MDD and patients’ 
perception of their disease activity or a substantive impact on patients’ experience of pain 
through the interactions of the cognitive, behavioral, and biological aspects of depression, 
physical behavior, and musculoskeletal pain.  
 In addition to having an influence on the trajectory of RA disease activity, the 
third aim demonstrated significant moderating effects of depression on biologic DMARD 
treatment.  The presence of depressive symptoms proximal to initiating a biologic agent 
were associated with a decreased probability of achieving clinical remission as measured 
by the CDAI.  Furthermore, there was effect heterogeneity in terms of depression 
symptomatic onset, and patients with the incident onset of symptoms were more likely to 
achieve remission compared to individuals with concurrent and prior depressive 
symptoms.  However, this moderating effect did not extend low disease activity (LDA) 
and clinical response as measured using the twenty eight joint count disease activity score 
(DAS28).  The findings indicate that depression has a detrimental effect on clinical 
treatment, but the impact was limited to specific core component measures and did not 
extend to joint swelling or acute phase reactants indicative of serum inflammation.  Thus, 
depression can affect how clinicians perceive the effectiveness of therapy depending on 
how response is defined and patients’ psychiatric case severity. 
 This thesis research addresses an important issue surrounding a highly prevalent 
medical comorbidity in the most common autoimmune inflammatory arthritic condition 
in the US.  Using a comprehensive and systematic stepwise approach to assessing 
depression in a national RA registry sample, the findings from these series of studies 
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have yielded crucial information that will be used to meaningful improve RA patient care 
and medical management.  These data provide insights into the awareness of depression 
by specialty practitioners, the causal mechanisms that can account for the observed bi-
directional effects between MDD and RA, and the impact of this comorbidity on response 
to RA pharmacological treatments.  Additionally, the results have salience and can 
potentially be applied to research in the context and broader framework of co-occurring 
depression in patients with chronic physical disease. 
 
6.2 Strengths and Limitations 
 Novel research findings are presented here regarding the co-occurrence and bi-
directional evolution of RA and comorbid depression.  First, a large national American 
RA sample of patients, with physician diagnosed RA according the ACR criteria, was 
utilized to perform these evaluations.  Both patients and their treating physicians 
complete survey data collection forms during clinical visits, which permits the 
comparison of self and externally rated data as well as multiple avenues to pursue 
secondary and sensitivity analyses.  The CORRONA registry also collects comprehensive 
disease severity and medication utilization data, allowing for longitudinal assessments 
permitting temporal interpretations in terms of the multi-factorial nature of RA 
symptomatic measurement and robust statistical adjustment for an array of possible 
confounders.  Moreover, a meticulous design approach was implemented with a 
systematic and rigorous assessment of the different salient clinical aspects concerning the 
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presence of depression in RA patients in routine rheumatology practice.  Lastly, the large 
heterogeneous observational study population increases the generalizability of the 
findings to RA patients receiving clinical care in the community practice setting. 
 However, there are several important limitations that must be acknowledged.  
Foremost, the depression measures utilized were not indicative of MDD as evaluated 
using diagnostic criteria in the clinical environment, and neither the frequency nor 
severity of depressive symptoms were assessed.  Clearly, this is the most significant 
limitation and affects the internal validity.  The single item patient-reported depression 
measures could have resulted in high rates of false positives and only permitted 
inferences in terms of the presence and absence of depressive symptoms during patients’ 
pasts or observed follow-up periods.  This low depression measurement specificity may 
have resulted in the detection of spurious associations, an underestimation of the true 
effect sizes, and the identification of bi-directional depressive effects, rather than a true 
bi-directional association.  Also, as with all observational studies using convenience 
sampling, there is the potential for confounding by unmeasured factors and selection bias 
if the analytic cohorts were systematically different from the American RA population.  
Last are the limitations inherent to all surveillance studies, which include inconsistent 
follow-up time patterns and the potential differential implementation of the research 
protocol by participating physicians. 
 
6.3 Implications and Future Directions  
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 The consistent and strong rheumatologist under-reporting of depressive symptoms 
at study and entry and during follow-up suggest a lack of awareness regarding this 
comorbidity among arthritis care providers.  This is in contrast to clinical guidelines that 
advise medical specialists to be aware of depression in patients with chronic physical 
disease, and this research is the first large-scale study to empirically demonstrate this in 
the rheumatology setting.  MDD is an important challenge that practicing rheumatologists 
must be aware when providing RA care; and regular screening is paramount, whether it 
be through verbal communication, ultra-brief screening tools, or more sophisticated 
methods of depression measurement.  However, what lies beyond the scope of this 
research, is the recommendation for systematic screening guidelines to implement in 
routine rheumatology practice.  Future studies in this area should focus on potential 
interventions, health care processes, and screening methods, which can be feasibly 
utilized in the rheumatology healthcare setting to increase knowledge about depression, 
its impact on RA patients, and the necessity of coordinated treatment with mental health 
care providers, if and when applicable. 
 Measured bi-directional effects between RA disease activity and depressive 
symptomology indicate a relationship in which both of the conditions simultaneously 
influence and are affected by each other.  Of the potential causal mechanisms 
hypothesized to mediate the observed temporal associations, the most plausible seems to 
be the perseverative cognitions that characterize MDD.  The lack of any adjusted 
temporal effects concerning serum biomarkers and strong magnitude and consistency of 
the findings regarding the patient-reported measures of RA disease activity support this 
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premise.  Although, it is also possible the cognitive and behavioral aspects of depression 
interact with physical activity, function, and the sensory of musculoskeletal pain have a 
tangible effect on patients RA disease activity; yet, this assertion could not be tested in 
these studies because it requires objective functional performance measures (e.g., timed 
four meter walk).  These findings provide an overarching causal framework for future 
studies, and subsequent research into the bi-directional association between depression 
and inflammatory arthritic conditions should incorporate the multiple disease activity 
measurement domains, diagnostic depression assessments, and rigorous statistical 
adjustment for potential confounders.  Such work would yield data that could be used to 
ascertain if biological constituents have a role in this relationship or whether the effects 
are purely due to patients’ cognitions and stress related to their arthritis symptoms. 
 The moderating effects of depression on response to RA pharmacotherapies 
further complicate the provision of care from RA patients’ treating rheumatologists in 
those individuals suffering from depression.  Although our data only indicates it is 
present for clinical remission as measured using the CDAI, secondary assessments imply 
the possibility of large effect heterogeneity in the context of the depression onset, which 
theoretically is a crude proxy for patient’s case severity.  Thus, the negative impact of 
comorbid depression may extend substantially beyond what has been demonstrated in 
this research.  The effect on clinical response is likely due to the measureable impact on 
disease activity that in turn may influence rheumatologists’ clinical decision making 
regarding RA treatment.  More specifically, it is unclear if this temporal association with 
disease activity, which in turn impacts treatment response, is due to depressions influence 
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on subjective self- and provider-reported disease activity measures or a substantive effect 
on the experience of musculoskeletal pain, and rheumatologists could be continuing, 
stopping, or switching therapies in patients where it is not appropriate.  Using validated 
clinical depression measurement scales, further research is necessary to discern the full 
extent of the impact on RA treatment and should expand to assessments of biologic 
DMARD discontinuations and switches.        
 In closing, a multitude of insights can be elucidated from this research, all of 
which add important contributions to our collective understanding of depression among 
RA patients in routine rheumatology practice and the potential challenges concerning 
rheumatologic clinical care associated with its presence. 
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Table A.1 Rates of agreement and test of symmetry for prevalent and incident reports of depression by the patients and 
rheumatologists. 
Lifetime Prevalent Depression Incident Depression  
  Patient     Patient   
Clinician Yes No Total Clinician Yes No Total 
Yes 1,619 
R(84.9%) 
C(41.5%) 
287 
R(15.1%) 
C(2.7%) 
1,906 Yes 14 
R(30.4%) 
C(1 5%) 
32 
R(69.6%) 
C(0.1%) 
46 
No 2,284 
R(17.8%) 
C(58.5%) 
10,565 
R(82.2%) 
C(97.3%) 
12,849 No 900 
R(3 2%) 
C(99.5%) 
27161 
R(96.8%) 
C(99 9%) 
28,061 
Total 3,903 10,852 14,755 Total 914 27,193 28,107 
Observed 
Agreement 
82.58% 
Expected 
Agreement 
67.46% 
Observed 
Agreement 
96.68% 
Expected 
Agreement 
96.60% 
Cohen's Kappa* 0.46 + 0.008 P Value <0.001 Cohen's Kappa* 0.03 + 0.025 P Value <0.001 
McNemar's Chi-
square 1,551.15 P Value <0.001 
McNemar's Chi-
square 808.39 P Value <0.001 
Prevalent Depression Onset <1 Year  Prevalent Depression Onset >=1 Year 
  Patient     Patient   
Clinician Yes No Total Clinician Yes No Total 
Yes 76 
R(52.4%) 
C(4.4%) 
69 
R(47.6%) 
C(0.5%) 
145 Yes 833 
R(49.3%) 
C(40.9%) 
855 
R(50.7%) 
C(6.8%) 
1,688 
No 1,638 
R(11.3%) 
C(95.6%) 
12,811 
R(88.7%) 
C(99.5%) 
14,449 No 1,204 
R(9 3%) 
C(59.1%) 
11,702 
R(90.7%) 
C(93 2%) 
12,906 
Total 1,714 12,880 14,594 Total 2,037 12,557 14,594 
Observed 
Agreement 
88.30% 
Expected 
Agreement 
87.50% 
Observed 
Agreement 
85.89% 
Expected 
Agreement 
77.70% 
Cohen's Kappa* 0.07 + 0.004 P Value <0.001 Cohen's Kappa* 0.37 + 0.008 P Value <0.001 
McNemar's Chi-
square 1,442.16 P Value <0.001 
McNemar's Chi-
square 59.16 P Value <0.001 
* Indicates variance is shown as standard error; R: row percent; C: column percentile. 
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Table A.2 Gender, race/ethnicity, and age specific lifetime depression prevalence estimates by 
depression measurement modality, using composite depression measures. 
  ¶ Composite Depression 1 ¶ Composite Depression 2 
Group N Events Prevalence Events Prevalence 
Overall 14,755 1,619 10.97% [10.37-11.48] 2,153 14.59% [14.02-15.16] 
Male 3,417 225 6.58% [5.75-7.42] 279 8.17% [7.25-9.08] 
Female 11,325 1,394 12.31% [11.70-12.91] 1,874 16.55% [15.86-17.23] 
White 12,257 1,428 11.65% [11.08-12.22] 1,909 15.57% [14.93-16.22] 
Hispanic 869 81 9.32% [7.39-11.26] 95 10.93% [8.86-13.01] 
Black 1,148 79 6.88% [5.42-8.35] 102 8.89% [7.24-10.53] 
Asian 250 4 1.60% [0.04-3.16] 12 4.80% [2.15-7.46] 
Other 177 26 14.69% [9.46-19.92] 30 16.95% [11.41-22.49] 
18-24 153 11 7.19% [3.08-11.30] 13 8.50% [4.06-12.93] 
25-34 698 72 10.32% [8.06-12.57] 79 11.32% [8.97-13.67] 
35-44 1,630 181 11.10% [9.58-12.63] 237 14.54% [12.83-16.25] 
45-54 3,243 369 11.38% [10.29-12.47] 522 16.10% [14.83-17.36] 
55-64 4,227 565 13.37% [12.34-14.39] 752 17.79% [16.64-18.94] 
65-74 3,209 304 9.47% [8.46-10.49] 414 12.90% [11.74-14.06] 
75-74 1,301 95 7.30% [5.89-8.72] 117 8.99% [7.44-10.55] 
85+ 272 22 8.09% [4.84-11.33] 19 6.99% [3.95-10.02] 
¶ Restricted to patients enrolled after July of 2008, among those with no missing data for either patient-
reported or clinician-reported depression at baseline. 
Composite Depression 1: Defined as an endorsement of having a history of depression at enrollment by 
both the patient and clinician. 
Composite Depression 2: Defined as a patient-reported history of depression and use of an 
antidepressant medication at the time of enrollment. 
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Table A.3 Gender, race/ethnicity, and age specific annualized incidence rates by depression 
measurement modality, using composite incident depression definitions. 
  ¶ Composite Depression 1 ¶ Composite Depression 2 
  
N Events 
Person 
Time 
(years) 
¥ Incidence Rate Events 
Person 
Time 
(years) 
¥ Incidence Rate 
Overall 7,555 26 12,590 0.21 [0.14-0.30] 291 12,349 2.36 [2.10-2.64] 
Male 1,972 9 3,289 0.27 [0.14-0.53] 49 3,249 1.51 [1.14-2.00] 
Female 5,581 17 9,299 0.18 [0.11-0.29] 242 9,095 2.66 [2.35-3.02] 
White 6,296 22 10,603 0.21 [0.14-0.32] 258 10,379 2.49 [2.20-2.81] 
Hispanic 393 3 550 0.55 [0.18-1.69] 11 547 2.01 [1.11-3.63] 
Black 626 1 1,011 0.10 [0.01-0.67] 20 996 2.01 [1.30-3.11] 
Asian 147 0 274 - 1 274 0.37 [0.05-2.59] 
Other 74 0 138 - 0 138 - 
18-24 89 0 127 - 7 121 5.77 [2.75-12.10] 
25-34 345 1 542 0.19 [0.03-1.31] 21 524 4.04 [2.61-6.14] 
35-44 808 7 1,354 0.52  [0.25-1.09] 33 1,327 2.49 [1.76-3.50] 
45-54 1,678 8 2,862 0.28 [0.14-0.56] 78 2,796 2.79 [2.23-3.48] 
55-64 2,075 5 3,536 0.14 [0.06-0.34] 85 3,454 2.46 [1.99-3.04] 
65-74 1,710 4 2,843 0.14 [0.05-0.38] 40 2,812 1.42 [1.04-1.94] 
75-74 706 1 1,124 0.09 [0.01-0.63] 22 1,111 1.98 [1.30-3.01] 
85+ 138 0 195 - 4 194 2.06 [0.77-5.50] 
¶ Restricted to patients enrolled after July of 2008, among those with no missing data or reports of 
prevalent depression for either the patient or clinician depression measures at baseline 
¥ Incidence rates (IR) are reported per 100 patient-years of observation 
Composite Depression 1:  Defined as incident reports of patient-reported and clinician-reported 
depression that occur at the same, or adjacent follow-up visits. 
Composite Depression 2: Defined as an incident patient report of depression where there is a self-report 
of anti-depressant use at the same, or the following clinical visit. 
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Table A.4 Unadjusted and adjusted associations of RA disease activity with the rheumatologist-reported lifetime 
prevalence of depression in the CORRONA registry. 
    † Unadjusted † Adjusted 
Variable N OR 95% CI P OR 95% CI P 
CDAI           
Quintile 1 2,353 - - <0.001 - - 0.02 
Quintile 2 2,189 1.67 [1.37-2.04]   1.32 [1.06-1.64]  
Quintile 3 2,273 1.71 [1.40-2.09]   1.20 [0.96-1.50]  
Quintile 4 2,303 2.08 [1.71-2.54]   1.36 [1.08-1.70]  
Quintile 5 2,232 2.62 [2.15-3.20]   1.46 [1.16-1.83]   
DAS28          
Quintile 1 1,175 - - <0.001 - - 0.30 
Quintile 2 1,175 1.42 [1.09-1.83]  1.13 [0.83-1.53]  
Quintile 3 1,175 1.28 [0.98-1.67]  0.84 [0.62-1.15]  
Quintile 4 1,174 1.71 [1.32-2.22]  0.98 [0.72-1.33]  
Quintile 5 1,174 1.98 [1.52-2.56]   1.09 [0.79-1.50]   
TJC           
Quintile 1 3,961 - - <0.001 - - <0.001 
Quintile 2 1,179 1.26 [1.03-1.55]   1.27 [1.01-1.61]  
Quintile 3 1,917 1.40 [1.17-1.66]   1.26 [1.03-1.54]  
Quintile 4 2,340 1.48 [1.25-1.76]   1.14 [0.94-1.38]  
Quintile 5 2,094 1.92 [1.62-2.27]   1.42 [1.02-1.51]   
SJC           
Quintile 1 4,085 - - 0.03    0.42 
Quintile 2 1,110 1.10 [0.90-1.35]   1.19 [0.95-1.51]  
Quintile 3 1,916 1.11 [0.94-1.32]   1.18 [0.97-1.43]  
Quintile 4 2,169 1.25 [1.06-1.47]   1.10 [0.91-1.33]  
Quintile 5 2,210 1.27 [1.07-1.50]   1.11 [0.92-1.36]   
PGA          
Quintile 1 2,746 - - <0.001 - - 0.002 
Quintile 2 1,843 1.16 [0.95-1.44]  1.06 [0.84-1.34]  
Quintile 3 2,285 1.65 [1.37-1.99]  1.17 [0.94-1.44]  
Quintile 4 2,594 2.07 [1.73-2.47]  1.27 [1.04-1.56]  
Quintile 5 1,966 2.88 [2.40-3.46]   1.52 [1.22-1.89]   
EGA          
Quintile 1 2,736 - - <0.001 - - 0.87 
Quintile 2 2,634 1.23 [1.03-1.47]  1.00 [0.82-1.23]  
Quintile 3 1,855 1.33 [1.09-1.61]  0.97 [0.78-1.21]  
Quintile 4 1,932 1.37 [1.13-1.66]  1.06 [0.85-1.32]  
Quintile 5 2,266 1.64 [1.36-1.98]   1.08 [0.87-1.34]   
Patient-Pain VAS          
Quintile 1 2,438 - - <0.001 - - <0.001 
Quintile 2 2,397 1.12 [0.92-1.38]  0.97 [0.78-1.22]  
Quintile 3 2,153 1.69 [1.39-2.05]  1.18 [0.94-1.47]  
Quintile 4 2,558 2.19 [1.82-2.63]  1.31 [1.06-1.62]  
Quintile 5 1,884 2.87 [2.35-3.45]   1.58 [1.26-1.98]   
HAQ           
Quintile 1 2,306 - - <0.001 - - <0.001 
Quintile 2 2,210 1.69 [1.35-2.11]   1.24 [0.94-1.63]  
Quintile 3 2,256 2.71 [2.19-3.35]   1.65 [1.29-2.10]  
Quintile 4 2,261 3.15 [2.55-3.88]   1.70 [1.33-2.18]  
Quintile 5 2,253 4.26 [3.47-5.24]   1.80 [1.39-2.33]   
† Indicates mixed effects models were clustered by data collection site. 
Confounders: age, gender, race, ethnicity, marital status, education, employment, health insurance, disease duration, BMI, 
composite comorbidity, smoking, alcohol consumption, and exercise. 
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Table A.5 Univariate associations of patient characteristics with incident and persistent reports of patient measured 
depression among the primary analytic cohort of CORRONA RA patients. 
  Incident Reports Depression Persistent Reports Depression 
Variable Hazard Ratio 95% CI P Value Hazard Ratio 95% CI P Value 
Female 1.44 [1.33-1 56] <0.001 1.35 [1.13-1.62] 0.001 
Race/Ethnicity     <0.001     0.30 
White - - - - - - 
Hispanic 1.38 [1.22-1 58] <0.001 1.34 [0.99-1.80] 0.06 
Black 1.06 [0.93-1 21] 0.39 1.10 [0.82-1.48] 0.54 
Asian 0.86 [0.65-1 12] 0.26 0.81 [0.43-1.50] 0.50 
Other 1.23 [0.97-1 57] 0.09 0.82 [0.42-1.58] 0.55 
Age    <0.001    <0.001 
18-24 - - - - - - 
25-34 1.02 [0.67-1 54] 0.92 1.19 [0.41-3.42] 0.75 
35-44 0.90 [0.61-1 33] 0.59 1.20 [0.44-3.30] 0.72 
45-54 0.89 [0.61-1 31] 0.57 1.19 [0.44-3.22] 0.73 
55-64 0.77 [0.53-1 14] 0.19 0.98 [0.36-2.63] 0.96 
65-74 0.66 [0.45-0 96] 0.03 0.65 [0.24-1.77] 0.4 
75-84 0.75 [0.51-1 11] 0.15 0.91 [0.34-2.49] 0.86 
85+ 0.87 [0.57-1 34] 0.54 0.54 [0.17-1.71] 0.29 
Education     <0.001     0.90 
Primary  - - - - - - 
High School 0.88 [0.75-1.02] 0.09 0.93 [0.65-1.34] 0.70 
College/University 0.76 [0.65-0.88] <0.001 0.90 [0.63-1.29] 0.57 
Don’t Remember 0.92 [0.64-1 33] 0.65 1.07 [0.47-2.42] 0.87 
Insurance     <0.001    <0.001 
None - - - - - - 
Medicaid 1.19 [0.89-1 58] 0.24 1.04 [0.56-1.92] 0.91 
Medicare 0.57 [0.45-0.71] <0.001 0.47 [0.29-0.76] 0.002 
Private 0.56 [0.45-0.70] <0.001 0.50 [0.32-0.79] 0.003 
Marital Status     <0.001     0.07 
Single - - - - - - 
Married/Partnered 0.89 [0.80-0 99] 0.03 0.94 [0.74-1.20] 0.62 
Widowed 1.07 [0.94-1 23] 0.30 0.90 [0.65-1.25] 0.54 
Divorced/Separated 1.31 [1.14-1 50] 0.001 1.28 [0.94-1.75] 0.11 
Employment   <0.001    <0.001 
Full Time - - -      
Part Time 1.22 [1.08-1 37] 0.001 1.08 [0.82-1.44] 0.57 
Unemployed 1.52 [1.37-1.69] <0.001 1.40 [1.09-1.79] 0.008 
Student  1.29 [0.82-2.03] 0.27 1.07 [0.34-3.34] 0.91 
Disabled 2.15 [1.94-2 39] <0.001 2.61 [2.10-3.23] <0.001 
Retired 1.03 [0.94-1 12] 0.53 0.95 [0.78-1.16] 0.62 
Disease Duration     <0.001     0.006 
Quintile 1 - - - - - - 
Quintile 2 0.84 [0.76-0 93] 0.001 0.76 [0.60-0.95] 0.02 
Quintile 3 0.77 [0.70-0.86] <0.001 0.67 [0.54-0.85] 0.001 
Quintile 4 0.78 [0.71-0.87] <0.001 0.74 [0.59-0.92] 0.008 
Quintile 5 0.82 [0.74-0 90] <0.001 0.76 [0.61-0.96] 0.02 
Alcohol Use 0.83 [0.77-0.88] <0.001 0.80 [0.69-0.94] 0.005 
Smoking 1.45 [1.32-1 58] <0.001 1.52 [1.25-1.85] <0.001 
Exercise     <0.001     <0.001 
None - - - - - - 
1-2 times/week 0.81 [0.74-0.88] <0.001 0.66 [0.55-0.79] <0.001 
3-4 times/week 0.69 [0.63-0.76] <0.001 0.62 [0.51-0.76] <0.001 
5-6 times/week 0.53 [0.45-0.62] <0.001 0.43 [0.29-0.63] <0.001 
Daily 0.78 [0.69-0.88] <0.001 0.62 [0.47-0.81] <0.001 
BMI 1.01 [1.007-1.015] <0.001 1.02 [1.01-1.03] 0.003 
Comorbidity 1.10 [1.07-1 13] <0.001 1.15 [1.08-1.22] <0.001 
Antidepressant Use 2.04 [1.85-2 26] <0.001 3.59 [3.00-4.29] <0.001 
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Table A.6 Unadjusted and adjusted temporal associations (HR) of patients' lagged 
time-varying CDAI and DAS28 quintiles with incident and persistent self-reports of 
depressive symptoms from interval censored survival regression models. 
Variable N Hazard Ratio P Value Hazard Ratio P Value 
    Unadjusted Incident Symptoms Adjusted Incident Symptoms 
CDAI Quintile 17,273  <0.001   <0.001 
Quintile 1  - - - - 
Quintile 2  1.56 [1.35-1.81] <0.001 1.58 [1.37-1.83] <0.001 
Quintile 3  1.99 [1.73-2.29] <0.001 2.02 [1.75-2.33] <0.001 
Quintile 4  2.63 [2.30-3.02] <0.001 2.56 [2.23-2.95] <0.001 
Quintile 5   4.04 [3.54-4.62] <0.001 3.50 [3.06-4.02] <0.001 
DAS28 Quintile 12,540  <0.001   <0.001 
Quintile 1  - - - - 
Quintile 2  1.20 [1.01-1.42] 0.04 1.24 [1.05-1.48] 0.01 
Quintile 3  1.29 [1.09-1.53] 0.003 1.33 [1.12-1.58] 0.00 
Quintile 4  1.96 [1.68-2.30] <0.001 1.97 [1.67-2.32] <0.001 
Quintile 5   2.76 [2.37-3.21] <0.001 2.43 [2.06-2.85] <0.001 
    Unadjusted Persistent Symptoms Adjusted Persistent Symptoms 
CDAI Quintile    <0.001   <0.001 
Quintile 1 18,919 
 
- - - - 
Quintile 2  1.76 [1.23-2.51] 0.002 1.81 [1.27-2.59] 0.001 
Quintile 3  2.28 [1.62-3.21] <0.001 2.38 [1.69-3.36] <0.001 
Quintile 4  3.52 [2.54-4.89] <0.001 3.56 [2.55-4.97] <0.001 
Quintile 5   5.94 [4.34-8.13] <0.001 5.28 [3.83-7.29] <0.001 
DAS28 Quintile 13,959      
Quintile 1  - - - - 
Quintile 2  1.11 [0.77-1.62] 0.57 1.20 [0.82-1.75] 0.34 
Quintile 3  1.18 [0.82-1.69] 0.39 1.28 [0.88-1.87] 0.19 
Quintile 4  1.78 [1.27-2.50] 0.001 1.89 [1.33-2.70] <0.001 
Quintile 5   2.80 [2.04-3.85] <0.001 2.52 [1.79-3.55] <0.001 
Adjusted for the following confounders: gender, race, ethnicity, age group, education, health 
insurance, marital status, employment, disease duration, alcohol use, smoking, exercise, 
BMI, comorbidity, and antidepressant use. 
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Table A.7 Unadjusted and adjusted temporal associations (HR) of patients' CDAI 
and DAS28 measures with incident self-reports of depression and persistent reports 
of depression restricted to patients with equidistant follow-up visits. 
Variable   Hazard Ratio P Value Hazard Ratio P Value 
  N Unadjusted Incident Depression Adjusted Incident Depression 
CDAI Quintile 4,037 
  
  <0.001  <0.001 
Quintile 1  - - - - 
Quintile 2  1.51 [1.06-2.16] 0.02 1.48 [1.04-2.12] 0.03 
Quintile 3  1.97 [1.41-2.76] <0.001 1.84 [1.31-2.58] <0.001 
Quintile 4  2.44 [1.75-3.38] <0.001 2.12 [1.52-2.97] <0.001 
Quintile 5   3.17 [2.31-4.36] <0.001 2.48 [1.79-3.46] <0.001 
DAS28 Quintile 2,616  <0.001  0.04 
Quintile 1  - - - - 
Quintile 2  1.25 [0.83-1.87] 0.28 1.12 [0.74-1.69] 0.59 
Quintile 3  1.20 [0.80-1.80] 0.39 1.04 [0.69-1.57] 0.86 
Quintile 4  1.79 [1.24-2.58] 0.002 1.58 [1.08-2.31] 0.02 
Quintile 5   1.96 [1.37-2.82] <0.001 1.45 [0.99-2.13] 0.06 
    Unadjusted Persistent Depression Adjusted Persistent Depression 
CDAI Quintile 4,063   <0.001  <0.001 
Quintile 1  - - - - 
Quintile 2  1.45 [0.59-3.55] 0.42 1.43 [0.58-3.52] 0.43 
Quintile 3  2.31 [1.02-5.25] 0.04 2.18 [0.95-5.00] 0.07 
Quintile 4  3.50 [1.59-7.73] 0.002 3.10 [1.38-6.96] 0.006 
Quintile 5   4.46 [2.04-9.72] <0.001 3.74 [1.68-8.35] 0.001 
DAS28 Quintile 2,678  0.18  0.26 
Quintile 1  - - - - 
Quintile 2  0.66 [0.26-1.70] 0.39 0.61 [0.24-1.63] 0.33 
Quintile 3  1.12 [0.50-2.54] 0.78 1.06 [0.45-2.46] 0.90 
Quintile 4  1.57 [0.74-3.32] 0.24 1.60 [0.73-3.52] 0.24 
Quintile 5   1.63 [0.77-3.44] 0.20 1.33 [0.73-3.52] 0.50 
Adjusted for the following confounders: gender, race, ethnicity, age group, education, 
health insurance, marital status, employment, disease duration, alcohol use, smoking, 
exercise, BMI, comorbidity, and antidepressant use. 
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Table A.8 Unadjusted and adjusted temporal associations (HR) of patients' lagged time-varying 
CDAI and DAS28 quintiles with incident and persistent self-reports of depressive symptoms from 
semi-parametric gamma shared frailty models. 
Variable N Hazard Ratio P Value Hazard Ratio P Value 
    † Unadjusted Incident Symptoms † Adjusted Incident Symptoms 
CDAI Quintile 17,567  <0.001  <0.001 
Quintile 1  - - - - 
Quintile 2  1.48 [1.29-1.71] <0.001 1.43 [1.25-1.65] <0.001 
Quintile 3  1.83 [1.60-2.09] <0.001 1.69 [1.48-1.94] <0.001 
Quintile 4  2.13 [1.87-2.43] <0.001 1.89 [1.65-2.17] <0.001 
Quintile 5   2.87 [2.52-3.26] <0.001 2.35 [2.05-2.68] <0.001 
Frailty 
  Theta: 0.059 P: < 0.001 Tau: 0.029 Theta: 0.049 P: <0.001 
Tau: 
0.024 
DAS28 Quintile 12,101  <0.001  <0.001 
Quintile 1  - - - - 
Quintile 2  1.22 [1.05-1.44] 0.02 1.18 [0.99-1.40] 0.06 
Quintile 3  1.30 [1.10-1.53] 0.002 1.20 [1.02-1.42] 0.03 
Quintile 4  1.70 [1.46-1.99] <0.001 1.51 [1.29-1.77] <0.001 
Quintile 5   2.15 [1.85-2.50] <0.001 1.74 [1.48-2.04] <0.001 
Frailty 
 Theta: 0.065 P: < 0.001 Tau: 0.032 Theta: 0.049 P: <0.001 
Tau: 
0.024 
    † Unadjusted Persistent Symptoms † Adjusted Persistent Symptoms 
CDAI Quintile 17,859  <0.001  <0.001 
Quintile 1  - - - - 
Quintile 2  1.78 [1.25-2.53] 0.001 1.70 [1.19-2.42] 0.003 
Quintile 3  2.24 [1.60-3.15] <0.001 2.05 [1.45-2.88] <0.001 
Quintile 4  3.32 [2.41-4.59] <0.001 2.86 [2.06-3.96] <0.001 
Quintile 5   4.81 [3.51-6.51] <0.001 3.69 [2.68-5.10] <0.001 
Frailty 
  Theta: 0.033 P: 0.06 Tau: 0.016 Theta: 0.037 P: 0.02 
Tau: 
0.018 
DAS28 Quintile 12,688  <0.001  <0.001 
Quintile 1  - - - - 
Quintile 2  1.14 [0.79-1.65] 0.48 1.15 [0.79-1.67] 0.47 
Quintile 3  1.22 [0.85-1.76] 0.28 1.18 [0.82-1.71] 0.38 
Quintile 4  1.67 [1.19-2.34] 0.003 1.52 [1.07-2.16] 0.02 
Quintile 5   2.45 [1.78-3.36] <0.001 1.91 [1.36-2.69] <0.001 
Frailty 
  Theta: 0.028 P: 0.17 Tau: 0.014 Theta: 0.041 P: 0.06 Tau: 0.02 
† Semi-parametric gamma shared frailty models were clustered by data collection site 
Adjusted for the following confounders: gender, race, ethnicity, age group, education, health insurance, 
marital status, employment, disease duration, alcohol use, smoking, exercise, BMI, comorbidity, and 
antidepressant use. 
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Table A.9 General descriptive data in CORRONA RA patients by lifetime depression status between the full and 
matched clinician-reported depression measurement samples. 
Variable Full Study Population Propensity Score Matched Sample 
  
No 
(N=8,202) 
Yes  
(N=1,203) 
P 
No 
(N=1,193) 
Yes  
(N=1,193) 
P 
Female 6,231 75.97% 1,037 86.20% <0.001 1,024 85.83% 1,027 86.09% 0.86 
Race/Ethnicity           
White 6,863 83.67% 1,082 89.94% <0.001 1,052 88.18% 1,072 89.86% 0.39 
Hispanic 421 5.13% 41 3.41%  51 4.27% 41 3.44%  
Black 679 8.28% 62 5.15%  72 6.04% 61 5.11%  
Asian 152 1.85% 4 0.33%  1 0.08% 4 0.34%  
Other 87 1.06% 14 1.16%   17 1.42% 15 1.26%   
Age1 (yrs) 57.7 13.5 56.6 12.1 <0.001 56.7 12.7 56.6 12.1 0.84 
Education           
Primary  167 2.04% 33 2.74% 0.03 23 1.93% 32 2.68% 0.23 
High School 3,281 40.00% 497 41.31%  513 43.00% 494 41.41%  
College/University 4,710 57.43% 670 55.69%  649 54.40% 664 55.66%  
Don’t Remember 44 0.54% 3 0.25%   8 0.67% 3 0.25%   
Insurance            
None 180 2.19% 33 2.74% <0.001 29 2.43% 32 2.68% 0.75 
Medicaid 191 2.33% 45 3.74%  56 4.69% 46 3.86%  
Medicare 1,542 18.80% 262 21.78%  248 20.79% 255 21.37%  
Private 6,289 76.68% 863 71.74%   860 72.09% 860 72.09%   
Marital Status           
Single 945 11.52% 124 10.31% <0.001 109 9.14% 125 10.48% 0.71 
Married/Partnered 5,548 67.64% 760 63.18%  766 64.21% 755 63.29%  
Widowed 753 9.18% 120 9.98%  125 10.48% 118 9.89%  
Divorced/Separated 956 11.66% 199 16.54%   193 16.18% 195 16.35%   
Employment           
Full Time 3,445 42.00% 386 32.09% <0.001 384 32.19% 388 32.52% 0.98 
Part Time 754 9.19% 89 7.40%  82 6.87% 89 7.46%  
Unemployed 831 10.13% 165 13.72%  166 13.91% 163 13.66%  
Student  75 0.91% 5 0.42%  6 0.50% 5 0.42%  
Disabled 741 9.03% 246 20.45%  250 20.96% 237 19.87%  
Retired 2,356 28.72% 312 25.94%   305 25.57% 311 26.07%   
Baseline CDAI 13.4 12.6 16.3 13.8 <0.001 16.1 13.5 16.2 13.8 0.77 
Disease Duration1 (yrs) 8 2 9.3 8.4 9.2 0.34 8.8 9.7 8.3 9 1 0.26 
Alcohol Use 4,111 50.12% 551 45.80% <0.001 549 46.02% 548 45.93% 0.98 
Smoking 1,160 14.14% 226 18.79% <0.001 197 16.51% 221 18.52% 0.19 
Exercise           
None 2,633 32.10% 465 38.65% <0.001 461 38.64% 461 38.64% 0.88 
1-2 times/week 2,518 30.70% 412 34.25%  403 33.78% 404 33.86%  
3-4 times/week 1,747 21.30% 200 16.63%  188 15.76% 201 16.85%  
5-6 times/week 523 6.38% 48 3.99%  48 4.02% 49 4.11%  
Daily 781 9.52% 78 6.48%   93 7.80% 78 6.54%   
BMI (kg/m^2) 29.1 6.8 31 7.4 <0.001 31.2 7.5 31.0 7.4 0.52 
Comorbidity2 1 [0-2] 1 [0-2] <0.001 1 [0-2] 1 [0-2] 0.77 
1Continuous value given as the mean value and standard deviation; 2Contiunous value given as the median and IQR.  
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Table A.10 Disease activity data by patient-reported incident depressive symptom status at 
the index data in the full study population and matched sample. 
Full Study Population 
Outcome 
Variable 
Range 
No 
Depression 
Depression 
P 
Value 
SD Standardized 
Difference 
CDAI 0-76 8.93 14.02 <0.001 9.90 0.51 
DAS28 0-10 3.01 3.68 <0.001 3.14 0.21 
TJC 0-28 2.34 4.12 <0.001 2.68 0.66 
SJC 0-28 2.77 3.84 <0.001 2.97 0.36 
Patient Global 0-100 23.11 38.83 <0.001 26.11 0.60 
Physician Global 0-100 15.08 21.72 <0.001 16.34 0.41 
Patient Pain 0-100 25.34 41.14 <0.001 28.35 0.56 
HAQ 0-3 0.71 1.08 <0.001 0.78 0.47 
CRP (mg/L) 0-200 8.88 10.68 0.09 9.18 0.20 
ESR (mm/hr) 0-300 21.64 24.15 <0.001 22.13 0.11 
Matched Sample  
CDAI 0-76 12.49 12.35 0.65 12.44 0.01 
DAS28 0-10 3.48 3.48 0.90 3.48 0.00 
TJC 0-28 3.42 3.44 0.90 3.42 0.01 
SJC 0-28 3.8 3.43 0.01 3.68 0.10 
Patient Global 0-100 32.78 35.16 0.00 33.57 0.07 
Physician Global 0-100 19.93 19.62 0.53 19.83 0.02 
Patient Pain 0-100 36.85 36.87 0.97 36.86 0.00 
HAQ 0-3 0.97 0.99 0.45 0.98 0.02 
CRP (mg/L) 0-200 9.78 9.27 0.60 9.62 0.05 
ESR (mm/hr) 0-300 24 22.88 0.21 23.63 0.05 
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Table A.11 Index date treatment characteristics by incident 
depressive symptom status in the full study population and matched 
sample at the time of their assigned index date. 
  Full Study Population      
Variable No Depression 
 (N=10,073) 
Depression 
 (N=2,372) 
P 
Value 
Biologic DMARD Use 4,572 45.39% 1,112 46.88% 0.19 
Biologic Experienced 5,528 54.88% 1,404 59.19% <0.001 
Combination Therapy 3,405 33.80% 837 35.29% 0.17 
No DMARDS 734 7.29% 199 8.39% 0.07 
Prednisone Use 2,240 22.24% 736 31.03% <0.001 
Methotrexate Use 6,629 65.81% 1,529 64.46% 0.21 
Matched Sample 
Variable No Depression 
(N=4,216) 
Depression 
 (N=2,108) 
P 
Value 
Biologic DMARD Use 2,062 48.91% 993 47.11% 0.18 
Biologic Experienced 2,491 59.08% 1,230 58.35% 0.58 
Combination Therapy 1,584 37.57% 749 35.53% 0.11 
No DMARDS 295 7.00% 168 7.97% 0.16 
Prednisone Use 1,235 29.29% 609 28.89% 0.74 
Methotrexate Use 2,792 66.22% 1,367 64.85% 0.28 
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Table A.12 Unadjusted model based estimates of disease activity by patient-reported lifetime depression status at baseline and the 
corresponding change at 1 year and 2 years follow-up in the full study sample. 
Depression Outcome N Scale Baseline  Year 1 ∆ Year 2 ∆ 
No CDAI 12,703 0-76 16.07 [15.17-16.97] -2.99 [-3.32 - -2.68] -2.81 [-3.32 - -2.31] 
Yes CDAI 4,303 0-76 12.76 [11.89-13.62] -2.98 [-3.16 - -2.80] -2.93 [-3.21 - -2.66] 
No DAS28 6,352 0-10 3.51 [3.39-3.62] -0.30 [-0.33 - -0.28] -0.33 [-0.37 - -0.29] 
Yes DAS28 2,148 0-10 3.92 [3.80-4.04] -0.24 [-0.29 - -0.20] -0.29 [-0.37 - -0.22] 
No TJC 12,703 0-28 3.86 [3.47-4.25] -1.08 [-1.17 - -0.98] -1.00 [-1.17 - -0.98] 
Yes TJC 4,303 0-28 5.35 [4.94-5.75] -1.15 [-1.31 - -0.99] -0.97 [-1.21 - -0.72] 
No SJC 12,703 0-28 3.82 [3.41-4.23] -1.14 [-1.22 - -1.06] -1.19 [-1.30 - -1.07] 
Yes SJC 4,303 0-28 4.19 [3.76-4.61] -1.08 [-1.22 - -0.94] -1.23 [-1.45 - -1.02] 
No PGA 12,703 0-10 2.74 [2.62-2.86] -0.22 [-0.26 - -0.18] -0.22 [-0.28 - -0.16] 
Yes PGA 4,303 0-10 3.81 [3.68-3.94] -0.20 [-0.27 - -0.12] -0.10 [-0.21 - 0.02] 
No EGA 12,703 0-10 2.38 [2.23-2.54] -0.59 [-0.62 - -0.56] -0.56 [-0.60 - -0.51] 
Yes EGA 4,303 0-10 2.76 [2.60-2.92] -0.61 [-0.66 - -0.56] -0.54 [-0.62 - -0.46] 
No Pain 12,703 0-10 3.03 [2.90-3.16] -0.24 [-0.28 - -0.19] -0.21 [-0.28 - -0.14] 
Yes Pain 4,303 0-10 4.11 [3.97-4.25] -0.22 [-0.30 - -0.15] -0.11 [-0.23 - 0.01] 
No HAQ 12,703 0-3 0.79 [0.76-0.81] -0.02 [-0.03 - -0.01] -0.01 [-0.02 - 0.001] 
Yes HAQ 4,303 0-3 1.10 [1.07-1.13] -0.03 [-0.04 - -0.01] 0.01 [-0.02 - 0.03] 
No Log CRP 7,074 N/A 0.67 [0.63-0.71] -0.06 [-0.07 - -0.04] -0.08 [-0.10 - -0.06] 
Yes Log CRP* 2,379 N/A 0.69 [0.64-0.73] -0.02 [-0.04 - 0.0002] -0.05 [-0.08 - -0.02] 
No Log ESR 8,936 N/A 1.20 [1.19-1.21] -0.026 [-0.032 - -0.019] -0.02 [-0.03 - -0.01] 
Yes Log ESR 3,037 N/A 1.22 [1.21-1.23] -0.02 [-0.03 - -0.004] -0.01 [-0.03 - 0.01] 
Prior depression by follow-up time interaction: * P <0.05; ** P <0.01; *** P <0.001  
N/A indicates the outcome measure was a continuous value with no definitive measurement scale. 
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Table A.13 Unadjusted model based estimates of disease activity by physician-reported lifetime depression status at 
baseline and the corresponding change at 1 year and 2 years follow-up in the full study sample. 
Depression Outcome N Scale Baseline  Year 1 ∆ Year 2 ∆ 
No CDAI 8,202 0-76 13.44 [12.40-14.7] -3.25 [-3.49 - -3.02] -2.64 [-3.03 - -2.25] 
Yes CDAI 1,203 0-76 16.43 [15.25-17.61] -3.40 [-4.01 - -2.79] -2.10 [-3.14 - -1.06] 
No DAS28 5,375 0-10 3.59 [3.46-3.72] -0.33 [-0.37 - -0.30]  -0.31 [-0.38 - -0.26] 
Yes DAS28 808 0-10 3.96 [3.80-4.12] -0.26 [-0.36 - -0.17] -0.26 [-0.43 - -0.10] 
No TJC 8,202 0-28 4.18 [3.71-4.64] -1.17 [-1.29 - -1.05] -0.85 [-1.06 - -0.66] 
Yes TJC 1,203 0-28 5.67 [5.13-6.21] -1.35 [-1.66 - -1.04] -0.40 [-0.91 - 0.12] 
No SJC 8,202 0-28 3.82 [3.38-4.26] -1.20 [-1.30 - -1.11] -1.01 [-1.16 - -0.86] 
Yes SJC 1,203 0-28 3.99 [3.51-4.48] -1.09 [-1.34 - -0.84] -0.91 [-1.32 - -0.50] 
No PGA 8,202 0-10 3.01 [2.86-3.16] -0.26 [-0.31 - -0.20] -0.26 [-0.35 - -0.17] 
Yes PGA 1,203 0-10 3.94 [3.74-4.14] -0.20 [-0.34 - -0.05] -0.25 [-0.50 - -0.01] 
No EGA 8,202 0-10 2.46 [2.26-2.66] -0.66 [-0.70 - -0.61] -0.55 [-0.61 - -0.48] 
Yes EGA 1,203 0-10 2.82 [2.60-3.04] -0.74 [-0.84 - -0.63] -0.56 [-0.74 - -0.39] 
No Pain 8,202 0-10 3.34 [3.17-3.50] -0.35 [-0.41 - -0.30] -0.32 [-0.42 - -0.22] 
Yes Pain 1,203 0-10 4.38 [4.17-4.59] -0.44 [-0.59 - -0.29] -0.29 [-0.55 - -0.03] 
No HAQ 8,202 0-3 0.84 [0.80-0.87] -0.04 [-0.05 - -0.03] -0.04 [-0.06 - -0.02] 
Yes HAQ 1,203 0-3 1.10 [1.05-1.14] -0.04 [-0.06 - -0.01] -0.04 [-0.09 - 0.01] 
No Log CRP 5,295 N/A 0.65 [0.61-0.70] -0.06 [-0.07 - -0.05] -0.09 [-0.12 - -0.07] 
Yes Log CRP 803 N/A 0.69 [0.63-0.74] -0.03 [-0.07 - 0.01] -0.05 [-0.12 - 0.01] 
No Log ESR 5,404 N/A 1.19 [1.18-1.20] -0.03 [-0.04 - -0.02] -0.03 [-0.05 - -0.02] 
Yes Log ESR* 812 N/A 1.18 [1.15-1.20 0.001 [-0.019 - 0.021] 0.01 [-0.03 - 0.04] 
Prior depression by follow-up time interaction: * P <0.05; ** P <0.01; *** P <0.001 
N/A indicates the outcome measure was a continuous value with no definitive measurement scale. 
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Table A.14 Model based estimates of disease activity by physician-reported lifetime depression status at baseline and the 
corresponding change at 1 year and 2 years follow-up among a propensity score matched sample. 
Depression Variable N Scale ● Baseline  ● Year 1 ∆ ● Year 2 ∆ 
No CDAI 1,193 0-76 15.92 [15.36-16.48] -4.26 [-4.91 - -3.62] -4.13 [-5.33 - -2.91] 
Yes CDAI 1,193 0-76 16.00 [15.43-16.58] -3.46 [-4.10 - -2.81] -2.12 [-3.35 - -0.91] 
No DAS28 560 0-10 3.94 [3.86-4.01] -0.34 [-0.46 - -0.23] -0.44 [-0.68 - -0.21] 
Yes DAS28 609 0-10 3.97 [3.89-4.05] -0.30 [-0.41 - -0.19] -0.24 [-0.47 - -0.01] 
No TJC 1,193 0-28 5.24 [4.94-5.53] -1.61 [-1.96 - -1.26] -1.42 [-2.07 - -0.76] 
Yes TJC 1,193 0-28 5.24 [4.92-5.54] -1.30 [-1.65 - -0.95] -0.37 [-1.03 - -0.29] 
No SJC 1,193 0-28 4.14 [3.86-4.42] -1.35 [-1.59 - -1.11] -1.33 [-1.76 - -0.90] 
Yes SJC 1,193 0-28 3.87 [3.58-4.15] -1.11 [-1.35 - -0.87] -0.92 [-1.36 - -0.49] 
No PGA 1,193 0-10 3.86 [3.75-3.96] -0.50 [-0.65 - -0.35] -0.48 [-0.78 - -0.19] 
Yes PGA* 1,193 0-10 3.98 [3.87-4.09] -0.22 [-0.37 - -0.07] -0.25 [-0.55 - 0.04] 
No EGA 1,193 0-10 2.76 [2.66-2.87] -0.83 [-0.93 - -0.72] -1.05 [-1.32 - -0.78] 
Yes EGA 1,193 0-10 2.77 [2.66-2.88] -0.75 [-0.86 - -0.65] -0.60 [-0.79 - -0.40] 
No Pain 1,193 0-10 4.33 [4.22-4.43] -0.76 [-0.93 - -0.60] -0.79 [-1.10 - -0.47] 
Yes Pain* 1,193 0-10 4.37 [4.26-4.48] -0.48 [-0.64 - -0.31] -0.31 [-0.63 - -0.01] 
No HAQ 1,193 0-3 1.08 [1.06-1.09] -0.09 [-0.12 - - 0.06] -0.10 [-0.16 - -0.04] 
Yes HAQ 1,193 0-3 1.08 [1.07-1.10] -0.05 [-0.08 - -0.02] -0.06 [-0.12 - -0.01] 
No Log CRP 535 N/A 0.69 [0.66-0.73] -0.04 [-0.08 - 0.01] -0.09 [-0.17 - -0.01] 
Yes Log CRP 544 N/A 0.69 [0.66-0.73] -0.04 [-0.08 - 0.01] -0.05 [-0.14 - 0.03] 
No Log ESR 562 N/A 1.21 [1.20-1.23] -0.01 [-0.03 - 0.01] -0.03 [-0.08 - 0.02] 
Yes Log ESR 615 N/A 1.20 [1.18-1.21] -0.01 [-0.03 - 0.02] 0.001 [-0.05 - 0.05] 
Prior depression by follow-up time interaction: * P <0.05; ** P <0.01; *** P <0.001  
● Indicates mixed effects models were further adjusted for both the main effect of the baseline outcome (categorized quintiles) and its 
interaction with follow-up time. 
N/A means the outcome measure was a continuous value with no definitive measurement scale. 
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Table A.15 Unadjusted model based estimates of disease activity by incident depression status at baseline and the 
corresponding change at 1 year and 2 years follow-up among all available patients. 
Depression Variable N Scale Baseline  Year 1 ∆ Year 2 ∆ 
No CDAI*** 10,073 0-76 9.37 [8.64-10.10] -0.65 [-0.82 - -0.48] -0.89 [-1.16 - -0.62] 
Yes CDAI 2,372 0-76 13.70 [12.90-14.50] -2.19 [-2.55 - -1.84] -2.13 [-2.64 - -1.84] 
No DAS28 10,073 0-10 3.16 [3.06-3.27] -0.08 [-0.10 - -0.06] -0.11 [-0.15 - -0.07] 
Yes DAS28 2,372 0-10 3.65 [3.53-3.77] -0.14 [-0.19 - -0.09] -0.19 [-0.26 - -0.11] 
No TJC 10,073 0-28 2.61 [2.29-2.93] -0.24 [-0.32 - -0.15] -0.32 [-0.45 - -0.19] 
Yes TJC*** 2,372 0-28 4.13 [3.77-4.48] -0.78 [-0.95 - -0.61] -0.68 [-0.92 - -0.43] 
No SJC 10,073 0-28 2.67 [2.33-3.02] -0.27 [-0.35 - -0.20] -0.48 [-0.61 - -0.36] 
Yes SJC** 2,372 0-28 3.46 [3.09-3.83] -0.54 [-0.70 - -0.38] -0.85 [-1.08 - -0.62] 
No PGA 10,073 0-10 2.32 [2.22-2.43] -0.03 [-0.07 - 0.02] 0.07 [0.004 - 0.141] 
Yes PGA*** 2,372 0-10 3.78 [3.64-3.91] -0.51 [-0.60 - -0.42] -0.26 [-0.38 - -0.13] 
No EGA 10,073 0-10 1.79 [1.62-1.96] -0.14 [-0.16 - -0.11] -0.13 [-0.18 - -0.09] 
Yes EGA*** 2,372 0-10 2.36 [2.18-2.53] -0.36 [-0.42 - -0.30] -0.36 [-0.45 - -0.28] 
No Pain 10,073 0-10 2.57 [2.45-2.69] -0.04 [-0.081 - 0.003] 0.04 [-0.03 - 0.11] 
Yes Pain*** 2,372 0-10 4.02 [3.87-4.16] -0.49 [-0.58 - -0.40] -0.19 [-0.32 - -0.06] 
No HAQ 10,073 0-3 0.72 [0.69-0.75] 0.004 [-0.004 - 0.012] 0.01 [-0.002 - 0.025 
Yes HAQ*** 2,372 0-3 1.07 [1.03-1.10] -0.07 [-0.09 - -0.06] -0.04 [-0.06 - -0.01] 
No Log CRP 6,125 N/A 0.65 [0.61-0.70] -0.03 [-0.04 - -0.02] -0.03 [-0.04 - -0.01] 
Yes Log CRP 1,360 N/A 0.72 [0.67-0.78] -0.04 [-0.07 - -0.02] -0.04 [-0.08 - -0.01] 
No Log ESR 7,629 N/A 1.19 [1.16-1.21] 0.002 [-0.004 - 0.007] -0.002 [-0.012 - 0.007] 
Yes Log ESR 1,905 N/A 1.21 [1.18-1.24] -0.002 [-0.014 - 0.009] 0.005 [-0.014 - 0.024] 
Incident depression by follow-up time interaction: * P <0.05; ** P <0.01; *** P <0.001 
N/A means the outcome measure was a continuous value with no definitive measurement scale.  
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Table A.16 Model based estimates of disease activity by successive depression status at baseline and the corresponding change 
at 1 year and 2 years follow-up among a propensity score matched sample. 
Depression Variable N Scale ● Baseline  ● Year 1 ∆ ● Year 2 ∆ 
No CDAI 952 0-76 14.53 [13.92-15 13] -2.73 [-3.36 - -2.09] -2.69 [-3.72 - 1.65] 
Yes CDAI 476 0-76 14.99 [14.21-15.76] -1.98 [-2.90 - -1.06] -2.38 [-3.82 - -0.94] 
No DAS28 702 0-10 3.75 [3.68-3.82] -0.22 [-0.29 - -0.14] -0.27 [-0.41 - -0.14] 
Yes DAS28 355 0-10 3.76 [3.67-3.85] -0.12 [-0.24 - -0.01] -0.31 [-0.50 - -0.12] 
No TJC 952 0-28 4.39 [4.06-4.72] -1.16 [-1.49 - -0.84] -0.93 [-1.45 - -0.42] 
Yes TJC 476 0-28 4.35 [3.93-4.76] -0.70 [-1.16 - -0.23] -0.58 [-1.30 - 0.13] 
No SJC 952 0-28 4.05 [3.74-4.36] -0.83 [-1.11 - -0.55] -0.99 [-1.43 - -0.55] 
Yes SJC 476 0-28 4.12 [3.74-4.49] -0.68 [-1.07 - -0.28] -1.29 [-1.90 - -0.68] 
No PGA 952 0-10 3.80 [3.69-3.92] -0.45 [-0.60 - -0.30] -0.42 [-0.67 - -0.17] 
Yes PGA 476 0-10 3.91 [3.76-4.07] -0.21 [-0.43 - 0.01] -0.09 [-0.45 - 0.26] 
No EGA 952 0-10 1.35 [1.18-1.52] -0.39 [-0.50 - -0.29] -0.46 [-0.63 - -0.29] 
Yes EGA 476 0-10 1.41 [1.22-1.59] -0.43 [-0.58 - -0.29] -0.40 [-0.64 - -0.16] 
No Pain 952 0-10 4.20 [4.09-4.31] -0.62 [-0.77 - -0.47] -0.47 [-0.73 - -0.21] 
Yes Pain 476 0-10 4.28 [4.13-4.43] -0.23 [-0.49 - 0.03] -0.16 [-0.52 - 0.21] 
No HAQ 952 0-3 1.09 [1.07-1.11] -0.07 [-0.10 - -0.05] -0.06 [-0.11 - -0.01] 
Yes HAQ 476 0-3 1.09 [1.06-1.12] -0.03 [-0.07 - 0.01] 0.02 [-0.04 - 0.09] 
No Log CRP 391 N/A 0.65 [0.61-0.70] -0.05 [-0.08 - -0.01] -0.03 [-0.10 - 0.04] 
Yes Log CRP 187 N/A 0.68 [0.63-0.73] -0.01 [-0.07 - 0.05] -0.03 [-0.14 - 0.07] 
No Log ESR 709 N/A 1.23 [1.22-1.24] -0.003 [-0.019 - 0.018] 0.004 [-0.029 - 0.037] 
Yes Log ESR 358 N/A 1.24 [1.22-1.26] -0.004 [-0.031 - 0.023] -0.03 [-0.08 - 0.02] 
Successive depression by follow-up time interaction: * P <0.05; ** P <0.01; *** P <0.001 
● Indicates mixed effects models were further adjusted for both the main effect of the baseline outcome (categorized quintiles) and 
its interaction with follow-up time. 
N/A means the outcome measure was a continuous value with no definitive measurement scale. 
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Table A.17 Disease activity differences by co-occurring depressive symptom status 
at the time of treatment initiation. 
Variable 
(mean) 
¶  Controls 
¶  Depressive 
Symptoms 
SD 
P 
Value 
Standardized 
Difference 
CDAI 20.86 23.77 13.59 <0.001 0.21 
DAS  4.33 4.79 1.47 <0.001 0.31 
TJC 6.36 8.23 7.07 <0.001 0.26 
SJC 7.01 6.49 6.27 0.11 0.08 
PGA 40.85 54.89 25.99 <0.001 0.54 
EGA 33.98 35.63 21.09 0.14 0.08 
Pain 43.01 56.68 26.51 <0.001 0.52 
HAQ 1.02 1.39 0.65 <0.001 0.57 
CRP 13.27 14.24 22.25 0.68 0.04 
ESR 25.30 25.80 22.00 0.75 0.02 
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Table A.18 Baseline characteristics of patients initiating their first observed biologic 
DMARD in the CORRONA registry during among patients with depressive symptoms 
stratified by time of symptomatic onset. 
Variable (n, %) 
¶ Incident Onset 
(N=111) 
¶ Symptom History  
(N=371) 
P 
Standardized  
Difference 
Female 84 75.68% 307 82.75% 0.09 0.17 
Race/Ethnicity     0.49 0.04 
White 93 83.78% 310 83.56%   
Hispanic 9 8.11% 24 6.47%   
Black 5 4.50% 24 6.47%   
Asian 3 2.70% 4 1.08%   
Other 1 0.90% 9 2.43%     
Age1 (yrs) 53.9 12.6 55.3 11.6 0.25 0.12 
Education     0.18 0.08 
Primary  8 7.21% 12 3 23%   
High School 41 36.94% 149 40.16%   
College/University 62 55.86% 210 56.60%     
Insurance      0.51 0.07 
None 3 2.70% 6 1.62%   
Medicaid 4 3.60% 19 5 12%   
Medicare 16 14.41% 71 19.14%   
Private 88 79.28% 275 74.12%     
Marital Status     0.12 0.09 
Single 10 9.01% 49 13.21%   
Married/Partnered 83 74.77% 233 62.80%   
Widowed 6 5.41% 37 9 97%   
Divorced/Separated 12 10.81% 52 14.02%     
Employment     0.002 0.25 
Full Time 49 44.14% 100 26.95%   
Part Time 9 8.11% 37 9 97%   
Unemployed 11 9.91% 48 12.94%   
Student  0 0.00% 4 1.08%   
Disabled 17 15.32% 115 31.00%   
Retired 25 22.52% 67 18.06%     
Disease Activity     0.97 0.01 
Low 17 15.32% 58 15.63%   
Moderate 40 36.04% 129 34.77%   
Severe 54 48.65% 184 49.60%     
Disease Duration1 (yrs) 9.0 9.5 10.6 9.5 0.11 0.17 
Alcohol Use 45 40.54% 142 38.27% 0.67 0.05 
Smoking 22 19.82% 93 25.07% 0.26 0.13 
Exercise     0.11 0.22 
None 34 30.63% 163 43.94%   
1-2 times/week 38 34.23% 107 28.84%   
3-4 times/week 21 18.92% 57 15.36%   
5-6 times/week 8 7.21% 14 3.77%   
Daily 10 9.01% 30 8.09%     
BMI (kg/m^2) 30.1 6.2 31.1 8.5 0.25 0.13 
Comorbidity2 0 [0-2] 1 [0-2] 0.002 0.29 
Antidepressant Use 25 22.52% 202 55.45% <0.001 0.69 
1Continuous value given as the mean value and standard deviation; 2Contiunous value given as the median and IQR.  
¶ Restricted to patients in low, moderate, and severe disease activity at treatment initiation. 
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Table A.19 Concomitant treatment characteristics among patients with depressive symptom 
status at the time of treatment initiation by time of symptomatic onset. 
Variable (n, %) 
¶  Incident Onset 
(N=111) 
¶  Symptom 
History 
(N=371) 
P Value 
Standardized 
Difference 
Biologic Naïve 68 61.62% 169 45.55% 0.004 0.32 
Anti-TNF 81 72.97% 269 72.51% 0.92 0.01 
Combination Therapy 91 81.98% 280 75.47% 0.15 0.16 
Prednisone Use 37 33.33% 147 39.62% 0.23 0.13 
Methotrexate Use 74 66.67% 224 60.38% 0.23 0.13 
Biologic Agent     0.49  
Enbrel 24 21.62% 82 22.10%   
Humira 29 26.13% 109 29.38%   
Remicade 23 20.72% 55 14.82%   
Cimzia 1 0.90% 10 2.70%   
Simponi 4 3.60% 13 3.50%   
Actemra 2 1.80% 13 3.50%   
Orencia 18 16.22% 59 15.90%   
Kineret 2 1.80% 1 0.27%   
Rituxan 8 7.21% 29 7.82%     
# Prior Biologics     0.01 0.22 
0 68 61.26% 169 45.55%   
1 25 22.52% 121 32.61%   
2 8 7.21% 55 14.82%   
>3 10 9.01% 26 7.01%     
¶ Restricted to patients in low, moderate, and severe disease activity at treatment initiation. 
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Table A.20 Disease activity differences among patients with depressive symptom 
status at the time of treatment initiation by time of symptomatic onset. 
Variable 
(mean) 
¶  Incident 
Onset 
¶  Symptom  
History 
SD 
P 
Value 
Standardized 
Difference 
CDAI 21.92 24.33 13.27 0.09 0.18 
DAS  4.67 4.83 1.38 0.52 0.12 
TJC 6.90 8.63 7.67 0.04 0.23 
SJC 6.70 6.43 6.07 0.68 0.04 
PGA 49.59 56.47 24.75 0.01 0.28 
EGA 33.61 36.23 21.25 0.26 0.12 
Pain 52.47 57.94 24.98 0.04 0.22 
HAQ 1.28 1.42 0.62 0.03 0.23 
CRP 9.65 15.29 19.97 0.23 0.28 
ESR 30.22 24.71 22.83 0.17 0.24 
¶ Restricted to patients in low, moderate, and severe disease activity at treatment initiation. 
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Table A.21 Component disease activity values and differences at 6 and 12 months follow-up by 
self-reported depressive symptom status at treatment initiation.   
Variable 
Controls 
6 Months 
Depressed 
6 Months 
¶ Difference 
Controls 
12 Months 
Depressed 
12 Months 
¶ Difference 
TJC 3.6 + 5.7 5.1 + 7.2 0.25 3.2 + 5.6 5.3 + 7.3 0.35 
SJC 4.2 + 5.5 3.9 + 5.1 0.06 3.9 + 5.6 3.9 + 5.3 0.00 
PGA 30.9  + 25.9 45.0 + 26.5 0.53 29.1 + 25.3 44.0 + 26.8 0.56 
EGA 20.0 + 18.3 22.5 + 19.4 0.14 18.0 + 18.2 22.1 + 18.9 0.22 
ESR 22.4 + 21.7 23.5 + 22.6 0.05 22.8 + 22.3 20.8 + 18.8 0.07 
¶ Indicates value is calculated as a standardized difference. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
